WO2021037077A1 - Patentiflorin a analogs as antiviral agents - Google Patents
Patentiflorin a analogs as antiviral agents Download PDFInfo
- Publication number
- WO2021037077A1 WO2021037077A1 PCT/CN2020/111463 CN2020111463W WO2021037077A1 WO 2021037077 A1 WO2021037077 A1 WO 2021037077A1 CN 2020111463 W CN2020111463 W CN 2020111463W WO 2021037077 A1 WO2021037077 A1 WO 2021037077A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- independently selected
- optionally substituted
- och
- taken together
- Prior art date
Links
- NLWUWPJUIJTHAN-ZWQUELFCSA-N 9-(1,3-benzodioxol-5-yl)-6,7-dimethoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-3h-benzo[f][2]benzofuran-1-one Chemical class C1=2COC(=O)C=2C(C=2C=C3OCOC3=CC=2)=C2C=C(OC)C(OC)=CC2=C1O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O)[C@H]1O NLWUWPJUIJTHAN-ZWQUELFCSA-N 0.000 title abstract description 18
- 239000003443 antiviral agent Substances 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 216
- -1 cyano, amino, hydroxy Chemical group 0.000 claims description 136
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 128
- 239000001257 hydrogen Substances 0.000 claims description 114
- 229910052739 hydrogen Inorganic materials 0.000 claims description 114
- 229910052736 halogen Inorganic materials 0.000 claims description 111
- 150000002367 halogens Chemical class 0.000 claims description 111
- 125000000217 alkyl group Chemical group 0.000 claims description 82
- 125000004432 carbon atom Chemical group C* 0.000 claims description 82
- 125000000623 heterocyclic group Chemical group 0.000 claims description 79
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 69
- 125000003545 alkoxy group Chemical group 0.000 claims description 52
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 43
- 150000002431 hydrogen Chemical class 0.000 claims description 42
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 39
- 150000002772 monosaccharides Chemical class 0.000 claims description 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 34
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 34
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 33
- 125000000304 alkynyl group Chemical group 0.000 claims description 30
- 150000002016 disaccharides Chemical class 0.000 claims description 29
- 150000004044 tetrasaccharides Chemical class 0.000 claims description 29
- 150000004043 trisaccharides Chemical class 0.000 claims description 29
- 241001115402 Ebolavirus Species 0.000 claims description 24
- 230000009385 viral infection Effects 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 241000712461 unidentified influenza virus Species 0.000 claims description 23
- 208000036142 Viral infection Diseases 0.000 claims description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 239000001301 oxygen Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- 239000005864 Sulphur Chemical group 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 241000711573 Coronaviridae Species 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 241001115401 Marburgvirus Species 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical group B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 150000004676 glycans Polymers 0.000 claims description 5
- 150000004804 polysaccharides Polymers 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 19
- 230000036436 anti-hiv Effects 0.000 abstract description 18
- 230000003612 virological effect Effects 0.000 abstract description 17
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract description 13
- 206010022000 influenza Diseases 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 229940121357 antivirals Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 90
- 238000005160 1H NMR spectroscopy Methods 0.000 description 82
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 82
- 238000006243 chemical reaction Methods 0.000 description 80
- 241000725303 Human immunodeficiency virus Species 0.000 description 69
- 239000000243 solution Substances 0.000 description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 44
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 43
- 238000002360 preparation method Methods 0.000 description 43
- 238000004809 thin layer chromatography Methods 0.000 description 41
- 239000000047 product Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 35
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 34
- 239000003153 chemical reaction reagent Substances 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 32
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 30
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 241000700605 Viruses Species 0.000 description 25
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000011734 sodium Substances 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 22
- VMEJANRODATDOF-UHFFFAOYSA-N Diphyllin Chemical class C1=C2OCOC2=CC(C=2C=3C(=O)OCC=3C(O)=C3C=C(C(=CC3=2)OC)OC)=C1 VMEJANRODATDOF-UHFFFAOYSA-N 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 229930182470 glycoside Natural products 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 17
- 238000001816 cooling Methods 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 101710154606 Hemagglutinin Proteins 0.000 description 16
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 16
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 16
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 16
- 101710176177 Protein A56 Proteins 0.000 description 16
- 229930013686 lignan Natural products 0.000 description 16
- 235000009408 lignans Nutrition 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- RFXQCUDAHXPYOF-UHFFFAOYSA-N diphyllin Natural products COc1cc2c(c3ccc4OCOc4c3)c5C(=O)OCc5c(O)c2cc1O RFXQCUDAHXPYOF-UHFFFAOYSA-N 0.000 description 15
- 229960002819 diprophylline Drugs 0.000 description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- 229930192474 thiophene Natural products 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000000185 hemagglutinin Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 210000002845 virion Anatomy 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 150000002338 glycosides Chemical class 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 11
- 229960002555 zidovudine Drugs 0.000 description 11
- 241001473385 H5N1 subtype Species 0.000 description 10
- 208000031886 HIV Infections Diseases 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- REEHSAJWGAOIIW-UHFFFAOYSA-N 3,6-dihydro-2h-pyridine Chemical compound C1CC=CC[N]1 REEHSAJWGAOIIW-UHFFFAOYSA-N 0.000 description 9
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 0 COC1OC(*)(*)C(*)(*)C(*)(*)C1(*)* Chemical compound COC1OC(*)(*)C(*)(*)C(*)(*)C1(*)* 0.000 description 9
- 241001678559 COVID-19 virus Species 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 230000007502 viral entry Effects 0.000 description 9
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000711975 Vesicular stomatitis virus Species 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- NLWUWPJUIJTHAN-UHFFFAOYSA-N patentiflorin B Natural products C1=2COC(=O)C=2C(C=2C=C3OCOC3=CC=2)=C2C=C(OC)C(OC)=CC2=C1OC1OC(C)C(O)C(O)C1O NLWUWPJUIJTHAN-UHFFFAOYSA-N 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000711950 Filoviridae Species 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 102000005348 Neuraminidase Human genes 0.000 description 5
- 108010006232 Neuraminidase Proteins 0.000 description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
- 239000012346 acetyl chloride Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 150000005692 lignans Chemical class 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- UUHANZROYPDHAB-UHFFFAOYSA-N 2-(2-bromo-4,5-dimethoxyphenyl)-1,3-dioxolane Chemical compound C1=C(OC)C(OC)=CC(Br)=C1C1OCCO1 UUHANZROYPDHAB-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 101710205625 Capsid protein p24 Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 241000712431 Influenza A virus Species 0.000 description 4
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 101710149279 Small delta antigen Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 206010064097 avian influenza Diseases 0.000 description 4
- 125000004452 carbocyclyl group Chemical group 0.000 description 4
- 125000000837 carbohydrate group Chemical group 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 210000005265 lung cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- MCZDHTKJGDCTAE-UHFFFAOYSA-M tetrabutylazanium;acetate Chemical compound CC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC MCZDHTKJGDCTAE-UHFFFAOYSA-M 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 3
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 3
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 208000037797 influenza A Diseases 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 3
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 3
- 229960004626 umifenovir Drugs 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 description 2
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- GELKGHVAFRCJNA-UHFFFAOYSA-N 2,2-Dimethyloxirane Chemical compound CC1(C)CO1 GELKGHVAFRCJNA-UHFFFAOYSA-N 0.000 description 2
- FJMQJSUOOGOWBD-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one Chemical compound O=C1N(CC(F)(F)C)CCOC=2C1=NN(C=1C(=CC=CC=1)Cl)C=2C1=CC=C(Cl)C=C1 FJMQJSUOOGOWBD-UHFFFAOYSA-N 0.000 description 2
- WGABOZPQOOZAOI-UHFFFAOYSA-N 2-[4-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]acetic acid Chemical compound COC1=C(C)C(OC)=CC(C(=O)N(CCCC=2C=CC=CC=2)CC=2C=CC(CC(O)=O)=CC=2)=C1 WGABOZPQOOZAOI-UHFFFAOYSA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 2
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 2
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 2
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000007136 Filoviridae Infections Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061192 Haemorrhagic fever Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 244000308415 Justicia procumbens Species 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 241001115394 Reston ebolavirus Species 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001115376 Sudan ebolavirus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241001115374 Tai Forest ebolavirus Species 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 241001115400 Zaire ebolavirus Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 125000003828 azulenyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125876 compound 15a Drugs 0.000 description 2
- 229940126212 compound 17a Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 2
- 229950008454 favipiravir Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000004658 ketimines Chemical class 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- CJPMSUUANYLPET-UHFFFAOYSA-N n-[3-[[5-cyclopropyl-2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCCNC(C(=CN=1)C2CC2)=NC=1NC(C=C1)=CC=C1N1CCOCC1 CJPMSUUANYLPET-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000003408 phase transfer catalysis Methods 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- CAEWJEXPFKNBQL-UHFFFAOYSA-N prop-2-enyl carbonochloridate Chemical compound ClC(=O)OCC=C CAEWJEXPFKNBQL-UHFFFAOYSA-N 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- DGWDWLRHFOUZCX-UHFFFAOYSA-N (25R)-26-[(D-Glucopyranosyl)oxy]-2hydroxyfurosta-5,20(22)-dien-3yl O-D-glucopyranosyl-(1‘Â∆3)-O-D-glucopyranosyl-(1‘Â∆2)-O-[D-xylopyranosyl-(1‘Â∆3)]-O-D-glucopyranosyl-(1‘Â∆4)-D-ga Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(O1)=C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O DGWDWLRHFOUZCX-UHFFFAOYSA-N 0.000 description 1
- AYIYPHDKKVWZKI-LJTMIZJLSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;piperazine Chemical compound C1CNCCN1.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO AYIYPHDKKVWZKI-LJTMIZJLSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- CWRWJDAEKWYUJT-CGKXPTHNSA-N 1-(9S,13S,12-oxophytodienoyl)-2-(7Z,10Z,13Z)-hexadecatrienoyl-3-(beta-D-galactosyl)-sn-glycerol Chemical compound C([C@H](OC(=O)CCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC[C@@H]1[C@@H](C(=O)C=C1)C\C=C/CC)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O CWRWJDAEKWYUJT-CGKXPTHNSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- YRTFLDFDKPFNCJ-UHFFFAOYSA-N 1-[4-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-2-oxo-4-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,8-naphthyridin-3-yl]urea;dihydrochloride Chemical compound Cl.Cl.CC(C)C=1C=C(N)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C(C=1)=CC=CC=1OCCCN1CCCC1 YRTFLDFDKPFNCJ-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- HOWBPCMQSAYSRQ-UHFFFAOYSA-N 2,3-dimethyl-1-phenylnaphthalene Chemical compound CC=1C(C)=CC2=CC=CC=C2C=1C1=CC=CC=C1 HOWBPCMQSAYSRQ-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- CJLZUKCACMUYFP-GOSISDBHSA-N 2-[(5R)-4-[2-[3-(3-methylbutanoyloxy)phenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound CC(C)CC(=O)OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 CJLZUKCACMUYFP-GOSISDBHSA-N 0.000 description 1
- PFOQIHIIOLBCEQ-UHFFFAOYSA-N 2-[4-[2-(2,6-dimethoxyphenyl)-7-methyl-3h-benzimidazol-5-yl]piperidin-1-yl]-n-methylethanamine Chemical compound C1CN(CCNC)CCC1C1=CC(C)=C(NC(=N2)C=3C(=CC=CC=3OC)OC)C2=C1 PFOQIHIIOLBCEQ-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- UQQROBHFUDBOOK-UHFFFAOYSA-N 2-bromo-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(Br)=C(C=O)C=C1OC UQQROBHFUDBOOK-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000000850 2H-chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-M 4-chlorobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-M 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 1
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 229930191593 Alloside Natural products 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001292006 Arteriviridae Species 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000884921 Bundibugyo ebolavirus Species 0.000 description 1
- JAOGFYSXDYNYSX-UHFFFAOYSA-N CC(C)(C(N=CC(Cl)=C1)=C1C(C=CC(Cl)=C1)=C1N1C(C=C2)=CC=C2N(C2)CC2(CNC(CC2)CCC2C(O)=O)F)C1=O Chemical compound CC(C)(C(N=CC(Cl)=C1)=C1C(C=CC(Cl)=C1)=C1N1C(C=C2)=CC=C2N(C2)CC2(CNC(CC2)CCC2C(O)=O)F)C1=O JAOGFYSXDYNYSX-UHFFFAOYSA-N 0.000 description 1
- PMJUVXNBXQVOOP-BFPJFKNKSA-N CC(C)(O[C@@H]1[C@@H](CO)OC2Oc(c(CO3)c4C3=O)c(cc(c(OC)c3)OC)c3c4-c(cc3)cc4c3OCO4)O[C@@H]1[C@H]2O Chemical compound CC(C)(O[C@@H]1[C@@H](CO)OC2Oc(c(CO3)c4C3=O)c(cc(c(OC)c3)OC)c3c4-c(cc3)cc4c3OCO4)O[C@@H]1[C@H]2O PMJUVXNBXQVOOP-BFPJFKNKSA-N 0.000 description 1
- PPAUVLHMIQCXGY-WBZIQRTNSA-N CC(C)(O[C@H]12)O[C@H]1C(Oc(c(CO1)c3C1=O)c(cc(c(O)c1)O)c1c3-c(cc1)cc(OC3)c1[O]3=C)O[C@H](CO)[C@@H]2O Chemical compound CC(C)(O[C@H]12)O[C@H]1C(Oc(c(CO1)c3C1=O)c(cc(c(O)c1)O)c1c3-c(cc1)cc(OC3)c1[O]3=C)O[C@H](CO)[C@@H]2O PPAUVLHMIQCXGY-WBZIQRTNSA-N 0.000 description 1
- WKELRQBASNTBAF-XNAWRJNDSA-N CC(O[C@@H]([C@@H](COC1Oc(c(CO2)c3C2=O)c(cc(c(OC)c2)OC)c2c3-c(cc2)cc3c2OCO3)O)[C@H]1O)=O Chemical compound CC(O[C@@H]([C@@H](COC1Oc(c(CO2)c3C2=O)c(cc(c(OC)c2)OC)c2c3-c(cc2)cc3c2OCO3)O)[C@H]1O)=O WKELRQBASNTBAF-XNAWRJNDSA-N 0.000 description 1
- KDSXWRMGIMENBF-ZGLLQENJSA-N CC(O[C@H]([C@H]1O)C(Oc(c(CO2)c3C2=O)c(cc(c(OC)c2)OC)c2c3-c(cc2)cc3c2OCO3)OC[C@H]1O)=O Chemical compound CC(O[C@H]([C@H]1O)C(Oc(c(CO2)c3C2=O)c(cc(c(OC)c2)OC)c2c3-c(cc2)cc3c2OCO3)OC[C@H]1O)=O KDSXWRMGIMENBF-ZGLLQENJSA-N 0.000 description 1
- ACXBSYBPNYAAIL-VIEDPAQBSA-N CCC(O[C@@H]([C@@H]([C@@H](C)OC1Oc(c(CO2)c3C2=O)c(cc(c(OC)c2)OC)c2c3-c(cc2)cc3c2OCO3)O)[C@H]1O)=O Chemical compound CCC(O[C@@H]([C@@H]([C@@H](C)OC1Oc(c(CO2)c3C2=O)c(cc(c(OC)c2)OC)c2c3-c(cc2)cc3c2OCO3)O)[C@H]1O)=O ACXBSYBPNYAAIL-VIEDPAQBSA-N 0.000 description 1
- OQWJGIIYAKDRGA-RLSZKKORSA-N CCCC(C(C1)C1([C@@H]([C@@H](C)OC1Oc(c(CO2)c3C2=N)c(cc(c(O)c2)O)c2c3-c2ccc3OCOc3c2)O)[C@H]1O)=O Chemical compound CCCC(C(C1)C1([C@@H]([C@@H](C)OC1Oc(c(CO2)c3C2=N)c(cc(c(O)c2)O)c2c3-c2ccc3OCOc3c2)O)[C@H]1O)=O OQWJGIIYAKDRGA-RLSZKKORSA-N 0.000 description 1
- GSVQAXUULKGRBP-ASVSOPFUSA-N COC(C([C@@H](C1O)[O]=C)C=C)O[C@H]1C=C Chemical compound COC(C([C@@H](C1O)[O]=C)C=C)O[C@H]1C=C GSVQAXUULKGRBP-ASVSOPFUSA-N 0.000 description 1
- XZAPQHJFKOVKAV-FVTPLPSFSA-N COC([C@@H](C12CC1)[O]=C)OC(C1)(C1[O]=C)[C@H]2[O]=C Chemical compound COC([C@@H](C12CC1)[O]=C)OC(C1)(C1[O]=C)[C@H]2[O]=C XZAPQHJFKOVKAV-FVTPLPSFSA-N 0.000 description 1
- WUZBOJXXYMKMMF-UHFFFAOYSA-N COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F Chemical compound COC1=CC2=NC=3N(C(N(C(C=3N2C=C1)=O)CCC)=O)CCCCNC(=O)C1=CC=C(C=C1)S(=O)(=O)F WUZBOJXXYMKMMF-UHFFFAOYSA-N 0.000 description 1
- AVYGDWFATMFGNJ-OSMSZNLCSA-N COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2O)O)OC[C@@H]2O)cc1c3-c1ccc2OCOc2c1 Chemical compound COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2O)O)OC[C@@H]2O)cc1c3-c1ccc2OCOc2c1 AVYGDWFATMFGNJ-OSMSZNLCSA-N 0.000 description 1
- BJGIWVGXMRUMNA-IHXSGJAZSA-N COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2O)O)O[C@H](CO)[C@@H]2O)cc1c3-c1ccc2OCOc2c1 Chemical compound COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2O)O)O[C@H](CO)[C@@H]2O)cc1c3-c1ccc2OCOc2c1 BJGIWVGXMRUMNA-IHXSGJAZSA-N 0.000 description 1
- BJGIWVGXMRUMNA-PZKZUJNYSA-N COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2O)O)O[C@H](CO)[C@H]2O)cc1c3-c(cc1)cc2c1OCO2 Chemical compound COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2O)O)O[C@H](CO)[C@H]2O)cc1c3-c(cc1)cc2c1OCO2 BJGIWVGXMRUMNA-PZKZUJNYSA-N 0.000 description 1
- VZRGWTDVBFZZEV-HZMKUAPKSA-N COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2OCc4ccccc4)O)OC[C@H]2O)cc1c3-c(cc1)cc2c1OCO2 Chemical compound COc(c(OC)cc1c(c(CO2)c3C2=O)OC([C@@H]([C@H]2OCc4ccccc4)O)OC[C@H]2O)cc1c3-c(cc1)cc2c1OCO2 VZRGWTDVBFZZEV-HZMKUAPKSA-N 0.000 description 1
- ZFHVDBYFZIXVSJ-NQTXRORDSA-N CS(OC(CC12CC1)OC[C@H]2[O]=C)=C Chemical compound CS(OC(CC12CC1)OC[C@H]2[O]=C)=C ZFHVDBYFZIXVSJ-NQTXRORDSA-N 0.000 description 1
- NLWUWPJUIJTHAN-AOFWZXPXSA-N C[C@H]([C@H]([C@@H]([C@H]1O)O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c(cc1)cc2c1OCO2 Chemical compound C[C@H]([C@H]([C@@H]([C@H]1O)O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c(cc1)cc2c1OCO2 NLWUWPJUIJTHAN-AOFWZXPXSA-N 0.000 description 1
- LPFRJCOBFJCTPR-DVUYIIRHSA-N C[C@H]([C@H]([C@@H]([C@H]1O)OC(C(Cl)(Cl)Cl)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c(cc1)cc2c1OCO2 Chemical compound C[C@H]([C@H]([C@@H]([C@H]1O)OC(C(Cl)(Cl)Cl)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c(cc1)cc2c1OCO2 LPFRJCOBFJCTPR-DVUYIIRHSA-N 0.000 description 1
- PQKYLPCOLHZBIB-HWPQXJAQSA-N C[C@H]([C@H]([C@@H]([C@H]1O)OC(C2CC2)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c1ccc2OCOc2c1 Chemical compound C[C@H]([C@H]([C@@H]([C@H]1O)OC(C2CC2)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c1ccc2OCOc2c1 PQKYLPCOLHZBIB-HWPQXJAQSA-N 0.000 description 1
- HESRNHJTGGQWLT-VKBMDKMWSA-N C[C@H]([C@H]([C@@H]([C@H]1O)OC(c(cc2)ccc2Cl)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c1ccc2OCOc2c1 Chemical compound C[C@H]([C@H]([C@@H]([C@H]1O)OC(c(cc2)ccc2Cl)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c1ccc2OCOc2c1 HESRNHJTGGQWLT-VKBMDKMWSA-N 0.000 description 1
- DKXSXUPHPAYYOP-KOVUKBGHSA-N C[C@H]([C@H]([C@@H]([C@H]1O)OC(c2nccnc2)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c(cc1)cc2c1OCO2 Chemical compound C[C@H]([C@H]([C@@H]([C@H]1O)OC(c2nccnc2)=O)O)OC1Oc(c(CO1)c2C1=O)c(cc(c(OC)c1)OC)c1c2-c(cc1)cc2c1OCO2 DKXSXUPHPAYYOP-KOVUKBGHSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000560067 HIV-1 group M Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000207984 Justicia Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100518544 Mus musculus Otud6a gene Proteins 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZWGCVJJBVVAFDS-VERBTTMYSA-N O[C@@H](C(Oc(c(CO1)c2C1=O)c(cc(c(O)c1)O)c1c2-c1ccc2OCOc2c1)OC12CC1)C(C1)(C1C(c1ccccc1)=O)[C@@H]2O Chemical compound O[C@@H](C(Oc(c(CO1)c2C1=O)c(cc(c(O)c1)O)c1c2-c1ccc2OCOc2c1)OC12CC1)C(C1)(C1C(c1ccccc1)=O)[C@@H]2O ZWGCVJJBVVAFDS-VERBTTMYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000271569 Rhea Species 0.000 description 1
- 241001534527 Roniviridae Species 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PNNNRSAQSRJVSB-KCDKBNATSA-N aldehydo-L-fucose Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-KCDKBNATSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000008181 allosides Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011950 automated reagin test Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004045 azirinyl group Chemical group 0.000 description 1
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WWIWLTSSHDKOKO-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 WWIWLTSSHDKOKO-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005303 dithiazolyl group Chemical group S1SNC(=C1)* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229930182479 fructoside Natural products 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000008272 galactosaminides Chemical class 0.000 description 1
- 125000000457 gamma-lactone group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000008271 glucosaminides Chemical class 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008149 gulosides Chemical group 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000002436 one-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 229960002194 oseltamivir phosphate Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229940081310 piperonal Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000008265 rhamnosides Chemical class 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 238000003210 sulforhodamine B staining Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000008202 talosides Chemical class 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 150000008248 threosides Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- 150000008501 α-D-glucopyranosides Chemical class 0.000 description 1
- 150000008505 β-D-glucopyranosides Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- the present disclosure generally relates to the arylnaphthalene glycoside derivatives, the process for their preparation, and their use as antiviral agents. More particularly, the present disclosure relates to patentiflorin A analogs that are useful as antiviral agents, such as anti-HIV, anti-coronaviral, anti-Ebola viral, anti-Marburg viral, and anti-influenza viral agents.
- the present disclosure also provides methods for treating viral infections, such as HIV, coronaviruses, Ebola virus, Marburg virus and influenza viruses infections.
- Viruses are important etiologic agents that cause infectious diseases in humans and other mammals. They differ greatly in size, shape, chemical composition, host range, and effects on hosts. After decades of studies, only a limited number of antiviral agents are available for the treatment and/or prevention of diseases caused by viruses such as HIV, coronaviruses, Ebola, Marburg, influenza A and B and hepatitis C viruses. Because of their toxic effects on a host, many antiviral agents are limited in their application. Drug resistance is often very quickly developed against the antiviral agent, and many viral diseases, such as HIV have no vaccines available to treat or prevent them. Accordingly, there is a need for safe and effective antiviral agents against a wide-spectrum of viruses with no or low toxicity to the host.
- NRTIs nucleoside reverse transcriptase inhibitors
- NRTIs non-nucleoside reverse transcriptase inhibitors
- PIs protease inhibitors
- entry and fusion inhibitors entry and fusion inhibitors
- HIV integrase strand transfer inhibitors HIV integrase strand transfer inhibitors.
- Influenza a severe viral infection of the respiratory system, remains a major threat to human health.
- the worldwide outbreak of highly pathogenic H5N1 subtype of avian influenza virus (AIV) and the recent appearance of new type human influenza A/H1N1 have heightened public awareness of potential global influenza pandemics.
- AIV can also infect wild birds, pigs, cats, humans, and other animals.
- Three drugs, Xofluza, zanamivir and oseltamivir phosphate have been approved for the treatment of influenza.
- the low oral bioavailability and rapid renal elimination of zanamivir, and the rapid emergence of oseltamivir-resistant influenza viruses have prompted the further development of more potent, longer duration therapeutic drugs to combat potential human influenza pandemics.
- Viruses belonging to Filoviridae contain minus-strand RNA as their genome. There are two genera, namely Marburgvirus and Ebolavirus, under the Filoviridae family. Marburg virus is the only member in Marburgvirus genus. There are five members in Ebolavirus genus, namely Zaire ebolavirus, Sudan ebolavirus, Cote d’Irete ebolavirus, Reston ebolavirus and Bundibugyo. Owning to their pathogenic potential, high case mortality rate and the lack of effective therapeutics for infected humans, the members of family Filoviridae have been classified as "biosafety level 4" agents. The infection of filovirus may lead to hemorrhagic fever.
- Coronaviruses are enveloped, single-stranded, positive-sense RNA virus, which include Coronaviridae, Arteriviridae, and Roniviridae families.
- SARS-CoV-2 that causes the current COVID-19 pandemic, is a ⁇ -coronavirus.
- CoVs There have been six CoVs identified as human-susceptible viruses. Two of them, SARS-CoV and MERS-CoV, could lead to severe or even fatal respiratory tract infections. As of August 21, 2020, the COVID-19 epidemic has caused 797, 428 deaths among over 15.5 million infected cases.
- the present disclosure relates to a new class of patentiflorin A analogs, the preparation of these compounds and new intermediates, and their use for treatment of viral infections, such as HIV, CoV, EBOV and AIV.
- a compound in the manufacture of a medicament for treating a viral infection wherein the compound has the Formula (I) :
- X is oxygen or sulphur
- R 1 is R 15 , -OR 15 , -C (O) R 15 , or -C (O) OR 15 ;
- R 3 and R 4 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15 ; or R 3 and R 4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ;
- R 7 , R 8 , and R 9 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15 ; or R 7 and R 8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ; or R 8 and R 9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ;
- R 17 and R 18 for each occurrence are independently hydrogen, alkyl, alkynyl, cycloalkyl, aryl, or heteroaryl, or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy;
- each of R 3 and R 4 is -O-alkyl; R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring;
- the viral infection is selected from the group consisting of HIV, coronaviruses, influenza viruses, Ebola virus, and Marburg virus.
- R 1 is alkynyl, pinacolboryl, -OCH 2 -cyano, -OCH 2 -C (O) N (R 17 ) R 18 , or -OCH 2 -C (O) OR 17 ; each of R 3 and R 4 is -OCH 3 ; R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; R 11 and R 12 taken together form oxo; and the viral infection is HIV.
- R 1 is a glycosidic group represented by the Formula (V) :
- R 19 and R 20 taken together to form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ;
- R 21 and R 22 taken together to form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 21 and R 22 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ; or R 20 and R 22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ;
- R 25 and R 26 taken together form oxo; or while one of R 25 and R 26 is hydrogen or halogen, the other one of R 25 and R 26 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , -OC (O) OR 27 , -CH 2 R 27 , and -C (O) R 27 ; or R 24 and R 26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ;
- the glycloside is a monosacchairde selected from the group consisting of an ⁇ -L isomer and an ⁇ -L isomer.
- the compound is selected from the group consisting of 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
- the viral infection is selected from the group consisting of HIV, coronaviruses, influenza viruses, Ebola virus, and Marburg virus.
- each of R 3 and R 4 is -OCH 3 ;
- R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring;
- R 11 and R 12 taken together form oxo;
- R 19 , R 21 , R 23 , and R 25 are each hydrogen;
- R 20 , R 22 , and R 24 are each independently selected from the group consisting of -OR 27 , -OC (O) N (R 27 ) R 27 , -OC (O) R 27 and -OC (O) OR 27 ;
- R 26 is hydrogen, methyl, -OR 27 , -OC (O) R 27 or -CH 2 -OC (O) R 27 ; or
- R 20 and R 22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1 or 2 group (s) independently selected from C 1-6 alkyl; or R 22 and R 24 taken together with the carbon
- R 1 is R 15 , -OR 15 , -C (O) R 15 , or -C (O) OR 15 ;
- R 2 , R 5 , R 6 , R 10 , R 13 , and R 14 are each hydrogen;
- R 3 and R 4 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15 ; or R 3 and R 4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;
- R 7 , R 8 , and R 9 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15 ; or R 7 and R 8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; or R 8 and R 9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;
- R 11 and R 12 taken together form oxo; or while one of R 11 and R 12 is hydrogen or halogen, the other one of R 11 and R 12 is selected from the group consisting of R 15 , -OR 15 , -C (O) R 15 and -C (O) OR 15 ;
- the compound of Formula (I) is not a compound selected from the group consisting of 5, 15a, 15b, 16, 17b, 19d, 25a-25g, and 26a-26g:
- each of R 3 and R 4 is -O-alkyl; R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; and R 11 and R 12 taken together form oxo.
- R 1 is alkynyl, pinacolboryl; -N (R 17 ) R 18 , -OCH 2 -cyano, -OCH 2 -alkynyl, -OCH 2 -C (O) N (R 17 ) R 18 , or -OCH 2 -C (O) OR 17 .
- the compound is selected from the group consisting of 12a, 12b, 13, 14a, 14b, 17a, 17c, 17d, 17e, 17f, 17g, 17h, 18, 19a, 19b, 19c, 19e, 19f, 19g, 19h, 19i, 19j, 19k, 19l, 19m, 19n, 19o, 19p, 20, 21, 22, 23 and 24:
- R 1 is a glycosidic group selected from the group consisting of a monosaccharide, disaccharide, trisaccharide, tetrasaccharide and polysaccharide group containing less than 30 monosaccharides, wherein the glycosidic group comprises one or more monosacchairdes isomers selected from the group consisting of ⁇ -D, ⁇ -L, ⁇ -D, and ⁇ -L.
- R 1 is a glycosidic group represented by the Formula (V) :
- R 19 and R 20 taken together to form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ;
- R 21 and R 22 taken together to form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 21 and R 22 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ; or R 20 and R 22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;
- R 23 and R 24 taken together to form oxo; or while one of R 23 and R 24 is hydrogen or halogen, the other one of R 23 and R 24 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ; or R 22 and R 24 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;
- R 25 and R 26 taken together to form oxo; or while one of R 24 and R 25 is hydrogen or halogen, the other one of R 25 and R 26 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , -OC (O) OR 27 , -CH 2 R 27 , and -C (O) R 27 ; or R 24 and R 26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;
- R 27 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , -N (R 29 ) S (O) 2 R 30 , hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28 , heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28 , and - (CH 2 ) k -heterocycly
- R 29 and R 30 for each occurrence areeach independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- R 19 , R 21 , R 23 , and R 25 are each hydrogen;
- R 20 , R 2 , and R 24 are each independently selected from the group consisting of -OR 27 , -OC (O) N (R 27 ) R 27 , -OC (O) R 27 and -OC (O) OR 27 ;
- R 26 is hydrogen, methyl, -OR 27 , -OC (O) R 27 , or -CH 2 -OC (O) R 27 ; or
- R 20 and R 22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; or
- R 22 and R 24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C
- the glycloside is a monosacchairde selected from the group consisting of an ⁇ -L isomer and an ⁇ -L isomer.
- the compound is selected from the group consisting of 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
- a pharmaceutical composition comprising a compound as described herein and at least one pharmaceutically acceptable excipient.
- arylnaphthalene lignan compounds having the general Formula (I) or (II) or a pharmaceutically acceptable salt or pro-drug thereof, for use in the treatment, prevention or delay of progression of a virus infection in a patient.
- X is oxygen or sulphur
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, boron, nitrogen, oxygen, silicon and sulphur; or R 2 and R 3 , R 3 and R 4 , R 4 and R 5 , R 6 and R 7 , R 7 and R 8 , R 8 and R 9 or R 9 and R 10 may be taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen and a moiety comprising 1 to 30 plural valence atoms selected from carbon, boron, nitrogen, oxygen, silicon, and sulphur;
- R 11 and R 12 taken together form oxo; or while one of R 11 and R 12 is hydrogen or halogen, the other one of R 11 and R 12 is selected from R 15 , -OR 15 , -C (O) R 15 and -C (O) OR 15 ;
- R 13 and R 14 taken together form oxo; or while one of R 13 and R 14 is hydrogen or halogen, the other one of R 13 and R 14 is selected from R 15 , -OR 15 , -C (O) R 15 and -C (O) OR 15 ;
- R 15 is independently selected from hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 17 , -C (O) R 18 , -C (O) N (R 17 ) R 18 , -C (O) OR 17 , -OC (O) R 17 , -S (O) 2 R 17 , -S (O) 2 N (R 17 ) R 18 , -N (R 17 ) R 18 , -N (R 17 ) N (R 17 ) R 18 , -N (R 17 ) C (O) R 18 , -N (R 17 ) S (O) 2 R 18 , hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 , heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 , and - (CH 2 ) k -heterocyclyl optionally substituted with 1, 2, 3,
- R 17 and R 18 are each independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy; and
- R is hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- the present disclosure also provides an arylnaphthalene lignan compound having the general Formula (III) or (IV) or a pharmaceutically acceptable salt or pro-drug thereof, for use in the treatment, prevention or delay of progression of a virus infection in a patient.
- X is oxygen or sulphur
- the glycosidic group is generally a carbohydrate group, especially a monosaccharide, disaccharide, trisaccharide, tetrasaccharide or polysaccharide group, and may exist in various isomeric forms, for example ⁇ -D, ⁇ -L, ⁇ -D or ⁇ -L forms; the carbohydrate group may be optionally substituted with other type of substituents or even additional glycosidic groups; the total number of monosaccharide and substituted monosaccharide contained in the chemical structure of the compound of Formula (III) and Formula (IV) may not exceed 30;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur; or R 1 and R 2 , R 2 and R 3 , R 3 and R 4 , R 5 and R 6 , R 6 and R 7 , R 7 and R 8 , R 8 and R 9 may be taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur;
- R 10 and R 11 may be taken together to form oxo; or while one of R 10 and R 11 is hydrogen or halogen, the other one of R 10 and R 11 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , and -C (O) OR 27 ;
- R 12 and R 13 may be taken together to form oxo; or while one of R 12 and R 13 is hydrogen or halogen, the other one of R 12 and R 13 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , and -C (O) OR 27 ;
- R 19 and R 20 taken together to form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
- R 21 and R 22 taken together to form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 21 and R 22 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
- R 23 and R 24 taken together form oxo; or while one of R 23 and R 24 is hydrogen or halogen, the other one of R 23 and R 24 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
- R 25 and R 26 taken together form oxo; or while one of R 25 and R 26 is hydrogen or halogen, the other one of R 25 and R 26 is selected from R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , -CH 2 R 31 and -C (O) R 31 ;
- R 27 is independently selected from hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , and -N (R 29 ) S (O) 2 R 30 , hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R 28 , heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R 28 , and - (CH 2 ) k -hetero
- R 29 and R 30 are each independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, cyano, amino, hydroxy, C 1-6 alkyl, and C 1-6 alkoxy;
- R 31 is independently selected from hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , -N (R 29 ) S (O) 2 R 30 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, substituted tetrasaccharide, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s)
- R is hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- a fourth aspect of the invention is a pharmaceutical formulation comprising an arylnaphthalene lignan compound, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
- a fifth aspect of the invention is a pharmaceutical formulation comprising a glycosidic arylnaphthalene lignan compound, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
- a sixth aspect of the invention is a pharmaceutical formulation comprising a diphyllin analog, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
- a seventh aspect of the invention is a pharmaceutical formulation comprising a patentiflorin A analog, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
- Another aspect of the invention concerns the method to provide synthesis of new arylnaphthalene lignan compounds as well as the intermediate compounds during the synthesis.
- the invention is directed to an intermediary compound useful in preparing other compounds of the invention.
- Compounds of the invention may exist in different forms, such as free acids, free bases, esters and other prodrugs, salts and tautomers, and the disclosure includes all variant forms of these compounds.
- the extent of protection includes counterfeit or fraudulent products which contain or purport to contain a compound of the invention irrespective of whether they do in fact contain such a compound and irrespective of whether any such compound is contained in a therapeutically effective amount.
- packages which include a description or instructions which indicate that the package contains a species or pharmaceutical formulation of the invention and a product which is or comprises, or purports to be or comprise, such a formulation or species.
- packages may be, but are not necessarily, counterfeit or fraudulent.
- Figure 1 shows the structure and carbon numbering of patentiflorin A and schematic preparation of diphyllin (5) .
- Figure 2 shows schematic preparation of diphyllin analogs 12-17 (for preparation of compound 14a, the reaction reagents and conditions of a: NH 4 Cl, HATU, Et 3 N, CH 2 Cl 2 ; for preparation of compound 14b, the reaction reagents and conditions of b: MeNH 2 , EDCI, HOBt and THF; for preparation of compound 15a, the reaction reagents and conditions of c: PdCl 2 , K 2 CO 3 , TBAB, H 2 O, 60°C; for preparation of compound 15b, the reaction reagents and conditions of d: Cs 2 CO 3 , DMF, 120°C; for preparation of compounds 17a-17c, the reaction reagents and conditions of e: Cs 2 CO 3 , acetone, r.t.; for preparation of compounds 17d, the reaction reagents and conditions of f: K 2 CO 3 , DMF, 100°C; for preparation of compounds 17e-17h, the reaction reagents and conditions of
- Figure 3 shows schematic preparation of diphyllin analogs 18-24 (for preparation of compound 19a, the reaction reagents and conditions of a: [Pd (dppf) Cl 2 ] CH 2 Cl 2 , KOAc, B 2 (Pin) 2 , dioxane, 100°C; for preparation of compound 19b, the reaction reagents and conditions of b: [Pd (dppf) Cl 2 ] CH 2 Cl 2 , AlMe 3 , toluene, 100°C; for preparation of compound 19c, the reaction reagents and conditions of c: [Pd (dppf) Cl 2 ] CH 2 Cl 2 , Na 2 CO 3 , pyridine-4-boronic acid, H 2 O, Dioxane, 100°C; for preparation of compound 19d, the reaction reagents and conditions of d: Pd (OAc) 2 , PPh 3 , Et 3 N, HCO 2 H, DMF, 100°C; for preparation of compounds 19e and 19f,
- FIG 4 shows schematic preparation of patentiflorin A analogs 25a-25g and 26a-26g.
- Compounds 26a, 26b, 26c, 26d, 26e, 26f and 26g are produced from 25a, 25b, 25c, 25d, 25e, 25f and 25g, respectively.
- Figure 5 shows schematic preparation of patentiflorin A analogs 27aa-27af, 27ba-27bf, 28ab1-28ab3, 28bb1-28bb3, 29a, 29b, 30a-30l and 31a-31l (for preparation of compounds 27aa-27af and 27ba-27bf, the reaction reagents and conditions of a: Ac 2 O, TBAOAc, MeCN, 40°C; for preparation of compounds 28ab1 to 28ab3 and 28bb1 to 28bb3, the reaction reagents and conditions of b: AllocOCl, Et 3 N, CH 2 Cl 2 , 0°C to r.t.; for preparation of compounds 29a and 29b, the reaction reagents and conditions of c: AcCl, CH 2 Cl 2 , MeOH, 0°C to r.t.; for preparation of compounds 30a-k, the reaction reagents and conditions of d: Et 3 N, DMAP, dry CH 2 Cl 2 , 0
- Compounds 27aa, 27ab, 27ac, 27ad, 27ae and 27af are produced from 26a.
- Compounds 27ba, 27bb, 27bc, 27bd, 27be and 27bf are produced from 26b.
- Compounds 28ab1, 28ab2 and 28ab3 are produced from 27ab.
- Compounds 28bb1, 28bb2 and 28bb3 are produced from 27bb.
- Compounds 29a and 29b are produced from 28ab3 and 28bb3, respectively.
- Compounds 30a and 30l are produced from 29a.
- Compounds 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j and 30k are produced from 29b.
- Compounds 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k and 31l are produced from 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k and 30l, respectively.
- FIG 6 shows schematic preparation of patentiflorin A analogs 32a-32d.
- Compounds 32a is produced from 26f.
- Compounds 32b-32d are produced from 26g.
- a “subject” is meant an individual.
- the “subject” can include domesticated animals (e.g., cats, dogs, etc. ) , livestock (e.g., cattle, horses, pigs, sheep, goats, etc. ) , laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc. ) , and birds.
- “Subject” can also include a mammal, such as a primate or a human.
- reduce or other forms of the word, such as “reducing” or “reduction, ” is meant lowering of an event or characteristic (e.g., tumor growth) . It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces tumor growth” means reducing the rate of growth of a tumor relative to a standard or a control.
- prevent or other forms of the word, such as “preventing” or “prevention, ” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed.
- treat or other forms of the word, such as “treated” or “treatment, ” is meant to administer a composition or to perform a method in order to reduce, prevent, inhibit, or eliminate a particular characteristic or event (e.g., tumor growth or survival) .
- control is used synonymously with the term “treat. ”
- terapéuticaally effective means the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.
- salts refers to any salt of the compound of this invention which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use.
- Such salts may be derived from a variety of organic and inorganic counterions well known in the art and include them.
- Such salts include: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3- (4-hydroxybenzoyl) benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1, 2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulf
- salts include sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrohalides (e.g., hydrochloride and hydrobromide) , sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate; fumarate, tartarate, citrate, benzoate, 3- (4-hydroxybenzoyl) benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate) , ethanesulfonate, 1,
- glycoside or “glycosidic” compound as used herein is interchangeable and includes reference to any of the class of compounds that yield a sugar and an aglycone upon hydrolysis.
- ANL or “aryl naphthalene lignan” or “arylnaphthalene lignan” compound as used herein is interchangeable.
- aryl naphthalene lignan or “arylnaphthalene lignan” or “ANL” as used herein includes reference to a compound comprising the basic structure of 2, 3-dimethyl-1-phenyl-naphthalene shown as below:
- aryl naphthalene lignan molecule as used herein includes reference to a compound comprising numbering system shown as below:
- the two methyl groups are forming a ⁇ -lactone ring to become as aryl naphthofuran-2-one lignan or aryl naphthofuran-3-one lignan shown as below:
- the carbon numbering of an aryl naphthalene lignan glycoside molecule as used herein includes reference to a compound comprising numbering system shown as below:
- hydrocarbyl as used herein includes reference to a moiety consisting exclusively of hydrogen and carbon atoms; such a moiety may comprise an aliphatic and/or an aromatic moiety. The moiety may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms.
- hydrocarbyl groups include C 1-6 alkyl (e.g. C 1 , C 2 , C 3 or C 4 alkyl, for example methyl, ethyl, propyl, isopropyl. n-butyl, sec-butyl or tert-butyl) ; C 1-6 alkyl substituted by aryl (e.g.
- benzyl or by cycloalkyl (e.g. cyclopropylmethyl) ; cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) ; aryl (e.g. phenyl, naphthyl or fluorenyl) ; C 1-6 alkenyl (e.g. ethenyl, 2-propenyl or 3-butenyl) ; C 1-6 alkynyl (e.g. ethynyl, 2-propynyl or 3-butynyl) and the like.
- cycloalkyl e.g. cyclopropylmethyl
- cycloalkyl e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl
- aryl e.g. phenyl, naphthyl or fluoreny
- alkyl and C 1-6 alkyl as used herein include reference to a straight or branched chain alkyl moiety having 1, 2, 3, 4, 5 or 6 carbon atoms. This term includes reference to groups such as methyl, ethyl, propyl (n-propyl or isopropyl) , butyl (n-butyl, sec-butyl or tert-butyl) , pentyl, hexyl and the like.
- the alkyl moiety may have 1, 2, 3 or 4 carbon atoms.
- alkenyl as used herein include reference to a straight or branched chain alkyl moiety having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and having, in addition, at least one double bond, of either E or Z stereochemistry where applicable. This term includes reference to groups such as ethenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1-hexenyl, 2-hexenyl and 3-hexenyl and the like.
- alkynyl as used herein include reference to a straight or branched chain alkyl moiety having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and having, in addition, at least one triple bond. This term includes reference to groups such as ethynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 1-hexynyl, 2-hexynyl and 3-hexynyl and the like.
- alkoxy and C 1-6 alkoxy as used herein include reference to -O-alkyl, wherein alkyl is straight or branched chain and comprises 1, 2, 3, 4, 5 or 6 carbon atoms. In one class of embodiments, alkoxy has 1, 2, 3 or 4 carbon atoms. This term includes reference to groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tertbutoxy, pentoxy, hexoxy and the like.
- cycloalkyl as used herein includes reference to an alicyclic moiety having 3, 4, 5, 6, 7 or 8 carbon atoms.
- the group may be a bridged or polycyclic ring system. More often cycloalkyl groups are monocyclic. This term includes reference to groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbomyl, bicyclo [2.2.2] octyl and the like.
- aryl as used herein includes reference to an aromatic ring system comprising 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring carbon atoms.
- Aryl is often phenyl but may be a polycyclic ring system, having two or more rings, at least one of which is aromatic. This term includes reference to groups such as phenyl, naphthyl, fluorenyl, azulenyl, indenyl, anthryl and the like.
- Cyclic group means a ring or ring system, which may be unsaturated or partially unsaturated but is usually saturated, typically containing 5 to 13 ring-forming atoms, for example a 5-or 6-membered ring. It includes carbocyclyl and heterocyclyl moeities.
- carbocyclyl as used herein includes reference to a saturated (e.g. cycloalkyl) or unsaturated (e.g. aryl) ring moiety having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 carbon ring atoms.
- carbocyclyl includes a 3-to 10-membered ring or ring system and, in particular, 5-or 6-membered rings, which may be saturated or unsaturated.
- a carbocyclic moiety is, for example, selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbomyl, bicyclo [2.2.2] octyl, phenyl, naphthyl, fluorenyl, azulenyl, indenyl, anthryland the like.
- heterocyclyl as used herein includes reference to a saturated (e.g. heterocycloalkyl) or unsaturated (e.g. heteroaryl) heterocyclic ring moiety having from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms, at least one of which is selected from boron, nitrogen, oxygen, phosphorus, silicon and sulphur.
- heterocyclyl includes a 3-to 10-membered ring or ring system and more particularly a 5 or 6-membered ring, which may be saturated or unsaturated.
- a heterocyclic moiety is, for example, selected from oxiranyl, azirinyl, 1.2-oxathiolanyl, imidazolyl, thienyl, furyl, tetrahydrofuryl, pyranyl, thiopyranyl, thianthrenyl, isobenzofuranyl, benzofuranyl, chromenyl, 2H-pyrrolyl pyrrolyl pyrrolinyl, pyrrolidinyl, pyrrolizidinyl, imidazolyl, imidazolidinyl, benzimidazolyl, pyrazolyl pyrazinyl, pyrazolidinyl, thiazolyl, isothiazolyl, dithiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, piperidyl, piperazinyl, pyridazinyl, morpholiny
- heterocycloalkyl as used herein includes reference to a saturated heterocyclic moiety having 3, 4, 5, 6 or 7 ring carbon atoms and 1, 2, 3, 4 or 5 ring heteroatoms selected from nitrogen, oxygen, phosphorus and sulphur.
- the group may be a polycyclic ring system but more often is monocyclic.
- This term includes reference to groups such as azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxiranyl, pyrazolidinyl, imidazolyl, indolizidinyl, piperazinyl, thiazolidinyl, morpholinyl, thiomorpholinyl, quinolizidinyl and the like.
- heteroaryl as used herein includes reference to an aromatic heterocyclic ring system having 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms, at least one of which is selected from nitrogen, oxygen and sulphur.
- the group may be a polycyclic ring system, having two or more rings, at least one of which is aromatic, but is more often monocyclic.
- This term includes reference to groups such as pyrimidinyl, furanyl, benzobthiophenyl, thiophenyl, pyrrolyl, imidazolyl, pyrrolidinyl, pyridinyl, benzobfuranyl, pyrazinyl, purinyl, indolyl, benzimidazolyl, quinolinyl, phenothiazinyl, triazinyl, phthalazinyl, 2H-chromenyl, oxazolyl, isoxazolyl, thiazolyl, isoindolylindazolyl, purinyl, isoquinolinyl, quinazolinyl, pteridinyl and the like.
- halogen as used herein includes reference to F, Cl, Br or I.
- halogen containing moiety as used herein includes reference to a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur which moiety includes at least one halogen.
- the moiety may be hydrocarbyl for example C 1-6 alkyl or C 1-6 alkoxy, or carbocyclyl for example aryl.
- substituted as used herein in reference to a moiety means that one or more, especially up to 5, more especially 1, 2 or 3, of the hydrogen atoms in said moiety are replaced independently of each other by the corresponding number of the described substituents.
- optionally substituted as used herein means substituted or un-substituted. It will, of course, be understood that substituents are only at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort whether a particular substitution is possible.
- moieties are described as being “each independently” selected from a list of atoms or groups, this means that the moieties may be the same or different. The identity of each moiety is therefore independent of the identities of the one or more other moieties.
- enantiomer as used herein means one of two stereoisomers that have mirror images of one another.
- stereoisomer as used herein means one of class of isomeric molecules that have the same molecular formula and sequence of bonded atoms, but different three-dimensional orientations of their atoms in space.
- tautomer means isomeric molecules that readily interconvert by a chemical reaction. The reaction commonly results in the migration of a hydrogen atom, which results in a switch of a single bond and adjacent double bond.
- a prodrug is a medication that is administered as an inactive (or less than fully active) chemical derivative that is subsequently converted to an active pharmacological agent in the body, often through normal metabolic processes.
- CC 50 is a cytotoxicity measure of the concentration for a test drug to inhibit cell growth by 50%.
- EC 50 is an antiviral activity measure of the effective concentration for a test drug to inhibit viral growth by 50% .
- SI selectivity index
- the symbol in a chemical structure represents a position from where the specified chemical structure is bonded to another chemical structure.
- the symbol “ ⁇ ” in a chemical structure indicates that the bond connection is above (or before) the plane of the paper or screen.
- the symbol “ ⁇ ” in a chemical structure indicates that the bond connection is below (or behind) the plane of the paper or screen.
- a solid wedge in a chemical structure indicates that this bond is above (or before) the plane of the paper or screen toward to the viewer.
- a hashed (or broken) wedge in a chemical structure indicates that the bond connection is below (or behind) the plane of the paper or screen receding away from the viewer.
- a compound and use of the the compound in the manufacture of a medicament for treating a viral infection and a method of using the compound for treating a viral infection in a subject comprising the step of administering a therapeutically effective amount of the compound to the subject, wherein the compound has the Formula (I) :
- X is oxygen or sulphur
- R 1 is R 15 , -OR 15 , -C (O) R 15 , or -C (O) OR 15 ;
- R 2 , R 5 , R 6 , R 10 , R 13 , and R 14 are each independently hydrogen or halogen;
- R 3 and R 4 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15 ; or R 3 and R 4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ;
- R 7 , R 8 , and R 9 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15 ; or R 7 and R 8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ; or R 8 and R 9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16 ;
- R 11 and R 12 taken together form oxo; or while one of R 11 and R 12 is hydrogen or halogen, the other one of R 11 and R 12 is selected from the group consisting of R 15 , -OR 15 , -C (O) R 15 and -C (O) OR 15 ;
- R 17 and R 18 for each occurrence are independently hydrogen, alkyl, alkynyl, cycloalkyl, aryl, or heteroaryl, or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, trichloromethyl, trifluoromethyl, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- the compound of Formula (I) is not a compound selected from the group consisting of 5, 15a, 15b, 16, 17b, 19d, 25a-25g, and 26a-26g:
- R 1 is -O-CH 2 -R 16 , wherein R 16 is -C ⁇ CH, cyano, -OR 17 , -N (R 17 ) R 18 , -C (O) N (R 17 ) R 18 , or -C (O) OR 17 .
- each of R 3 and R 4 is independently selected from the group consisting of -OR 15 and -OC (O) R 15 , wherein R 15 is hydrogen, alkyl, cycloalkyl, heterocyclcyl, aryl, and heteroaryl; or R 3 and R 4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl.
- R 3 and R 4 is -OR 15 , wherein R 15 is C 1 -C 6 alkyl, C 1 -C 4 alkyl, or C 1 -C 2 alkyl.
- each of R 8 and R 9 is independently selected from the group consisting of -OR 15 and -OC (O) R 15 , wherein R 15 is hydrogen, alkyl, cycloalkyl, heterocyclcyl, aryl, and heteroaryl; or R 8 and R 9 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl. In certain embodiments, R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring.
- each of R 3 and R 4 is -O-alkyl; R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring;
- the compound is selected compounds 12a, 12b, 13, 14a, 14b, 17a, 17c, 17d, 17e, 17f, 17g, 17h, 18, 19a, 19b, 19c, 19e, 19f, 19g, 19h, 19i, 19j, 19k, 19l, 19m, 19n, 19o, 19p, 20, 21, 22, 23 and 24:
- R 1 is a glycosidic group represented by the Formula (V) :
- R 19 and R 20 taken together to form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ;
- R 21 and R 22 taken together to form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 21 and R 22 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ; or R 20 and R 22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy;
- R 23 and R 24 taken together to form oxo; or while one of R 23 and R 24 is hydrogen or halogen, the other one of R 23 and R 24 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , and -OC (O) OR 27 ; or R 22 and R 24 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy;
- R 25 and R 26 taken together form oxo; or while one of R 25 and R 26 is hydrogen or halogen, the other one of R 25 and R 26 is selected from the group consisting of R 27 , -OR 27 , -OC (O) R 27 , -OC (O) N (R 27 ) R 27 , -OC (O) OR 27 , -CH 2 R 27 , and -C (O) R 27 ; or R 24 and R 26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy;
- R 27 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , -N (R 29 ) S (O) 2 R 30 , hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R 28 , heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R 28 , and - (CH 2
- R 29 and R 30 for each occurrence areeach independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- the glycosidic group is a monosaccharide, disaccharide, trisaccharide, tetrasaccharide or polysaccharide group, and may exist in any isomeric form, for example ⁇ -D, ⁇ -L, ⁇ -D or ⁇ -L forms.
- the glycloside is a monosacchairde selected from the group consisting of an ⁇ -L isomer and an ⁇ -L isomer.
- R 19 , R 21 , R 23 , and R 25 are each hydrogen;
- R 20 , R 22 , and R 24 are each independently selected from the group consisting of -OR 27 , -OC (O) N (R 27 ) R 27 , -OC (O) R 27 and -OC (O) OR 27 ;
- R 26 is hydrogen, methyl, -OR 27 , -OC (O) R 27 , or -CH 2 -OC (O) R 27 ; or
- R 22 and R 24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C
- R 20 , R 22 , and R 24 are each independently selected from the group consisting of -OR 27 , -OC (O) N (R 27 ) R 27 , -OC (O) R 27 and -OC (O) OR 27 , wherein R 27 for each occurrence is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, aryl, aralkyl, heteroaryl, perhaloalkyl, and -C (O) CH 2 CN.
- the compound can be selected from the group consisting of: 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
- the present disclosure also provides aryl naphthalene glycoside compounds, including derivatives of diphyllin, patentiflorin A, justiprocuminA or justiprocumin B useful in the treatment of viral infections.
- the compound has the Formula (I) or (II) :
- X is oxygen or sulphur
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur; or R 2 and R 3 , R 3 and R 4 , R 4 and R 5 , R 6 and R 7 , R 7 and R 8 , R 8 and R 9 or R 9 and R 10 may be taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with halogen and a moiety comprising 1 to 30 plural valence atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur;
- R 11 and R 12 taken together form oxo; or while one of R 11 and R 12 is hydrogen or halogen, the other one of R 11 and R 12 is selected from the group consisting of R 15 , -OR 15 , -C (O) R 15 and -C (O) OR 15 ;
- R 13 and R 14 taken together form oxo; or while one of R 13 and R 14 is hydrogen or halogen, the other one of R 13 and R 14 is selected from the group consisting of R 15 , -OR 15 , -C (O) R 15 and -C (O) OR 15 ;
- R 15 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 R 16 , heterocyclcyl optionally substituted with1, 2, 3, 4 or 5 R 16 , - (CH 2 ) k -heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 R 16 , -OR 17 , -C (O) R 18 , -C (O) N (R 17 ) R 18 , -C (O) OR 17 , -OC (O) R 17 , -S (O) 2 R 17 , -S (O) 2 N (R 17 ) R 18 , -N (R 17 ) R 18 , -N (R 17 ) N (R 17 ) R 18 , -N (R 17 ) C (O) R 18 and -N (R 17 ) S (O) 2 R 18 , wherein k
- R 17 and R 18 are each independently hydrogen or selected from the group consisting of hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- the compounds has the Formula (III) or (IV) :
- X is sulfer or oxygen
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur; or R 1 and R 2 , R 2 and R 3 , R 3 and R 4 , R 5 and R 6 , R 6 and R 7 , R 7 and R 8 , and/or R 8 and R 9 taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from halogen and a moiety comprising 1 to 30 plural valence atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur;
- R 10 and R 11 taken together form oxo; or while one of R 10 and R 11 is hydrogen or halogen, the other one of R 10 and R 11 is selected from the group consisting of R 22 , -OR 22 , -C (O) R 22 , and -C (O) OR 22 ;
- R 12 and R 13 taken together form oxo; or while one of R 12 and R 13 is hydrogen or halogen, the other one of R 12 and R 13 is selected from the group consisting of R 22 , -OR 22 , -C (O) R 22 , and -C (O) OR 22 ;
- R 19 and R 20 taken together form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
- R 21 and R 22 taken together form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 16 and R 17 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide and substituted tetrasaccharide;
- R 23 and R 24 taken together form oxo; or while one of R 23 and R 24 is hydrogen or halogen, the other one of R 23 and R 24 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
- R 25 and R 26 taken together form oxo; or while one of R 25 and R 26 is hydrogen or halogen, the other one of R 25 and R 26 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , -CH 2 R 31 and -C (O) R 31 ;
- R 27 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , -N (R 29 ) S (O) 2 R 30 , hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from the group consisiting of R 23 , heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from the group consisting of R 28 , and - (CH 2 ) k
- R 29 and R 30 are each independently hydrogen or selected from the group consisting of hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy;
- R 31 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , -N (R 29 ) S (O) 2 R 30 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, substituted tetrasaccharide, hydrocarbyl optionally substituted with 1, 2, 3, 4 or
- R is hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- the glycosidic group can be a carbohydrate group, such as a monosaccharide, disaccharide, trisaccharide, tetrasaccharide or polysaccharide group, and may exist in any isomeric form, for example ⁇ -D, ⁇ -L, ⁇ -D or ⁇ -L forms.
- the carbohydrate group may be optionally substituted with other type of substituents or even additional glycosidic groups.
- the total number of monosaccharide and substituted monosaccharide contained in the chemical structure of a compound is generally 30 or less.
- the glycosidic group may comprise one or more monosaccaride units of Formula (V) or (VI) :
- R 19 and R 20 taken together form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
- R 21 and R 22 taken together form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 21 and R 22 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
- R 23 and R 24 taken together form oxo; or while one of R 23 and R 24 is hydrogen or halogen, the other one of R 23 and R 24 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide and substituted tetrasaccharide;
- R 25 and R 26 taken together form oxo; or while one of R 25 and R 26 is hydrogen or halogen, the other one of R 25 and R 26 is selected from the group consisting of R 27 , -OR 27 , -C (O) R 27 , -C (O) OR 27 , -CH 2 R 31 , and -C (O) R 31 ;
- R 27 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , -N (R 29 ) S (O) 2 R 30 , hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R 28 , heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R 28 , and - (CH 2 ) k
- R 29 and R 30 are each independently hydrogen or selected from the group consisting of hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy; and
- R 31 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29 , -C (O) R 30 , -C (O) N (R 29 ) R 30 , -C (O) OR 29 , -OC (O) R 29 , -S (O) 2 R 29 , -S (O) 2 N (R 29 ) R 30 , -N (R 29 ) R 30 , -N (R 29 ) N (R 29 ) R 30 , -N (R 29 ) C (O) R 30 , -N (R 29 ) S (O) 2 R 30 , monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, substituted tetrasaccharide, hydrocarbyl optionally substituted with 1, 2, 3, 4 or
- the glycosidic group comprises 1, 2, 3, or 4 monosaccaride units, wherein each monosaccharide unit in the glycosidic group is independently for each occurrence a monosaccaride unit of Formula (III) or Formula (IV) .
- R 1 , R 4 , R 5 , R 8 and R 9 are each independently hydrogen, hydroxy or methoxy;
- R 2 and R 3 are each independently hydrogen, hydroxy, methoxy, or taken together with the carbon atoms to which they are attached form a [1, 3] dioxole cyclic group;
- R 6 and R 7 are each independently hydrogen, hydroxy, methoxy; or R 6 and R 7 taken together with the carbon atoms to which they are attached form a [1, 3] dioxole cyclic group;
- R 12 and R 13 are each independently hydrogen; and
- X is oxygen.
- glycosidic groups include glucopyranoside, galactopyranoside, mannopyranoside, fucopyranoside, arabinopyranoside, glucopyranoside, galactopyranoside, glucuronide, lactopyranoside, xylopyranoside, glucosaminide, galactosaminide, alloside, lyxoside, taloside, threoside, riboside, fructoside, rhamnoside and guloside groups.
- the glycosidic group may be selected from ⁇ -D-glucopyranoside, ⁇ -D-galactopyranoside, ⁇ -D- mannopyranoside, ⁇ -L-fucopyranoside, ⁇ -L-arabinopyranoside, ⁇ -D-glucopyranoside, ⁇ -D-galactopyranoside, ⁇ -D-glucuronide, ⁇ -D-lactopyranoside, ⁇ -D-xylopyranoside, ⁇ -D-glucosaminide, ⁇ -D-galactosaminide, ⁇ -D-alloside, ⁇ -D-lyxoside, ⁇ -D-taloside, ⁇ -D-threoside, ⁇ -D-riboside, ⁇ -D-fructoside, ⁇ -D-rhamnoside and ⁇ -L-guoside groups.
- each compound may be in the form of the free compound, an acid or base addition salt, or a prodrug.
- the present disclosure also provides a pharmaceutical composition comprising at least one of the compounds described herein and at least one pharmaceutically acceptable excipient.
- the compounds described herein and their pharmaceutically acceptable salts can be administered to a subject either alone or in combination with pharmaceutically acceptable, excipients, carriers, and/or diluents in a pharmaceutical composition according to standard pharmaceutical practice.
- the compounds can be administered orally or parenterally.
- Parenteral administration includes intravenous, intramuscular, intraperitoneal, subcutaneous and topical, the preferred method being intravenous and topical administrations.
- compositions which comprise a therapeutically effective amount of one or more of the compounds described herein, formulated together with one or more pharmaceutically, excipients, acceptable carriers (additives) and/or diluents.
- compositions of the present disclosure may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; and (2) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions) , tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue.
- parenteral administration for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation
- oral administration for example, drenches (aqueous or non-aqueous solutions or suspensions) , tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules
- certain embodiments of the compounds described herein may contain a basic functional group, such as amino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.
- pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present disclosure. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed during subsequent purification.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
- the pharmaceutically acceptable salts of the compounds of the present disclosure include the conventional non-toxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
- the compounds described herein may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases.
- pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present disclosure. These salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine.
- Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives, solubilizing agents, buffers and antioxidants can also be present in the compositions.
- Methods of preparing these formulations or compounds include the step of bringing into association a compound described herein with the carrier or excipient and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present disclosure with liquid carriers (liquid formulation) , liquid carriers followed by lyophylization (powder formulation for reconstitution with sterile water or the like) , or finely divided solid carriers, or both, and then, if necessary, shaping or packaging the product.
- compositions of the present disclosure suitable for parenteral administration comprise one or more compounds described herein in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, chelating agents, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and non-aqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like) , and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- Prevention of the action of microorganisms upon the compounds of the present disclosure may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like.
- isotonic agents such as sugars, sodium chloride, and the like into the compositions.
- prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.
- the present disclosure provides diphyllin and patentiflorin A analogs with anti-HIV and anti-influenza virus activity and synthesis thereof.
- the compounds of the present disclosure were synthesized and evaluated for their anti-HIV and anti-influenza viral activity.
- the synthetic or semi-synthetic analogues of diphyllin can be exemplified by 12a, 12b, 13, 14a, 14b, 15a, 15b, 16, 17a, 17b, 17c, 17d, 17e, 17f, 17g, 17h, 18, 19a, 19b, 19c, 19d, 19e, 19f, 19g, 19h, 19i, 19j, 19k, 19l, 19m, 19n, 19o, 19p, 20, 21, 22, 23 and 24.
- the synthetic or semi-synthetic analogues of patentiflorin A can be exemplified by 25a, 25b, 25c, 25d, 25e, 25f, 25g, 26a, 26b, 26c, 26d, 26e, 26f, 26g, 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d.
- reaction conditions e.g., component concentrations, temperatures, pressures, and other reaction ranges and conditions that can be used to optimize the product purity and yield obtained from the described process. Only reasonable and routine experimentation will be required to optimize such process conditions.
- each compound may be in the form of the free compound, an acid or base addition salt, or a prodrug.
- esters 12a and 12b were prepared from 5 by a substitution reaction. Acidic hydrolysis of ester 12a provided acid 13, which was converted to amides 14a and 14b by coupling with ammonium chloride (NH 4 Cl) or an amine in the presence of 1- [bis (dimethylamino) methylene] -1H-1, 2, 3-triazolo [4, 5-b] pyridinium 3-oxid hexafluorophosphate (HATU) or 1-hydroxybenzotriazole hydrate (HOBt) .
- NH 4 Cl ammonium chloride
- HATU 1- [bis (dimethylamino) methylene] -1H-1, 2, 3-triazolo [4, 5-b] pyridinium 3-oxid hexafluorophosphate
- HOBt 1-hydroxybenzotriazole hydrate
- O-alkoxyl alcohols 15a and 15b were obtained from the reactions of 5 with the corresponding epoxides ethylene oxide and isobutylene oxide, respectively.
- Derivatives 17a-17h were prepared from 5, respectively, in one step. Alkylation of 5 with cesium carbonate (Cs 2 CO 3 ) followed by bromoacetonitrile, iodomethane or propargyl bromide rendered derivatives 17a-17c, respectively. Addition of potassium carbonate (K 2 CO 3 ) and 2-chloropyrimidinein to 5 in dimethylformamide (DMF) under 100 °C provided compound 17d.
- Cs 2 CO 3 cesium carbonate
- 2-chloropyrimidinein 2-chloropyrimidinein
- ANL analogs and compounds 25a-25g and 26a-26g containing different sugar units outlined in Figure 4 were prepared, and which were further modified to provide additional ANL analogs 27aa-27bf, 28ab1-28bb3, 29a, 29b, 30a-30l and 31a-30l outlined in Figure 5.
- compounds described herein can exhibit broad antiviral properties.
- compounds of Formula (I) are administered to a patient to inhibit replication of or reduce cytopathic effects of viruses, such as HIV, coronaviruses, Ebola virus, Marburg virus or influenza viruses.
- viruses that may be inhibited by compounds of Formula (I) include, but are not limited to, cytomegalovirus (CMV) , HSV-1 (herpes simplex virus type 1) , HSV-2 (herpes simplex virus type 2) , HBV (hepatitis B virus) , HCV (hepatitis C virus) , HPV (human papilloma virus) , influenza A, influenza B, RSV (respiratory syncitial virus) , RV (rhinovirus) , AV (adenovirus) , PIV (human parainfluenza viruses) , Epstein-Barr virus (EBV) , varicella zoster virus (VZV) , dengue virus and Zika virus.
- CMV cytomegalovirus
- HSV-1 herpes simplex virus type 1
- HSV-2 herpes simplex virus type 2
- HBV hepatitis B virus
- HCV hepatitis C virus
- HPV human papill
- the compounds, pharmaceutical compositions, and therapeutic methods described herein are useful for preventing or treating or ameliorating HIV infections.
- influenza viruses including but not limited to: any of the subtypes of influenza A, influenza B, or influenza C.
- the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by influenza A viruses, including but not limited to, any of the strains of H1N1, H1N2, H1N3, H1N4, H1N5, HIN6, H1N7, HIN8, H1N9, H2N1, H2N2, H2N3, H2N4, H2N5, H2N6, H2N7, H2N8, H2N9, H3N1, H3N2, H3N3, H3N4, H3N5, H3N6, H3N7, H3N8, H3N9, H4N1, H5N2, H5N3, H5N4, H5N5, H5N6, H5N7, H5N8, H5N9, H6N1, H6N2, H6N3, H6N4, H6N5, H6N6, H6N7, H6N8, H6N9, H7N1, H7N2, H6N3, H6N4, H6N5, H6N
- the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by influenza A virus strains having a type 5 hemagglutinin protein.
- influenza A virus strain has a type 5 hemagglutinin protein and neuraminidase protein selected from types 1 to 11.
- influenza A virus is selected from the group consisting of H5N1 and H5N2.
- the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by H5N1.
- HIV refers to the human immunodeficiency virus and includes HIV-1, HIV-2 and SIV. In certain embodiments, HIV refers to HIV-1 and/or HIV-2.
- HIV-1 means the human immunodeficiency virus type-1. HIV-1 can include but is not limited to extracellular virus particles and the forms of HIV-1 associated with HIV-1 infected cells. The HIV-1 virus can include any of the known major subtypes (classes A, B, C, D, E, F, G and H) or outlying subtype (group O) including laboratory strains and primary isolates.
- HIV-2 means the human immunodeficiency virus type-2.
- HIV-2 can include but is not limited to extracellular virus particles and the forms of HIV-2 associated with HIV-2 infected cells.
- SIV refers to simian immunodeficiency virus, which is an HIV-like virus that infects monkeys, chimpanzees, and other nonhuman primates. SIV can include but is not limited to extracellular virus particles and the forms of SIV associated with SIV infected cells.
- the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by HIV-1 and/or HIV-2. In certain embodiments, the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating or ameliorating infections caused by HIV-1 subtype B.
- the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by SIV.
- the compounds, pharmaceutical compositions, and therapeutic methods described herein are useful for preventing, treating, or ameliorating infections caused by filoviruses, including but not limited to: Marburg virus, Zaire ebolavirus, Sudan ebolavirus, Cote d’Irete ebolavirus, Reston ebolavirus and Bundibugyo ebolavirus.
- the compounds, pharmaceutical compositions, and therapeutic methods described herein are useful for preventing, treating, or ameliorating infections caused by coronaviruses including, but not limited to, SARS-CoV-2, SARS-CoV and MERS-CoV.
- HIV/VSVG or HIV/SARSP or HIV/HA or HIV/EBOV or HIV/MARV virions were produced, respectively, by co-transfecting with either 0.5 ⁇ g VSVG (vesicular stomatitis virus glycoprotein) envelope expression plasmid 0.5 ⁇ g SARSP (SARS-Cov-2 spike protein) expression plasmid or 0.5 ⁇ g hemagglutinin (HA) envelope expression plasmid with 0.5 ⁇ g neuraminidase (NA) expression plasmid or 0.5 ⁇ g EBVG (Ebola virus glycoprotein) envelope expression plasmid or 0.5 ⁇ g MAVG (Marburg virus glycoprotein) envelope expression plasmid and 2 ⁇ g replication-defective HIV vector (pNL4-3.
- 0.5 ⁇ g VSVG vesicular stomatitis virus glycoprotein envelope expression plasmid
- SARSP SARS-Cov-2 spike protein
- HA hemagglutinin
- NA
- Luc. RE into human embryonic kidney 293T cells (90%confluent) in six-well plates via PEI (polyethylenimine) (Invitrogen, Carlsbad, CA, USA) , as previously described with a modified procedure.
- the HIV vector pNL4-3. Luc. RE was obtained through the AIDS Research and Reference Reagent Program (Division of AIDS, NIAID, NIH) . Sixteen hours post-transfection, all media were replaced with fresh, complete DMEM. Eight hours post-transfection, all media were replaced with fresh complete DMEM. Forty-eight hours post-transfection, the supernatants were collected and filtered through a 0.45- ⁇ m-pore-size filter (Millipore, Billerica, MA, USA) and the pseudo virions were directly used for infection.
- PEI polyethylenimine
- Anti-HIV and anti-H5N1 Influenza Virus Evaluation Assay This protocol is to identify potential inhibitors for HIV and influenza virus replication (post-entry steps) .
- the HIV vector pNL4-3. Luc. RE was co-transfected with the VSVG to generate HIV/VSVG virions (HIV virion with VSV glycoprotein on the viral surface)
- HIV vector was co-transfected with the H5N1 HA and NA constructs to generate HIV virions with bird flu HA on the viral surface [HIV/HA (HIV virion with HA and NA glycoproteins on the viral surface) ] .
- This pNL4-3 was derived from an infectious molecular clone of a SI (syncytium inducing) , T-tropic virus, which is replication deficient since the HIV is Env - and Vpr - .
- SI singletium inducing
- luc the luciferase gene carried by this recombinant HIV vector served as the reporter for HIV replication (reverse transcription, integration and HIV gene expression) .
- the infection level was measured as relative light units (RLUs) in the infected cells.
- RLUs relative light units
- the luciferase activities of the 293T cells infected with the HIV vector pNL4-3. Luc. RE reached the range of 10 5 -10 6 RLUs, approximately 100-fold higher than the background levels when measured using the HIV virions without VSVG.
- the evaluation principle is that the level of the luciferase activity in the cells should be proportional to the level of viral entry and replication. If a sample can interfere with HIV replication/or HA-mediated viral entry, the level of the luciferase activity in the infected cells will be reduced. Thus, using this protocol, a sample capable of inhibiting HIV or influenza virus replication was identified.
- the test fractions or compounds were evaluated as follows. Target A549 human lung cells were seeded at 0.5 ⁇ 10 5 cells per well (24-well plate) in complete DMEM. The lung cell line was used since it is susceptible to HA-mediated viral entry.
- the stock HIV/VSVG or HIV/HA virions (approximately 2 ⁇ 10 6 relative light units, or RLUs, on the target cells) were mixed with the individual sample first, and the mixture was incubated with the A549 target cells for 24 hours.
- Ten microliters of serial concentrations for example, 20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 ⁇ g/mL
- 190 ⁇ L of the pseudovirus were incubated with target cells.
- Twenty-four (24) hours post-infection all media containing sample and virus was removed from target cells and replaced with fresh and complete DMEM. Forty-eight (48) hours post-infection, the target cells were lysed and the luciferase activity was determined.
- Anti-HIV, anti-Ebola and anti-Marburg Virus Evaluation Assay This protocol was modified from the aforementioned anti-H5N1 influenza virus evaluation assay, which was designed to identify potential inhibitors for HIV, Ebola and Marburg viruses replication (post-entry steps) .
- the HIV vector pNL4-3. Luc. R.E. was co-transfected with the VSVG to generate HIV/VSVG virions, and the same HIV vector was co-transfected with the Ebola or Marburg glycoprotein (GP) constructs to generate HIV virions with Ebola or Marburg GP on the viral surface (HIV/EBVG or HIV/MAVG) .
- the infection level was measured as relative light units (RLUs) in the infected cells.
- the luciferase activities of the 293T cells infected with the HIV vector pNL4-3. Luc. R.E. reached the range of 10 5 -10 6 RLUs, approximately 100-fold higher than the background levels when measured using the HIV virions without VSVG.
- the evaluation principle is that the level of the luciferase activity in the cells should be proportional to the level of viral entry and replication. If a compound can interfere with HIV replication/or EBVG or MAVG-mediated viral entry, the level of the luciferase activity in the infected cells will be reduced. Thus, using this protocol, compounds capable of inhibiting HIV, EBOV and MARV replication were identified. The test compounds were evaluated as follows.
- Target A549 human lung cells were seeded at 0.5 ⁇ 10 5 cells per well (24-well plate) in complete DMEM.
- the lung cell line was used since it is susceptible to EBVG or MAVG-mediated viral entry.
- the stock HIV/VSVG or HIV/EBVG or MAVG virions (approximately 2 ⁇ 10 6 relative light units, or RLUs, on the target cells) were mixed with the individual sample first, and the mixture was incubated with the A549 target cells for 24 hours.
- Ten microliter of each sample in varying concentrations and 190 ⁇ L of the pseudovirus were incubated with target cells. Twenty-four (24) hours post-infection, all media containing sample and virus was removed from target cells and replaced with fresh and complete DMEM. Forty-eight (48) hours post-infection, the target cells were lysed and the luciferase activity was determined.
- Anti-SARS-CoV-2 Evaluation Assay This protocol was modified from the aforementioned anti-H5N1 influenza virus evaluation assay, which was designed to identify potential inhibitors for SARS-CoV-2.
- the HIV vector pNL4-3. Luc. R.E. was co-transfected with SARS-CoV-2 spike protein (SARSP) expression plasmid to generate SARS-CoV-2 pseudovirions (HIV/SARSP) .
- Target Hep G2 liver cancer cells were seeded at 4 ⁇ 10 3 cells per well (96-well plate) in complete EMEM. The liver cell line was used because it is susceptible to SARS-CoV-2 mediated viral entry.
- the HIV-1 clinical strains such as BAL and SF162 (macrophage-tropic: M-tropic) , BAL (T-cell line tropic: T-tropic) , and 89.6 (a dual tropic strain) , HIV-1 LAV (wild type) , NRTI (nucleoside reverse transcriptase inhibitor) -resistant isolate (HIV-1 1617-1 ) (AZT resistant strain from AIDS repository) and NNRTI (non-nucleoside reverse transcriptase inhibitor) -resistant isolate (HIV-1 N119 ) (nevaripine resistant strain from AIDS repository) were used in the study.
- PBMC peripheral blood mononuclear cell culture
- donor PBMCs were suspended in R-3 medium [RPMI 1640 medium supplemented with 15-20%FBS (fetal bovine serum) , 5%IL-2 (human interleukin-2) , 250 U of penicillin per mL, 250 ⁇ g of streptomycin per mL and 2 mM L-glutamine] was stimulated with PHA (phytohaemagglutinin, 2-3 ⁇ g/mL) for seven days.
- the preparations (samples) were added to the cultured cells, and the different HIV-1 strains were used to challenge the cultured cells in 96-well plates [1 ⁇ 10 5 cells per well with 1000 TCID 50 (virus 50%tissue culture infectious doses) of HIV strain] .
- each drug was tested using a serial of concentrations (for example, 5, 1, 0.2, 0.04, 0.008, 0.016 and 0 ⁇ g/mL) .
- the IC 50 s were calculated by comparing p24 antigen values for the samples-containing wells with those for no drug control wells. For the p24 assay, the maximum cutoff should be around 120-150 pg/mL.
- influenza viruses such as influenza H1N1 (A/HK/415742/09) , H3N2 (A/Hong Kong/1/1968) , H5N1 (A/Vietnam/1203/2004H) , H7N1 (A/Rhea/North Carolina/39482/93) , H7N7 (A/Netherlands/219/2003) , H7N9 (A/Anhui/1/2013) and H9N2 (A/Chicken/Y280/97) were used in the studies. Samples were evaluated for their antiviral activities against the influenza viruses in A549 cells.
- the preparations were added to the cultured cells, and the different influenza strains were used to challenge the cultured cells in 24-well plates (1 ⁇ 10 5 cells per well) . After removal of the unbound viruses, the cells were incubated for 48 h. The viral supernatants were collected and viral titers were determined by standard plaque assay in MDCK (Madin-Darby canine kidney) cells.
- the cytotoxicity of the sample for A549 cells was measured using the sulforhodamine B (SRB) assay (Vichai V, Kirtikara K. Nature protocols 2006; 1: 1112–1116) . Briefly, 190 ⁇ L of A549 cells (2 ⁇ 10 4 cells/mL) was seeded in each well of a 96-well cell culture plate. After 24 hours, 10 ⁇ L of DMSO alone, 10 ⁇ L of zidovudine (AZT) as positive controlin 10%DMSO, and 10 ⁇ L of each sample in 10% (v/v) DMSO were respectively added into wells of a 96-well tissueculture plate.
- SRB sulforhodamine B
- the plates were allowed to dry at r.t. 100 mL of 10 mM Tris base solution (pH 10.5) was added to each well and the plates were shake on a gyratory shaker for at least 30 min to solubilize the protein-bound dye. The OD values were measured at 515 nm in a microplate reader. The CC 50 (the concentration of an agent causing 50%cytotoxicity) values were calculated using the GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA) .
- mice Toxicity Evaluation in Mice. Repeated-dose toxicity study in mice was applied on the selected samples. The animal study was approved and performed according to Animal Care and Use Guidelines of the Animal Ethics Committee at Hong Kong Institution University and performed following Animal Care and Use guidelines set by NIH (National Institute of Health, USA) .
- mice Weights of mice were measured twice a week until the end of the experiment. Skin conditions, food intake, water consumption and posture of mice were also inspected. All mice were sacrificed as the end of the experiment to inspect the essential organs such as liver, heart, kidney, lung and spleen.
- CC 50 the concentration caused inhibition of cell growth of host A549 cells by 50%
- EC 50 effective concentration of compound to inhibit viral growth by 50%
- Compound 26b (patentiflorin A) was identified as an anti-HIV lead compound from both methanol extracts of J. cf. patentiflora (the roots and stems of) and J. procumbens (aerial parts) , and compound 5 (diphyllin) was isolated as a pure compound from the methanol extract of J. procumbens (aerial parts) .
- Compound 5 was also obtained as an intermediate through the total synthesis of 26b in our previous studies.
- Compounds 26b and 5 showed anti-HIV activities with EC 50 values of 21.1 and 37.1 nM and SIs of 16.4 and 97.3, respectively, in our present “One-Stone-Two-Birds” evaluation system.
- the high anti-HIV activity and selectivity of 26d were achieved by replacing the D- (+) -fucose in 26e with L- (-) -fucose in 26d.
- Compounds 12b, 17a, 19a and 21 were selected to be further evaluated against a broad spectrum of HIV-1 clinical and resistant strains.
- Compound 12b showed inhibitory effects against SF162, 89.6, Bal, Lav. 04, 1617-1 and N119 with IC 50 values of 340, 376, 458, 312, 537 and 638 nM, respectively (the CC 50 value against PBMC at >100 ⁇ M) .
- Compound 17a showed inhibitory effects against SF162, 89.6, Bal, Lav.
- Compound 19a showed inhibitory effects against SF162, 89.6, Bal, Lav. 04, 1617-1 and N119 with IC 50 values of 154, 143, 188, 138, 152 and 185 nM, respectively (the CC 50 value against PBMC at >100 ⁇ M) .
- Compound 21 showed inhibitory effects against SF162, 89.6, Bal, Lav.
- Compounds 28ab1, 31e, 31g, 31l, 31j and 32b showed more than 77 %inhibitory effects against the three viruses (H5N1 virus, EBOV and VSV) in a concentration of below 12.5 ng/mL.
- the compound series of 26-32 were repeatedly tested for their antiviral activities against H5N1 virus, EBOV and VSV.
- TLC Thin-layer chromatography
- n-buyllithium (n-BuLi) (1.8 M, 69.3 mL, 124.8 mmol) was added drop-wise for an additional 30 min.
- the reaction mixture was stirred for 30 min at -50 °C, and then piperonal (114.4 mmol) was added.
- the mixture was stirred at -78 °C for 0.5 h, and then the reaction was allowed to warm to r.t. for an additional 2 h.
- the reaction was then quenched with water, and the aqueous layer was extracted with EtOAc.
- the combined organic layers were washed, dried and filtered through a plug of silica gel to remove the majority of impurities.
- the resulted red viscous oil was purified by recrystallization in ethanol (EtOH) .
- the crude diester (4a, 5 mmol) was dissolved in THF (70 mL) with the drop-wise addition of sodium borohydride (NaBH 4 ) (0.945 g, 25 mmol) , and the reaction was stirred at 80 °Cfor 12 h. The reaction was then cooled back to r.t.
- the resulting slurry was acidified to a pH value of approximately 2 with dilute HCl (2 M) .
- the crude ketimine 19p (115.8 mg, 0.21 mmol) was suspended in 1: 1 (v/v) ratio of 1N HCl: THF (4 mL) solution and stirred at r.t. for 3-5 h.
- THF was removed and the aqueous residue was basified using 1N KOH to a pH of 10-14.
- the aqueous layer was then extracted three times with ethyl acetate (30 mL) .
- the organic layer was dried with anhydrous NaSO 4 , filtered and concentrated in vacuo to give the crude amine.
- the pure product 22 70 mg, 84%) was obtained after solvent removal.
- the crude per-acetylated glycoside was dissolved in CH 2 Cl 2 (5 mL) and cooled to 0 °C before the drop-wise addition of hydrogen bromide (33%in acetic acid, 1.5 mL) .
- the reaction was warmed to r.t. and stirred for an additional 4 h. Following completion, the reaction was quenched with water, and the aqueous layer was extracted with CH 2 Cl 2 .
- the organic layers were combined and washed with water, sodium bicarbonate, and brine, dried with Na 2 SO 4, and concentrated under reduced pressure to afford the glycosyl bromide. After concentration, the crude product was directly used for next step without further purification.
- Diphyllin (5) (215 mg, 0.61 mmol) was dissolved in chloroform (CHCl 3 ) (15 mL) and aqueous sodium hydroxide (NaOH) (0.1 M, 20 mL) prior to adding tetra-n-butylammonium bromide (TBAB) (306 mg, 0.95 mmol) .
- the reaction was then heated to 40 °C for 10 min before adding the glycosyl bromide (0.61 mmol) , and the reaction was then stirred at 40 °C overnight. After cooling to r.t., the aqueous layer was extracted with CHCl 3 and the combined organic layers were washed with brine, dried with Na 2 SO 4 and concentrated under reduced pressure.
- Potassium carbonate (K 2 CO 3 ) (168.4 mg, 1.2 mmol) was added to a solution of a diphyllin per-acetylated glycoside (25a-25g) in MeOH (10 mL) and stirred at r.t. for 30 min. When no starting material was observed by TLC, the reaction was quenched by the addition of dilute HCl (2 M) , filtered through filter paper, and concentrated under reduced pressure. Flash chromatographic separation of the reaction mixture (silica gel, 2%-10%MeOH in CHCl 3 ) afforded the target glycoside (26a-26g) .
- Patentiflorin A (26b, total yield 68%)
- the glycoside 26a or 26b (0.3 mmol) was allowed to react with acetic anhydride (32 ⁇ L, 0.32 mmol) in dry acetonitrile (MeCN) (1.5 mL) at 40 °C for 12 h in the presence of tetrabutylammonium acetate (TBOAc) (27 mg, 0.09 mmol) .
- TBOAc tetrabutylammonium acetate
- the solution was concentrated in vacuo to yield a mixture containing 27aa-27af (the total mixture yield from 26a: 52%) or a mixture containing 27ba-27bf (the total mixture yield from 26b: 50%) as a pale-yellow solid.
- the organic layer was washed with brine, dried over Na 2 SO 4 , and evaporated under reduced pressure to give a compound mixture containing 28ab1-28ab3 (the total mixture yield from 27ab: 45%) or a compound mixture containing 28bb1-28bb3 (the total mixture yield from 27bb: 52%) as white solids.
- references cited herein are incorporated by reference herein in their entirety to indicate the state of the art as of their publication or filing date and it is intended that this information can be employed herein, if needed, to exclude specific embodiments that are in the prior art.
- composition of matter is claimed, it should be understood that compounds known and available in the art prior to applicants’ invention, including compounds for which an enabling disclosure is provided in the references cited herein, are not intended to be included in the composition of matter claims herein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
Description
CROSS REFERENCE OF RELATED APPLICATION
This application claims the benefit of priority of United States Provisional Patent Application Serial Number 62/891,441 filed on August 26, 2019 and of United States Non-Provisional Patent Application Serial Number 16/947,935 filed on August 25, 2020, which are hereby incorporated by reference in their entirety for all purposes.
The present disclosure generally relates to the arylnaphthalene glycoside derivatives, the process for their preparation, and their use as antiviral agents. More particularly, the present disclosure relates to patentiflorin A analogs that are useful as antiviral agents, such as anti-HIV, anti-coronaviral, anti-Ebola viral, anti-Marburg viral, and anti-influenza viral agents. The present disclosure also provides methods for treating viral infections, such as HIV, coronaviruses, Ebola virus, Marburg virus and influenza viruses infections.
Viruses are important etiologic agents that cause infectious diseases in humans and other mammals. They differ greatly in size, shape, chemical composition, host range, and effects on hosts. After decades of studies, only a limited number of antiviral agents are available for the treatment and/or prevention of diseases caused by viruses such as HIV, coronaviruses, Ebola, Marburg, influenza A and B and hepatitis C viruses. Because of their toxic effects on a host, many antiviral agents are limited in their application. Drug resistance is often very quickly developed against the antiviral agent, and many viral diseases, such as HIV have no vaccines available to treat or prevent them. Accordingly, there is a need for safe and effective antiviral agents against a wide-spectrum of viruses with no or low toxicity to the host.
AIDS (acquired immunodeficiency syndrome) remains one of the most serious threats to public health. In a UNAIDS (Uniting the world against AIDS) report, about 77 million people have been infected with the human immunodeficiency virus (HIV) , and 37.9 million people have died from AIDS-related illnesses since the onset of the HIV epidemic in 1981. Since the first anti-HIV drug zidovudine (AZT) was developed and approved in 1987, more than 40 anti-HIV drugs have been formally approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection. These drugs are categorized as nucleoside reverse transcriptase inhibitors (NRTIs) , non-nucleoside reverse transcriptase inhibitors (NNRTIs) , protease inhibitors (PIs) , entry and fusion inhibitors, and HIV integrase strand transfer inhibitors. Although these drugs have significantly extended the lifespan of HIV-positive people, it is worrisome that the prevalence of HIV drug resistance has increased from 11%to 29%since the global rollout of the antiretroviral therapy (ART) in 2001. In addition, the high cost and limited availability of the current ARTs has excluded patients in developing countries from the benefit of combination therapies. Therefore, there is an urgent need to continuously develop novel, more effective, accessible, and affordable anti-HIV therapeutics.
Influenza, a severe viral infection of the respiratory system, remains a major threat to human health. The worldwide outbreak of highly pathogenic H5N1 subtype of avian influenza virus (AIV) and the recent appearance of new type human influenza A/H1N1 have heightened public awareness of potential global influenza pandemics. In addition to domestic poultry, AIV can also infect wild birds, pigs, cats, humans, and other animals. Three drugs, Xofluza, zanamivir and oseltamivir phosphate, have been approved for the treatment of influenza. However, the low oral bioavailability and rapid renal elimination of zanamivir, and the rapid emergence of oseltamivir-resistant influenza viruses, have prompted the further development of more potent, longer duration therapeutic drugs to combat potential human influenza pandemics.
Viruses belonging to Filoviridae contain minus-strand RNA as their genome. There are two genera, namely Marburgvirus and Ebolavirus, under the Filoviridae family. Marburg virus is the only member in Marburgvirus genus. There are five members in Ebolavirus genus, namely Zaire ebolavirus, Sudan ebolavirus, Cote d’Ivoire ebolavirus, Reston ebolavirus and Bundibugyo. Owning to their pathogenic potential, high case mortality rate and the lack of effective therapeutics for infected humans, the members of family Filoviridae have been classified as "biosafety level 4" agents. The infection of filovirus may lead to hemorrhagic fever. In fact, both genera contain species that can cause epidemics of serious hemorrhagic fever in humans as well as non-human primates. The outbreak of Ebola virus (EBOV) disease many occurred in Democratic Republic of the Congo. There were numerous Ebola outbreaks since 1976. The first outbreak was in 1976 at Yambuku, with 318 cases reported and 88%death rate. Later, there were two large outbreaks in 1995 and 2007, in which over 250 Ebola cases were reported in each outbreak. In 2014-2015, West Africa experienced the largest Ebola outbreak. Over 28,000 cases were reported and the fatality rate reached to 40%. Recently, an Ebola outbreak occurred again from April 4, 2018. As of May 30, 2019, a total of 1945 cases have been reported with a death rate of 67%. There is no FDA-approved therapeutic agent specific to treat subjects infected by filovirus. The patients suffered from filovirus infection mainly rely on convalescent whole blood or plasma during Ebola outbreaks. However, this kind of empirical treatment has many limitations, including difficulties in mass-production as well as the compatibility of blood group between donor and recipient. The use of some potential drug candidates, which include Favipiravir, ZMapp and GS-5734, are still under investigation. More clinical data is required to prove the safety and efficacy of these drug candidates in treating filovirus infection.
The emergence of novel coronavirus (SARS-CoV-2) raised international concerns and scientists strive to discover potent inhibitors against novel coronavirus. Coronaviruses (CoVs) are enveloped, single-stranded, positive-sense RNA virus, which include Coronaviridae, Arteriviridae, and Roniviridae families. SARS-CoV-2, that causes the current COVID-19 pandemic, is a β-coronavirus. There have been six CoVs identified as human-susceptible viruses. Two of them, SARS-CoV and MERS-CoV, could lead to severe or even fatal respiratory tract infections. As of August 21, 2020, the COVID-19 epidemic has caused 797, 428 deaths among over 15.5 million infected cases. Several EBOV inhibitors, such as remdesivir, toremifene, and favipiravir are repurposed as anti-viral agents active against SARS-CoV-2. However, none of them have been highly effective to curb the COVID-19 epidemic. Highly effective viral inhibitors are thus urgently needed to combat the coronaviruses.
Natural products have been a rich source for the discovery of lead compounds in the modern drug discovery. Justicia cf. patentiflora was identified as an anti-HIV plant lead through screening over 3, 500 plant extracts. Bioassay-directed fractionation of the methanol extract of the stems and barks of this plant led to the isolation of three ANL (arylnaphthalene) glycoside compounds, which displayed potent inhibitory activity against broad HIV clinical strains with EC
50 values in the range of 14-37 nM [Zidovudine (AZT) : 77-95 nM] . They also showed significant inhibitory effects against drug-resistance HIV strains.
Some arylnaphthalene lignans have been reported to have antiviral activity in the literature. Although some of these compounds showed significant antiviral activities against various virus strains, they were not considered as potential antiviral drug candidates due to their low selectivity indices (SIs) .
There thus exists a need to develop improved antiviral agents that address at least some of the aforementioned needs.
SUMMARY
The present disclosure relates to a new class of patentiflorin A analogs, the preparation of these compounds and new intermediates, and their use for treatment of viral infections, such as HIV, CoV, EBOV and AIV.
In a first aspect, provided herein is use of a compound in the manufacture of a medicament for treating a viral infection, wherein the compound has the Formula (I) :
or a pharmaceutically acceptable salt or pro-drug thereof wherein,
X is oxygen or sulphur;
R
1 is R
15, -OR
15, -C (O) R
15, or -C (O) OR
15;
R
2, R
5, R
6, R
10, R
13, and R
14 are each hydrogen;
R
3 and R
4 are each independently selected from the group consisting of -OR
15 and -OC (O) R
15; or R
3 and R
4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16;
R
7, R
8, and R
9 are each independently selected from the group consisting of -OR
15 and -OC (O) R
15; or R
7 and R
8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16; or R
8 and R
9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16;
R
11 and R
12 taken together form oxo; or while one of R
11 and R
12 is hydrogen or halogen, the other one of R
11 and R
12 is selected from the group consisting of R
15, -OR
15, -C (O) R
15 and -C (O) OR
15;
R
15 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, heteroaryl, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N=C (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18, -N (R
17) S (O)
2R
18, 1, 3, 2-dioxaborolane optionally substituted with 1, 2, 3, or 4 group (s) independently selected from alkyl, a glycosidic group, alkynyl optionally substituted with a trialkylsilane, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, wherein k is an integer between 1-6;
R
16 for each occurrence is independently selected from the group consisting of alkynyl, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
17, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18 and -N (R
17) S (O)
2R
18; and
R
17 and R
18 for each occurrence are independently hydrogen, alkyl, alkynyl, cycloalkyl, aryl, or heteroaryl, or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy;
with the proviso that the compound of Formula (I) is not a compound selected from the group consisting of 5, 15a, 15b, 16, 17b, 19d, 25a-25g, and 26a-26g:
In certain embodiments of the use, each of R
3 and R
4 is -O-alkyl; R
8 and R
9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring;
R
1 is heteroaryl, -OR
15, -C (O) R
15, -N (R
17) R
18, -N (R
17) C (O) R
18, -N=C (R
17) R
18, pinacolboryl, -OS (O)
2CF
3, a glycosidic group, heterocyclcyl optionally substituted with 1 or 2 group (s) independently selected from R
16, or alkynyl optionally substituted with a trialkylsilane; or
R
1 is -O (CH
2)
m-cyano, -O (CH
2)
m-alkynyl, -O (CH
2)
m-C (O) N (R
17) R
18, or -O (CH
2)
m-C (O) OR
17, wherein m is a whole number elected from 1-4; and R
11 and R
12 taken together form oxo.
In certain embodiments of the use, the compound is selected from the group consisting of 12a, 12b, 13, 14a, 14b, 17a, 17c, 17d, 17e, 17f, 17g, 17h, 18, 19a, 19b, 19c, 19e, 19f, 19g, 19h, 19i, 19j, 19k, 19l, 19m, 19n, 19o, 19p, 20, 21, 22, 23 and 24:
In certain embodiments of the use, the viral infection is selected from the group consisting of HIV, coronaviruses, influenza viruses, Ebola virus, and Marburg virus.
In certain embodiments of the use, R
1 is alkynyl, pinacolboryl, -OCH
2-cyano, -OCH
2-C (O) N (R
17) R
18, or -OCH
2-C (O) OR
17; each of R
3 and R
4 is -OCH
3; R
8 and R
9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; R
11 and R
12 taken together form oxo; and the viral infection is HIV.
In certain embodiments of the use, R
1 is a glycosidic group represented by the Formula (V) :
wherein, R
19 and R
20 taken together to form oxo; or while one of R
19 and R
20 is hydrogen or halogen, the other one of R
19 and R
20 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27;
R
21 and R
22 taken together to form oxo; or while one of R
21 and R
22 is hydrogen or halogen, the other one of R
21 and R
22 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27; or R
20 and R
22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16;
R
23 and R
24 taken together to form oxo; or while one of R
23 and R
24 is hydrogen or halogen, the other one of R
23 and R
24 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27; or R
22 and R
24 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16;
R
25 and R
26 taken together form oxo; or while one of R
25 and R
26 is hydrogen or halogen, the other one of R
25 and R
26 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, -OC (O) OR
27, -CH
2R
27, and -C (O) R
27; or R
24 and R
26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16;
R
27 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
28, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
28, wherein k is an integer between 1-6;
R
28 for each occurrence is independently selected from halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
29, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, - C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30 and -N (R
29) S (O)
2R
30; and
R
29 and R
30 for each occurrence areeach independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
In certain embodiments of the use, R
19, R
21, R
23, and R
25 are each hydrogen; R
20, R
22 and R
24 are each independently selected from the group consisting of -OR
27, -OC (O) N (R
27) R
27, -OC (O) R
27 and -OC (O) OR
27; and R
26 is hydrogen, methyl, -OR
27, -OC (O) R
27 or -CH
2-OC (O) R
27; or R
20 and R
22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; or R
22 and R
24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; or R
24 and R
26 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; and the glycloside is a monosaccaride.
In certain embodiments of the use, the glycloside is a monosacchairde selected from the group consisting of an α-L isomer and an β-L isomer.
In certain embodiments of the use, the compound is selected from the group consisting of 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
In certain embodiments of the use, the viral infection is selected from the group consisting of HIV, coronaviruses, influenza viruses, Ebola virus, and Marburg virus.
In certain embodiments of the use, each of R
3 and R
4 is -OCH
3; R
8 and R
9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; R
11 and R
12 taken together form oxo; R
19, R
21, R
23, and R
25 are each hydrogen; R
20, R
22, and R
24 are each independently selected from the group consisting of -OR
27, -OC (O) N (R
27) R
27, -OC (O) R
27 and -OC (O) OR
27; R
26 is hydrogen, methyl, -OR
27, -OC (O) R
27 or -CH
2-OC (O) R
27; or R
20 and R
22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1 or 2 group (s) independently selected from C
1-6 alkyl; or R
22 and R
24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1 or 2 group (s) independently selected from C
1-6 alkyl; or R
24 and R
26 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1 or 2 group (s) independently selected from C
1-6 alkyl; and the glycloside is a monosaccaride; and the viral infection is HIV, coronaviruses, influenza viruses, Ebola virus, or Marburg virus.
In a second aspect, provided herein is a compound of Formula (I) :
or a pharmaceutically acceptable salt or pro-drug thereof wherein,
X is oxygen or sulphur;
R
1 is R
15, -OR
15, -C (O) R
15, or -C (O) OR
15;
R
2, R
5, R
6, R
10, R
13, and R
14 are each hydrogen;
R
3 and R
4 are each independently selected from the group consisting of -OR
15 and -OC (O) R
15; or R
3 and R
4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy;
R
7, R
8, and R
9 are each independently selected from the group consisting of -OR
15 and -OC (O) R
15; or R
7 and R
8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; or R
8 and R
9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy;
R
11 and R
12 taken together form oxo; or while one of R
11 and R
12 is hydrogen or halogen, the other one of R
11 and R
12 is selected from the group consisting of R
15, -OR
15, -C (O) R
15 and -C (O) OR
15;
R
15 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, heteroaryl, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N=C (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18, -N (R
17) S (O)
2R
18, 1, 3, 2-dioxaborolane optionally substituted with 1, 2, 3, or 4 group (s) independently selected from alkyl, a glycosidic group, alkynyl optionally substituted with a trialkylsilane, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, wherein k is an integer between 1-6;
R
16 for each occurrence is independently selected from the group consisting of alkynyl, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
17, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18 and -N (R
17) S (O)
2R
18; and
R
17 and R
18 for each occurrence are independently hydrogen, alkyl, alkynyl, cycloalkyl, aryl, or heteroaryl, or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy,
with the proviso that the compound of Formula (I) is not a compound selected from the group consisting of 5, 15a, 15b, 16, 17b, 19d, 25a-25g, and 26a-26g:
In certain embodiments of the compound, each of R
3 and R
4 is -O-alkyl; R
8 and R
9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; and R
11 and R
12 taken together form oxo.
In certain embodiments of the compound, R
1 is heteroaryl, -OR
15, -C (O) R
15, -N (R
17) R
18, -N (R
17) C (O) R
18, -N=C (R
17) R
18, pinacolboryl, -OS (O)
2CF
3, alkynyl optionally substituted with a trialkylsilane, or heterocyclcyl optionally substituted with 1 or 2 group (s) independently selected from R
16; or R
1 is -O (CH
2)
m-cyano, -O (CH
2)
m-alkynyl, -O (CH
2)
m-C (O) N (R
17) R
18, or -O (CH
2)
m-C (O) OR
17, wherein m is a whole number selected from 1-4.
In certain embodiments of the compound, R
1 is heteroaryl, -OR
15, -C (O) R
15, -N (R
17) R
18, -N (R
17) C (O) R
18, -N=C (R
17) R
18, pinacolboryl, -OS (O)
2CF
3, heterocyclcyl optionally substituted with 1 or 2 group (s) independently selected from R
16, or alkynyl optionally substituted with a trialkylsilane; or R
1 is -O (CH
2)
m-cyano, -O (CH
2)
m-alkynyl, -O (CH
2)
m-C (O) N (R
17) R
18, or -O (CH
2)
m-C (O) OR
17, wherein m is a whole number selected from 1-4; each of R
3 and R
4 is -OMe; R
8 and R
9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; and R
11 and R
12 taken together form oxo.
In certain embodiments of the compound, R
1 is alkynyl, pinacolboryl; -N (R
17) R
18, -OCH
2-cyano, -OCH
2-alkynyl, -OCH
2-C (O) N (R
17) R
18, or -OCH
2-C (O) OR
17.
In certain embodiments of the compound, the compound is selected from the group consisting of 12a, 12b, 13, 14a, 14b, 17a, 17c, 17d, 17e, 17f, 17g, 17h, 18, 19a, 19b, 19c, 19e, 19f, 19g, 19h, 19i, 19j, 19k, 19l, 19m, 19n, 19o, 19p, 20, 21, 22, 23 and 24:
In certain embodiments of the compound, R
1 is a glycosidic group selected from the group consisting of a monosaccharide, disaccharide, trisaccharide, tetrasaccharide and polysaccharide group containing less than 30 monosaccharides, wherein the glycosidic group comprises one or more monosacchairdes isomers selected from the group consisting of α-D, α-L, β-D, and β-L.
In certain embodiments of the compound, R
1 is a glycosidic group represented by the Formula (V) :
wherein, R
19 and R
20 taken together to form oxo; or while one of R
19 and R
20 is hydrogen or halogen, the other one of R
19 and R
20 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27;
R
21 and R
22 taken together to form oxo; or while one of R
21 and R
22 is hydrogen or halogen, the other one of R
21 and R
22 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27; or R
20 and R
22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy;
R
23 and R
24 taken together to form oxo; or while one of R
23 and R
24 is hydrogen or halogen, the other one of R
23 and R
24 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27; or R
22 and R
24 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy;
R
25 and R
26 taken together to form oxo; or while one of R
24 and R
25 is hydrogen or halogen, the other one of R
25 and R
26 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, -OC (O) OR
27, -CH
2R
27, and -C (O) R
27; or R
24 and R
26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy;
R
27 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
28, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
28, wherein k is an integer between 1-6;
R
28 for each occurrence is independently selected from halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
29, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30 and -N (R
29) S (O)
2R
30; and
R
29 and R
30 for each occurrence areeach independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
In certain embodiments of the compound, R
19, R
21, R
23, and R
25 are each hydrogen; R
20, R
2, and R
24 are each independently selected from the group consisting of -OR
27, -OC (O) N (R
27) R
27, -OC (O) R
27 and -OC (O) OR
27; and R
26 is hydrogen, methyl, -OR
27, -OC (O) R
27, or -CH
2-OC (O) R
27; or R
20 and R
22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; or R
22 and R
24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; or R
24 and R
26 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; and the glycloside is a monosaccaride.
In certain embodiments of the compound, the glycloside is a monosacchairde selected from the group consisting of an α-L isomer and an β-L isomer.
In certain embodiments of the compound, the compound is selected from the group consisting of 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
In a third aspect, provided herein is a pharmaceutical composition comprising a compound as described herein and at least one pharmaceutically acceptable excipient.
Also provided herein is an arylnaphthalene lignan compounds having the general Formula (I) or (II) or a pharmaceutically acceptable salt or pro-drug thereof, for use in the treatment, prevention or delay of progression of a virus infection in a patient.
or a stereoisomer thereof; or an enantiomer thereof; or a pharmaceutically acceptable salt or pro-drug thereof, wherein
X is oxygen or sulphur;
R
1, R
2, R
3, R
4, R
5, R
6, R
7, R
8, R
9 and R
10 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, boron, nitrogen, oxygen, silicon and sulphur; or R
2 and R
3, R
3 and R
4, R
4 and R
5, R
6 and R
7, R
7 and R
8, R
8 and R
9 or R
9 and R
10 may be taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen and a moiety comprising 1 to 30 plural valence atoms selected from carbon, boron, nitrogen, oxygen, silicon, and sulphur;
R
11 and R
12 taken together form oxo; or while one of R
11 and R
12 is hydrogen or halogen, the other one of R
11 and R
12 is selected from R
15, -OR
15, -C (O) R
15 and -C (O) OR
15;
R
13 and R
14 taken together form oxo; or while one of R
13 and R
14 is hydrogen or halogen, the other one of R
13 and R
14 is selected from R
15, -OR
15, -C (O) R
15 and -C (O) OR
15;
R
15 is independently selected from hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18, -N (R
17) S (O)
2R
18, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, wherein k is an integer between 1 and 6 (e.g. 1, 2 or 3) ;
R
16 is independently selected from halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
17, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18 and -N (R
17) S (O)
2R
18;
R
17 and R
18 are each independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy; and
R is hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
The present disclosure also provides an arylnaphthalene lignan compound having the general Formula (III) or (IV) or a pharmaceutically acceptable salt or pro-drug thereof, for use in the treatment, prevention or delay of progression of a virus infection in a patient.
or a stereoisomer thereof; or an enantiomer thereof; or a pharmaceutically acceptable salt or pro-drug thereof wherein,
X is oxygen or sulphur;
the glycosidic group is generally a carbohydrate group, especially a monosaccharide, disaccharide, trisaccharide, tetrasaccharide or polysaccharide group, and may exist in various isomeric forms, for example α-D, α-L, β-D or β-L forms; the carbohydrate group may be optionally substituted with other type of substituents or even additional glycosidic groups; the total number of monosaccharide and substituted monosaccharide contained in the chemical structure of the compound of Formula (III) and Formula (IV) may not exceed 30;
R
1, R
2, R
3, R
4, R
5, R
6, R
7, R
8 and R
9 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur; or R
1 and R
2, R
2 and R
3, R
3 and R
4, R
5 and R
6, R
6 and R
7, R
7 and R
8, R
8 and R
9 may be taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur;
R
10 and R
11 may be taken together to form oxo; or while one of R
10 and R
11 is hydrogen or halogen, the other one of R
10 and R
11 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, and -C (O) OR
27;
R
12 and R
13 may be taken together to form oxo; or while one of R
12 and R
13 is hydrogen or halogen, the other one of R
12 and R
13 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, and -C (O) OR
27;
R
19 and R
20 taken together to form oxo; or while one of R
19 and R
20 is hydrogen or halogen, the other one of R
19 and R
20 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
R
21 and R
22 taken together to form oxo; or while one of R
21 and R
22 is hydrogen or halogen, the other one of R
21 and R
22 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
R
23 and R
24 taken together form oxo; or while one of R
23 and R
24 is hydrogen or halogen, the other one of R
23 and R
24 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
R
25 and R
26 taken together form oxo; or while one of R
25 and R
26 is hydrogen or halogen, the other one of R
25 and R
26 is selected from R
27, -OR
27, -C (O) R
27, -C (O) OR
27, -CH
2R
31 and -C (O) R
31;
R
27 is independently selected from hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, and -N (R
29) S (O)
2R
30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, wherein k is an integer between 1 and 6 (e.g. 1, 2 or 3) ;
R
28 is independently selected from halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
29, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, and -N (R
29) S (O)
2R
30;
R
29 and R
30 are each independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, cyano, amino, hydroxy, C
1-6 alkyl, and C
1-6 alkoxy;
R
31 is independently selected from hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, substituted tetrasaccharide, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, and heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28; and
R is hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
A fourth aspect of the invention is a pharmaceutical formulation comprising an arylnaphthalene lignan compound, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
A fifth aspect of the invention is a pharmaceutical formulation comprising a glycosidic arylnaphthalene lignan compound, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
A sixth aspect of the invention is a pharmaceutical formulation comprising a diphyllin analog, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
A seventh aspect of the invention is a pharmaceutical formulation comprising a patentiflorin A analog, or a pharmaceutically acceptable salt or prodrug thereof, for use in the treatment, prevention or delay of progression of a viral infection in a patient.
Another aspect of the invention concerns the method to provide synthesis of new arylnaphthalene lignan compounds as well as the intermediate compounds during the synthesis. In addition, the invention is directed to an intermediary compound useful in preparing other compounds of the invention.
Compounds of the invention may exist in different forms, such as free acids, free bases, esters and other prodrugs, salts and tautomers, and the disclosure includes all variant forms of these compounds.
The extent of protection includes counterfeit or fraudulent products which contain or purport to contain a compound of the invention irrespective of whether they do in fact contain such a compound and irrespective of whether any such compound is contained in a therapeutically effective amount.
Included in the scope of protection are packages which include a description or instructions which indicate that the package contains a species or pharmaceutical formulation of the invention and a product which is or comprises, or purports to be or comprise, such a formulation or species. Such packages may be, but are not necessarily, counterfeit or fraudulent.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
Figure 1 shows the structure and carbon numbering of patentiflorin A and schematic preparation of diphyllin (5) .
Figure 2 shows schematic preparation of diphyllin analogs 12-17 (for preparation of compound 14a, the reaction reagents and conditions of a: NH
4Cl, HATU, Et
3N, CH
2Cl
2; for preparation of compound 14b, the reaction reagents and conditions of b: MeNH
2, EDCI, HOBt and THF; for preparation of compound 15a, the reaction reagents and conditions of c: PdCl
2, K
2CO
3, TBAB, H
2O, 60℃; for preparation of compound 15b, the reaction reagents and conditions of d: Cs
2CO
3, DMF, 120℃; for preparation of compounds 17a-17c, the reaction reagents and conditions of e: Cs
2CO
3, acetone, r.t.; for preparation of compounds 17d, the reaction reagents and conditions of f: K
2CO
3, DMF, 100℃; for preparation of compounds 17e-17h, the reaction reagents and conditions of g: Et
3N, DMAP, CH
2Cl
2, 25℃) .
Figure 3 shows schematic preparation of diphyllin analogs 18-24 (for preparation of compound 19a, the reaction reagents and conditions of a: [Pd (dppf) Cl
2] CH
2Cl
2, KOAc, B
2 (Pin)
2, dioxane, 100℃; for preparation of compound 19b, the reaction reagents and conditions of b: [Pd (dppf) Cl
2] CH
2Cl
2, AlMe
3, toluene, 100℃; for preparation of compound 19c, the reaction reagents and conditions of c: [Pd (dppf) Cl
2] CH
2Cl
2, Na
2CO
3, pyridine-4-boronic acid, H
2O, Dioxane, 100℃; for preparation of compound 19d, the reaction reagents and conditions of d: Pd (OAc)
2, PPh
3, Et
3N, HCO
2H, DMF, 100℃; for preparation of compounds 19e and 19f, the reaction reagents and conditions of e: Pd (OAc)
2, BINAP, Cs
2CO
3, RH, toluene, 100℃; for preparation of compound 19g, the reaction reagents and conditions of f: Pd (PPh
3)
4, Et
2Zn, THF, 100℃; for preparation of compounds 19h-19j, the reaction reagents and conditions of g: Pd (PPh
3)
4, K
2CO
3, RB (OH)
2, DMF, 100℃; for preparation of compound 19k, the reaction reagents and conditions of h: Pd (PPh
3)
4, Na
2CO
3, furan-2-boronic acid, H
2O, Dioxane, 100℃; for preparation of compound 19l, the reaction reagents and conditions of i: Pd (PPh
3)
4, Na
2CO
3, 1-Boc-3, 6-dihydro-2H-pyridine-4- boronic acid pinacol ester, H
2O, Dioxane, 100℃; for preparation of compound 19m, the reaction reagents and conditions of j: Pd
2 (dba)
3, XantPhos, Cs
2CO
3, morpholine DMF, 100℃; for preparation of compound 19n, the reaction reagents and conditions of k: Pd (PPh
3)
2Cl
2, tributyl (1-ethoxyvinyl) tin, PhMe, 100 ℃, followed by 50%HCl; for preparation of compound 19o, the reaction reagents and conditions of l: Pd (PPh
3)
2Cl
2, CuI, Et
3N, DMF, trimethylsilylacetylene, 80℃; for preparation of compound 19p, the reaction reagents and conditions of m: Pd (OAc)
2, Cs
2CO
3, Xantphos, Et
3N, benzophenone imine, dioxane, 100℃; for preparation of compound 20, the reaction reagents and conditions of n: NaBH
4, MeOH, rt; for preparation of compound 21, the reaction reagents and conditions of o: K
2CO
3, MeOH, r.t.; for preparation of compound 22, the reaction reagents and conditions of p: HCl, THF, r.t., followed by KOH, r.t.; for preparation of compound 23, the reaction reagents and conditions of q: Cs
2CO
3, propargyl bromide, MeCN, r.t.; for preparation of compound 24, the reaction reagents and conditions of r: Ac
2O, pyridine, r.t. ) .
Figure 4 shows schematic preparation of patentiflorin A analogs 25a-25g and 26a-26g. Compounds 26a, 26b, 26c, 26d, 26e, 26f and 26g are produced from 25a, 25b, 25c, 25d, 25e, 25f and 25g, respectively.
Figure 5 shows schematic preparation of patentiflorin A analogs 27aa-27af, 27ba-27bf, 28ab1-28ab3, 28bb1-28bb3, 29a, 29b, 30a-30l and 31a-31l (for preparation of compounds 27aa-27af and 27ba-27bf, the reaction reagents and conditions of a: Ac
2O, TBAOAc, MeCN, 40℃; for preparation of compounds 28ab1 to 28ab3 and 28bb1 to 28bb3, the reaction reagents and conditions of b: AllocOCl, Et
3N, CH
2Cl
2, 0℃ to r.t.; for preparation of compounds 29a and 29b, the reaction reagents and conditions of c: AcCl, CH
2Cl
2, MeOH, 0℃ to r.t.; for preparation of compounds 30a-k, the reaction reagents and conditions of d: Et
3N, DMAP, dry CH
2Cl
2, 0℃ to r.t.; for preparation of compounds 30l, the reaction reagents and conditions of e: KOH, 18-Crown-6, THF, r.t.; for preparation of compounds 31a-l, the reaction reagents and conditions of f: (PPh
3)
4Pd, PPh
3, Et
3N, HCOOH, THF, N
2, 55℃) . Compounds 27aa, 27ab, 27ac, 27ad, 27ae and 27af are produced from 26a. Compounds 27ba, 27bb, 27bc, 27bd, 27be and 27bf are produced from 26b. Compounds 28ab1, 28ab2 and 28ab3 are produced from 27ab. Compounds 28bb1, 28bb2 and 28bb3 are produced from 27bb. Compounds 29a and 29b are produced from 28ab3 and 28bb3, respectively. Compounds 30a and 30l are produced from 29a. Compounds 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j and 30k are produced from 29b. Compounds 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k and 31l are produced from 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k and 30l, respectively.
Figure 6 shows schematic preparation of patentiflorin A analogs 32a-32d. Compounds 32a is produced from 26f. Compounds 32b-32d are produced from 26g.
The present disclosure is not to be limited in scope by any of the specific embodiments described herein. The following embodiments are presented for exemplification only.
Throughout the description and claims of this specification the word “comprise” and other forms of the word such as “comprising” and “comprises, ” means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps.
As used in the description and the appended claims, the singular forms “a, ” “an, ” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a composition” includes mixtures of two or more such compositions, reference to “the compound” includes mixtures of two or more such compounds, reference to “an agent” includes mixture of two or more such agents, and the like.
“Optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
As used herein by a “subject” is meant an individual. Thus, the “subject” can include domesticated animals (e.g., cats, dogs, etc. ) , livestock (e.g., cattle, horses, pigs, sheep, goats, etc. ) , laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc. ) , and birds. “Subject” can also include a mammal, such as a primate or a human.
By “reduce” or other forms of the word, such as “reducing” or “reduction, ” is meant lowering of an event or characteristic (e.g., tumor growth) . It is understood that this is typically in relation to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces tumor growth” means reducing the rate of growth of a tumor relative to a standard or a control.
By “prevent” or other forms of the word, such as “preventing” or “prevention, ” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented. Likewise, something could be prevented but not reduced, but something that is prevented could also be reduced. It is understood that where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed.
By “treat” or other forms of the word, such as “treated” or “treatment, ” is meant to administer a composition or to perform a method in order to reduce, prevent, inhibit, or eliminate a particular characteristic or event (e.g., tumor growth or survival) . The term “control” is used synonymously with the term “treat. ”
The term “antiviral” refers to the ability to inhibit the replication of the particular virus, to inhibit viral transmission, or to prevent the virus from establishing itself in its host, and to ameliorate or alleviate the symptoms of the disease caused by the viral infection. The treatment is considered therapeutic if there is a reduction in viral load, decrease in mortality and/or morbidity.
The term “therapeutically effective” means the amount of the composition used is of sufficient quantity to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration only requires a reduction or alteration, not necessarily elimination.
As used herein, the term pharmaceutically acceptable salt refers to any salt of the compound of this invention which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use. Such salts may be derived from a variety of organic and inorganic counterions well known in the art and include them. Such salts include: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3- (4-hydroxybenzoyl) benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1, 2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo [2.2.2] -oct-2-ene-1-carboxylic, glucoheptonic, 3-phenylpropionic, trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, benzoic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid and the like acids; or (2) salts formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth ion or an aluminum ion) , or alkali metal or alkaline earth metal hydroxides (e.g., sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide) , ammonia or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N, N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucamine piperazine, tris (hydroxymethyl) -aminomethane, tetramethylammonium hydroxide, and the like. In addition, examples of salts include sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrohalides (e.g., hydrochloride and hydrobromide) , sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate; fumarate, tartarate, citrate, benzoate, 3- (4-hydroxybenzoyl) benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate) , ethanesulfonate, 1, 2-ethane-disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate) , 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-methylbicyclo [2.2.2] -oct-2-ene-1-carboxylate, glucoheptonate, 3-phenylpropionate, trimethylacetate, tert-butylacetate, lauryl sulfate, gluconate, benzoate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, muconate and the like.
The term “glycoside” or “glycosidic” compound as used herein is interchangeable and includes reference to any of the class of compounds that yield a sugar and an aglycone upon hydrolysis.
The term “ANL” or “aryl naphthalene lignan” or “arylnaphthalene lignan” compound as used herein is interchangeable.
The term “aryl naphthalene lignan” or “arylnaphthalene lignan” or “ANL” as used herein includes reference to a compound comprising the basic structure of 2, 3-dimethyl-1-phenyl-naphthalene shown as below:
The carbon numbering of aryl naphthalene lignan molecule as used herein includes reference to a compound comprising numbering system shown as below:
In one class of the core structure of an aryl naphthalene compound, the two methyl groups are forming a γ-lactone ring to become as aryl naphthofuran-2-one lignan or aryl naphthofuran-3-one lignan shown as below:
Aryl naphthofuran-2-one lignan or
Aryl naphthofuran-3-one lignan
The carbon numbering of an aryl naphthalene lignan glycoside molecule as used herein includes reference to a compound comprising numbering system shown as below:
The term “hydrocarbyl” as used herein includes reference to a moiety consisting exclusively of hydrogen and carbon atoms; such a moiety may comprise an aliphatic and/or an aromatic moiety. The moiety may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. Examples of hydrocarbyl groups include C
1-6 alkyl (e.g. C
1, C
2, C
3 or C
4 alkyl, for example methyl, ethyl, propyl, isopropyl. n-butyl, sec-butyl or tert-butyl) ; C
1-6 alkyl substituted by aryl (e.g. benzyl) or by cycloalkyl (e.g. cyclopropylmethyl) ; cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) ; aryl (e.g. phenyl, naphthyl or fluorenyl) ; C
1-6 alkenyl (e.g. ethenyl, 2-propenyl or 3-butenyl) ; C
1-6 alkynyl (e.g. ethynyl, 2-propynyl or 3-butynyl) and the like.
The terms “alkyl” and “C
1-6 alkyl” as used herein include reference to a straight or branched chain alkyl moiety having 1, 2, 3, 4, 5 or 6 carbon atoms. This term includes reference to groups such as methyl, ethyl, propyl (n-propyl or isopropyl) , butyl (n-butyl, sec-butyl or tert-butyl) , pentyl, hexyl and the like. In particular, the alkyl moiety may have 1, 2, 3 or 4 carbon atoms.
The terms “alkenyl” as used herein include reference to a straight or branched chain alkyl moiety having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and having, in addition, at least one double bond, of either E or Z stereochemistry where applicable. This term includes reference to groups such as ethenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1-hexenyl, 2-hexenyl and 3-hexenyl and the like.
The terms “alkynyl” as used herein include reference to a straight or branched chain alkyl moiety having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms and having, in addition, at least one triple bond. This term includes reference to groups such as ethynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 1-hexynyl, 2-hexynyl and 3-hexynyl and the like.
The terms “alkoxy” and “C
1-6 alkoxy” as used herein include reference to -O-alkyl, wherein alkyl is straight or branched chain and comprises 1, 2, 3, 4, 5 or 6 carbon atoms. In one class of embodiments, alkoxy has 1, 2, 3 or 4 carbon atoms. This term includes reference to groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tertbutoxy, pentoxy, hexoxy and the like.
The term “cycloalkyl” as used herein includes reference to an alicyclic moiety having 3, 4, 5, 6, 7 or 8 carbon atoms. The group may be a bridged or polycyclic ring system. More often cycloalkyl groups are monocyclic. This term includes reference to groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbomyl, bicyclo [2.2.2] octyl and the like.
The term “aryl” as used herein includes reference to an aromatic ring system comprising 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring carbon atoms. Aryl is often phenyl but may be a polycyclic ring system, having two or more rings, at least one of which is aromatic. This term includes reference to groups such as phenyl, naphthyl, fluorenyl, azulenyl, indenyl, anthryl and the like.
“Cyclic group” means a ring or ring system, which may be unsaturated or partially unsaturated but is usually saturated, typically containing 5 to 13 ring-forming atoms, for example a 5-or 6-membered ring. It includes carbocyclyl and heterocyclyl moeities.
The term "carbocyclyl” as used herein includes reference to a saturated (e.g. cycloalkyl) or unsaturated (e.g. aryl) ring moiety having 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 carbon ring atoms. In particular, carbocyclyl includes a 3-to 10-membered ring or ring system and, in particular, 5-or 6-membered rings, which may be saturated or unsaturated. A carbocyclic moiety is, for example, selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbomyl, bicyclo [2.2.2] octyl, phenyl, naphthyl, fluorenyl, azulenyl, indenyl, anthryland the like.
The term “heterocyclyl” as used herein includes reference to a saturated (e.g. heterocycloalkyl) or unsaturated (e.g. heteroaryl) heterocyclic ring moiety having from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms, at least one of which is selected from boron, nitrogen, oxygen, phosphorus, silicon and sulphur. In particular, heterocyclyl includes a 3-to 10-membered ring or ring system and more particularly a 5 or 6-membered ring, which may be saturated or unsaturated.
A heterocyclic moiety is, for example, selected from oxiranyl, azirinyl, 1.2-oxathiolanyl, imidazolyl, thienyl, furyl, tetrahydrofuryl, pyranyl, thiopyranyl, thianthrenyl, isobenzofuranyl, benzofuranyl, chromenyl, 2H-pyrrolyl pyrrolyl pyrrolinyl, pyrrolidinyl, pyrrolizidinyl, imidazolyl, imidazolidinyl, benzimidazolyl, pyrazolyl pyrazinyl, pyrazolidinyl, thiazolyl, isothiazolyl, dithiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, piperidyl, piperazinyl, pyridazinyl, morpholinyl, thiomorpholinyl, especially thiomorpholino, indolizinyl, isoindolyl, 3H-indolyl, indolyl, benzimidazolyl, cumaryl, indazolyl, triazolyl, tetrazolyl, purinyl, 4N-quinolizinyl, isoquinolyl, quinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, decahydroquinolyl, octahydroisoquinolyl, benzofuranyl, dibenzofuranyl, benzothiophenyl, dibenzothiophenyl, phthalazinyl, naphthyridinyl, quinoxalyl, quinazolinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, B-carbolinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, furazanyl, phenazinyl, phenothiazinyl, phenoxazinyl, chromenyl, isochromanyl, chromanyl, 1, 3, 2-dioxaborolane, and the like.
The term "heterocycloalkyl” as used herein includes reference to a saturated heterocyclic moiety having 3, 4, 5, 6 or 7 ring carbon atoms and 1, 2, 3, 4 or 5 ring heteroatoms selected from nitrogen, oxygen, phosphorus and sulphur. The group may be a polycyclic ring system but more often is monocyclic. This term includes reference to groups such as azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, oxiranyl, pyrazolidinyl, imidazolyl, indolizidinyl, piperazinyl, thiazolidinyl, morpholinyl, thiomorpholinyl, quinolizidinyl and the like.
The term “heteroaryl” as used herein includes reference to an aromatic heterocyclic ring system having 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 ring atoms, at least one of which is selected from nitrogen, oxygen and sulphur. The group may be a polycyclic ring system, having two or more rings, at least one of which is aromatic, but is more often monocyclic. This term includes reference to groups such as pyrimidinyl, furanyl, benzobthiophenyl, thiophenyl, pyrrolyl, imidazolyl, pyrrolidinyl, pyridinyl, benzobfuranyl, pyrazinyl, purinyl, indolyl, benzimidazolyl, quinolinyl, phenothiazinyl, triazinyl, phthalazinyl, 2H-chromenyl, oxazolyl, isoxazolyl, thiazolyl, isoindolylindazolyl, purinyl, isoquinolinyl, quinazolinyl, pteridinyl and the like.
The term “halogen” as used herein includes reference to F, Cl, Br or I.
The expression “halogen containing moiety” as used herein includes reference to a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur which moiety includes at least one halogen. The moiety may be hydrocarbyl for example C
1-6 alkyl or C
1-6 alkoxy, or carbocyclyl for example aryl.
The term “substituted” as used herein in reference to a moiety means that one or more, especially up to 5, more especially 1, 2 or 3, of the hydrogen atoms in said moiety are replaced independently of each other by the corresponding number of the described substituents. The term “optionally substituted as used herein means substituted or un-substituted. It will, of course, be understood that substituents are only at positions where they are chemically possible, the person skilled in the art being able to decide (either experimentally or theoretically) without inappropriate effort whether a particular substitution is possible.
Where two or more moieties are described as being “each independently” selected from a list of atoms or groups, this means that the moieties may be the same or different. The identity of each moiety is therefore independent of the identities of the one or more other moieties.
The term “enantiomer” as used herein means one of two stereoisomers that have mirror images of one another.
The term “stereoisomer” as used herein means one of class of isomeric molecules that have the same molecular formula and sequence of bonded atoms, but different three-dimensional orientations of their atoms in space.
The term “tautomer” means isomeric molecules that readily interconvert by a chemical reaction. The reaction commonly results in the migration of a hydrogen atom, which results in a switch of a single bond and adjacent double bond.
A prodrug is a medication that is administered as an inactive (or less than fully active) chemical derivative that is subsequently converted to an active pharmacological agent in the body, often through normal metabolic processes.
CC
50 is a cytotoxicity measure of the concentration for a test drug to inhibit cell growth by 50%.
EC
50 is an antiviral activity measure of the effective concentration for a test drug to inhibit viral growth by 50%
.
The term “selectivity index” or “SI” means a ratio that measures the window between cytotoxicity and antiviral activity by dividing the given CC
50 value into the IC
50 value (CC
50/IC
50) of a test drug. The higher SI ratio means more effective and safer a test drug would be for a given viral infection in an in vitro experiment.
The symbol
in a chemical structure represents a position from where the specified chemical structure is bonded to another chemical structure.
The symbol “β” in a chemical structure indicates that the bond connection is above (or before) the plane of the paper or screen. The symbol “α” in a chemical structure indicates that the bond connection is below (or behind) the plane of the paper or screen.
A solid wedge in a chemical structure indicates that this bond is above (or before) the plane of the paper or screen toward to the viewer. A hashed (or broken) wedge in a chemical structure indicates that the bond connection is below (or behind) the plane of the paper or screen receding away from the viewer.
Provided herein is a compound and use of the the compound in the manufacture of a medicament for treating a viral infection and a method of using the compound for treating a viral infection in a subject, comprising the step of administering a therapeutically effective amount of the compound to the subject, wherein the compound has the Formula (I) :
or a pharmaceutically acceptable salt or pro-drug thereof wherein,
X is oxygen or sulphur;
R
1 is R
15, -OR
15, -C (O) R
15, or -C (O) OR
15;
R
2, R
5, R
6, R
10, R
13, and R
14 are each independently hydrogen or halogen;
R
3 and R
4 are each independently selected from the group consisting of -OR
15 and -OC (O) R
15; or R
3 and R
4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16;
R
7, R
8, and R
9 are each independently selected from the group consisting of -OR
15 and -OC (O) R
15; or R
7 and R
8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16; or R
8 and R
9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16;
R
11 and R
12 taken together form oxo; or while one of R
11 and R
12 is hydrogen or halogen, the other one of R
11 and R
12 is selected from the group consisting of R
15, -OR
15, -C (O) R
15 and -C (O) OR
15;
R
15 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, heteroaryl, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, - S (O)
2N (R
17) R
18, -N=C (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18, -N (R
17) S (O)
2R
18, 1, 3, 2-dioxaborolane optionally substituted with 1, 2, 3, or 4 group (s) independently selected from alkyl, a glycosidic group, alkynyl optionally substituted with a trialkylsilane, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R
16, wherein k is an integer between 1-6;
R
16 for each occurrence is independently selected from the group consisting of alkynyl, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
17, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18 and -N (R
17) S (O)
2R
18; and
R
17 and R
18 for each occurrence are independently hydrogen, alkyl, alkynyl, cycloalkyl, aryl, or heteroaryl, or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, trichloromethyl, trifluoromethyl, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
In certain embodiments, the compound of Formula (I) is not a compound selected from the group consisting of 5, 15a, 15b, 16, 17b, 19d, 25a-25g, and 26a-26g:
In certain embdoiments, R
1 is hydrogen, alkyl, aryl, heteroaryl (such as furan, thiophene, pyridine, and the like) , -N (R
17) R
18, -N=C (R
17) (R
18) , alkynyl optionally substituted with a trialkylsilane, a glycosidic group, 1, 3, 2-dioxaborolane optionally substituted with 1, 2, 3, or 4 group (s) independently selected from alkyl, or -O- (CR
2)
m-R
16, wherein m is a whole number selected from 1-4, 1-3, or 1-2; R for each occurrence is independently hydrogen, alkyl, cycloalkyl, or aryl; and R
16 is alkynyl, cyano, -OR
17, -N (R
17) R
18, -C (O) N (R
17) R
18, or -C (O) OR
17.
In certain embdoiments, R
1 is -O-CH
2-R
16, wherein R
16 is -C≡CH, cyano, -OR
17, -N (R
17) R
18, -C (O) N (R
17) R
18, or -C (O) OR
17.
In certain embodiments, each of R
3 and R
4 is independently selected from the group consisting of -OR
15 and -OC (O) R
15, wherein R
15 is hydrogen, alkyl, cycloalkyl, heterocyclcyl, aryl, and heteroaryl; or R
3 and R
4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl. In certain embodiments, R
3 and R
4 is -OR
15, wherein R
15 is C
1-C
6 alkyl, C
1-C
4 alkyl, or C
1-C
2 alkyl.
In certain embodiments, each of R
8 and R
9 is independently selected from the group consisting of -OR
15 and -OC (O) R
15, wherein R
15 is hydrogen, alkyl, cycloalkyl, heterocyclcyl, aryl, and heteroaryl; or R
8 and R
9 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl. In certain embodiments, R
8 and R
9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring.
In certain embodiments, R
11 and R
12 taken together form oxo.
In certain embodiments, each of R
3 and R
4 is -O-alkyl; R
8 and R
9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; R
1 is heteroaryl, -OR
15, -C (O) R
15, -N (R
17) R
18, -N (R
17) C (O) R
18, -N=C (R
17) R
18, pinacolboryl, -OS (O)
2CF
3, a glycosidic group, heterocyclcyl optionally substituted with 1 or 2 group (s) independently selected from R
16, or alkynyl optionally substituted with a trialkylsilane; or R
1 is -OCH
2-cyano, -OCH
2-C≡CH, -OCH
2-C (O) N (R
17) R
18, or -C (O) OR
17; and R
11 and R
12 taken together form oxo.
In certain embodiments, the compound is selected compounds 12a, 12b, 13, 14a, 14b, 17a, 17c, 17d, 17e, 17f, 17g, 17h, 18, 19a, 19b, 19c, 19e, 19f, 19g, 19h, 19i, 19j, 19k, 19l, 19m, 19n, 19o, 19p, 20, 21, 22, 23 and 24:
In certain embodiments, R
1 is a glycosidic group represented by the Formula (V) :
wherein, R
19 and R
20 taken together to form oxo; or while one of R
19 and R
20 is hydrogen or halogen, the other one of R
19 and R
20 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27;
R
21 and R
22 taken together to form oxo; or while one of R
21 and R
22 is hydrogen or halogen, the other one of R
21 and R
22 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27; or R
20 and R
22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy;
R
23 and R
24 taken together to form oxo; or while one of R
23 and R
24 is hydrogen or halogen, the other one of R
23 and R
24 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, and -OC (O) OR
27; or R
22 and R
24 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy;
R
25 and R
26 taken together form oxo; or while one of R
25 and R
26 is hydrogen or halogen, the other one of R
25 and R
26 is selected from the group consisting of R
27, -OR
27, -OC (O) R
27, -OC (O) N (R
27) R
27, -OC (O) OR
27, -CH
2R
27, and -C (O) R
27; or R
24 and R
26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy;
R
27 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, wherein k is an integer between 1-6;
R
28 for each occurrence is independently selected from halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
29, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30 and -N (R
29) S (O)
2R
30; and
R
29 and R
30 for each occurrence areeach independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
In certain embodiments, the glycosidic group is a monosaccharide, disaccharide, trisaccharide, tetrasaccharide or polysaccharide group, and may exist in any isomeric form, for example α-D, α-L, β-D or β-L forms. In certain embodiments, the glycloside is a monosacchairde selected from the group consisting of an α-L isomer and an β-L isomer.
In certain embodiments, R
19, R
21, R
23, and R
25 are each hydrogen; R
20, R
22, and R
24 are each independently selected from the group consisting of -OR
27, -OC (O) N (R
27) R
27, -OC (O) R
27 and -OC (O) OR
27; and R
26 is hydrogen, methyl, -OR
27, -OC (O) R
27, or -CH
2-OC (O) R
27; or R
20 and R
22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; or R
22 and R
24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; or R
24 and R
26 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C
1-6 alkyl and C
1-6 alkoxy; and the glycloside is a monosaccaride.
In certain embodiments, R
20, R
22, and R
24 are each independently selected from the group consisting of -OR
27, -OC (O) N (R
27) R
27, -OC (O) R
27 and -OC (O) OR
27, wherein R
27 for each occurrence is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, aryl, aralkyl, heteroaryl, perhaloalkyl, and -C (O) CH
2CN.
In instances in which R
1 is a glycosidic group, the compound can be selected from the group consisting of: 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
The present disclosure also provides aryl naphthalene glycoside compounds, including derivatives of diphyllin, patentiflorin A, justiprocuminA or justiprocumin B useful in the treatment of viral infections.
In certain embodiments, the compound has the Formula (I) or (II) :
or a stereoisomer thereof; or an enantiomer thereof; or a pharmaceutically acceptable salt or pro-drug thereof wherein
X is oxygen or sulphur;
R
1, R
2, R
3, R
4, R
5, R
6, R
7, R
8, R
9 and R
10 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur; or R
2 and R
3, R
3 and R
4, R
4 and R
5, R
6 and R
7, R
7 and R
8, R
8 and R
9 or R
9 and R
10 may be taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with halogen and a moiety comprising 1 to 30 plural valence atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur;
R
11 and R
12 taken together form oxo; or while one of R
11 and R
12 is hydrogen or halogen, the other one of R
11 and R
12 is selected from the group consisting of R
15, -OR
15, -C (O) R
15 and -C (O) OR
15;
R
13 and R
14 taken together form oxo; or while one of R
13 and R
14 is hydrogen or halogen, the other one of R
13 and R
14 is selected from the group consisting of R
15, -OR
15, -C (O) R
15 and -C (O) OR
15;
R
15 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 R
16, heterocyclcyl optionally substituted with1, 2, 3, 4 or 5 R
16, - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 R
16, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18 and -N (R
17) S (O)
2R
18, wherein k is an integer between 1 and 6 (e.g. 1, 2 or 3) ;
R
16 is independently selected from the group consisting of halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
17, -OR
17, -C (O) R
18, -C (O) N (R
17) R
18, -C (O) OR
17, -OC (O) R
17, -S (O)
2R
17, -S (O)
2N (R
17) R
18, -N (R
17) R
18, -N (R
17) N (R
17) R
18, -N (R
17) C (O) R
18 and -N (R
17) S (O)
2R
18; and
R
17 and R
18 are each independently hydrogen or selected from the group consisting of hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
In certain embodiments, the compounds has the Formula (III) or (IV) :
or a steroisomer thereof; or an enantiomer thereof; of a pharmacueitcally acceptable salt or pro-drug thereof wherein,
X is sulfer or oxygen;
R
1, R
2, R
3, R
4, R
5, R
6, R
7, R
8 and R
9 are each independently hydrogen, halogen or a moiety comprising 1 to 30 plural valence atoms selected from carbon, nitrogen, oxygen and sulphur; or R
1 and R
2, R
2 and R
3, R
3 and R
4, R
5 and R
6, R
6 and R
7, R
7 and R
8, and/or R
8 and R
9 taken together with the carbon atoms to which they are attached to form a cyclic group which is optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from halogen and a moiety comprising 1 to 30 plural valence atoms selected from the group consisting of carbon, nitrogen, oxygen and sulphur;
R
10 and R
11 taken together form oxo; or while one of R
10 and R
11 is hydrogen or halogen, the other one of R
10 and R
11 is selected from the group consisting of R
22, -OR
22, -C (O) R
22, and -C (O) OR
22;
R
12 and R
13 taken together form oxo; or while one of R
12 and R
13 is hydrogen or halogen, the other one of R
12 and R
13 is selected from the group consisting of R
22, -OR
22, -C (O) R
22, and -C (O) OR
22;
R
19 and R
20 taken together form oxo; or while one of R
19 and R
20 is hydrogen or halogen, the other one of R
19 and R
20 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
R
21 and R
22 taken together form oxo; or while one of R
21 and R
22 is hydrogen or halogen, the other one of R
16 and R
17 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide and substituted tetrasaccharide;
R
23 and R
24 taken together form oxo; or while one of R
23 and R
24 is hydrogen or halogen, the other one of R
23 and R
24 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
R
25 and R
26 taken together form oxo; or while one of R
25 and R
26 is hydrogen or halogen, the other one of R
25 and R
26 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, -CH
2R
31 and -C (O) R
31;
R
27 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from the group consisiting of R
23, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from the group consisting of R
28, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from group (s) independently selected R
28, wherein k is an integer between 1 and 6 (e.g. 1, 2 or 3) ;
R
28 is independently selected from the group consisting of halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
29, -OR
29, -C (O) R
30, - C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30 and -N (R
29) S (O)
2R
30;
R
29 and R
30 are each independently hydrogen or selected from the group consisting of hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy;
R
31 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, substituted tetrasaccharide, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from the group consisting of R
28, and heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) selected from the group consisting of R
28; and
R is hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy.
In certain embodiments, the glycosidic group can be a carbohydrate group, such as a monosaccharide, disaccharide, trisaccharide, tetrasaccharide or polysaccharide group, and may exist in any isomeric form, for example α-D, α-L, β-D or β-L forms. The carbohydrate group may be optionally substituted with other type of substituents or even additional glycosidic groups. However, the total number of monosaccharide and substituted monosaccharide contained in the chemical structure of a compound is generally 30 or less.
In certain embodiments, the glycosidic group may comprise one or more monosaccaride units of Formula (V) or (VI) :
wherein R
19 and R
20 taken together form oxo; or while one of R
19 and R
20 is hydrogen or halogen, the other one of R
19 and R
20 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
R
21 and R
22 taken together form oxo; or while one of R
21 and R
22 is hydrogen or halogen, the other one of R
21 and R
22 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, and substituted tetrasaccharide;
R
23 and R
24 taken together form oxo; or while one of R
23 and R
24 is hydrogen or halogen, the other one of R
23 and R
24 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide and substituted tetrasaccharide;
R
25 and R
26 taken together form oxo; or while one of R
25 and R
26 is hydrogen or halogen, the other one of R
25 and R
26 is selected from the group consisting of R
27, -OR
27, -C (O) R
27, -C (O) OR
27, -CH
2R
31, and -C (O) R
31;
R
27 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, wherein k is an integer between 1 and 6 (e.g. 1, 2 or 3) ;
R
28 is independently selected from the group consisting of halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR
29, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30 and -N (R
29) S (O)
2R
30;
R
29 and R
30 are each independently hydrogen or selected from the group consisting of hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C
1-6 alkyl and C
1-6 alkoxy; and
R
31 is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR
29, -C (O) R
30, -C (O) N (R
29) R
30, -C (O) OR
29, -OC (O) R
29, -S (O)
2R
29, -S (O)
2N (R
29) R
30, -N (R
29) R
30, -N (R
29) N (R
29) R
30, -N (R
29) C (O) R
30, -N (R
29) S (O)
2R
30, monosaccharide, substituted monosaccharide, disaccharide, substituted disaccharide, trisaccharide, substituted trisaccharide, tetrasaccharide, substituted tetrasaccharide, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, and - (CH
2)
k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of R
28, wherein k is an integer between 1 and 6 (e.g. 1, 2 or 3) .
In certain embodiments, the glycosidic group comprises 1, 2, 3, or 4 monosaccaride units, wherein each monosaccharide unit in the glycosidic group is independently for each occurrence a monosaccaride unit of Formula (III) or Formula (IV) .
In certain embodiments, R
1, R
4, R
5, R
8 and R
9 are each independently hydrogen, hydroxy or methoxy; R
2 and R
3 are each independently hydrogen, hydroxy, methoxy, or taken together with the carbon atoms to which they are attached form a [1, 3] dioxole cyclic group; R
6 and R
7 are each independently hydrogen, hydroxy, methoxy; or R
6 and R
7 taken together with the carbon atoms to which they are attached form a [1, 3] dioxole cyclic group; R
10 and R
11 taken together form oxo; R
12 and R
13 are each independently hydrogen; and X is oxygen.
Exemplary glycosidic groups include glucopyranoside, galactopyranoside, mannopyranoside, fucopyranoside, arabinopyranoside, glucopyranoside, galactopyranoside, glucuronide, lactopyranoside, xylopyranoside, glucosaminide, galactosaminide, alloside, lyxoside, taloside, threoside, riboside, fructoside, rhamnoside and guloside groups. More particularly, the glycosidic group may be selected from α-D-glucopyranoside, α-D-galactopyranoside, α-D- mannopyranoside, α-L-fucopyranoside, α-L-arabinopyranoside, β-D-glucopyranoside, β-D-galactopyranoside, β-D-glucuronide, β-D-lactopyranoside, β-D-xylopyranoside, β-D-glucosaminide, β-D-galactosaminide, β-D-alloside, β-D-lyxoside, β-D-taloside, β-D-threoside, β-D-riboside, β-D-fructoside, β-D-rhamnoside and β-L-guoside groups.
Examples of compounds of the present disclosure include those shown below. It will of course be appreciated that, where appropriate, each compound may be in the form of the free compound, an acid or base addition salt, or a prodrug.
The present disclosure also provides a pharmaceutical composition comprising at least one of the compounds described herein and at least one pharmaceutically acceptable excipient.
The compounds described herein and their pharmaceutically acceptable salts can be administered to a subject either alone or in combination with pharmaceutically acceptable, excipients, carriers, and/or diluents in a pharmaceutical composition according to standard pharmaceutical practice. The compounds can be administered orally or parenterally. Parenteral administration includes intravenous, intramuscular, intraperitoneal, subcutaneous and topical, the preferred method being intravenous and topical administrations.
Accordingly, the present disclosure provides pharmaceutically acceptable compositions, which comprise a therapeutically effective amount of one or more of the compounds described herein, formulated together with one or more pharmaceutically, excipients, acceptable carriers (additives) and/or diluents. The pharmaceutical compositions of the present disclosure may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; and (2) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions) , tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue.
As set out herein, certain embodiments of the compounds described herein may contain a basic functional group, such as amino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present disclosure. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting a purified compound of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed during subsequent purification. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like.
The pharmaceutically acceptable salts of the compounds of the present disclosure include the conventional non-toxic salts or quaternary ammonium salts of the compounds, e.g., from non-toxic organic or inorganic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic, and the like.
In other cases, the compounds described herein may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present disclosure. These salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia, or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives, solubilizing agents, buffers and antioxidants can also be present in the compositions.
Methods of preparing these formulations or compounds include the step of bringing into association a compound described herein with the carrier or excipient and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present disclosure with liquid carriers (liquid formulation) , liquid carriers followed by lyophylization (powder formulation for reconstitution with sterile water or the like) , or finely divided solid carriers, or both, and then, if necessary, shaping or packaging the product.
Pharmaceutical compositions of the present disclosure suitable for parenteral administration comprise one or more compounds described herein in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, chelating agents, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
Examples of suitable aqueous and non-aqueous carriers which may be employed in the pharmaceutical compositions of the disclosure include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like) , and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
These compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the compounds of the present disclosure may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption, such as aluminum monostearate and gelatin.
The present disclosure provides diphyllin and patentiflorin A analogs with anti-HIV and anti-influenza virus activity and synthesis thereof. The compounds of the present disclosure were synthesized and evaluated for their anti-HIV and anti-influenza viral activity.
The synthetic or semi-synthetic analogues of diphyllin can be exemplified by 12a, 12b, 13, 14a, 14b, 15a, 15b, 16, 17a, 17b, 17c, 17d, 17e, 17f, 17g, 17h, 18, 19a, 19b, 19c, 19d, 19e, 19f, 19g, 19h, 19i, 19j, 19k, 19l, 19m, 19n, 19o, 19p, 20, 21, 22, 23 and 24.
The synthetic or semi-synthetic analogues of patentiflorin A can be exemplified by 25a, 25b, 25c, 25d, 25e, 25f, 25g, 26a, 26b, 26c, 26d, 26e, 26f, 26g, 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d.
EXAMPLES
The following examples are set forth below to illustrate the methods and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods, compositions, and results. These examples are not intended to exclude equivalents and variations of the present invention, which are apparent to one skilled in the art.
Unless indicated otherwise, parts are parts by weight, temperature is ℃or is at ambient temperature, and pressure is at or near atmospheric. There are numerous variations and combinations of reaction conditions, e.g., component concentrations, temperatures, pressures, and other reaction ranges and conditions that can be used to optimize the product purity and yield obtained from the described process. Only reasonable and routine experimentation will be required to optimize such process conditions.
Examples of compounds of the present disclosure include those shown below. It will of course be appreciated that, where appropriate, each compound may be in the form of the free compound, an acid or base addition salt, or a prodrug.
By using diphyllin (5) as a structural scaffold, the general synthetic route for its C-O derivatization on C-7 is illustrated in Figure 2. Esters 12a and 12b were prepared from 5 by a substitution reaction. Acidic hydrolysis of ester 12a provided acid 13, which was converted to amides 14a and 14b by coupling with ammonium chloride (NH
4Cl) or an amine in the presence of 1- [bis (dimethylamino) methylene] -1H-1, 2, 3-triazolo [4, 5-b] pyridinium 3-oxid hexafluorophosphate (HATU) or 1-hydroxybenzotriazole hydrate (HOBt) . O-alkoxyl alcohols 15a and 15b were obtained from the reactions of 5 with the corresponding epoxides ethylene oxide and isobutylene oxide, respectively. Derivatives 17a-17h were prepared from 5, respectively, in one step. Alkylation of 5 with cesium carbonate (Cs
2CO
3) followed by bromoacetonitrile, iodomethane or propargyl bromide rendered derivatives 17a-17c, respectively. Addition of potassium carbonate (K
2CO
3) and 2-chloropyrimidinein to 5 in dimethylformamide (DMF) under 100 ℃ provided compound 17d. Similarly, the addition of trimethylamine (Me
3N) , 4-dimethylaminopyridine (DMAP) and corresponding acyl chlorides to 5 gave esters 17e-17h, respectively. The synthesis for C-7 alkyl derivatives (Figure 3) envisioned conversion of 5 to the corresponding trifluoromethanesulfonate 18, which would undergo palladium-catalyzed coupling reactions to afford derivatives 19a-19p and 20-24.
ANL analogs and compounds 25a-25g and 26a-26g containing different sugar units outlined in Figure 4 were prepared, and which were further modified to provide additional ANL analogs 27aa-27bf, 28ab1-28bb3, 29a, 29b, 30a-30l and 31a-30l outlined in Figure 5.
Glycosylation of diphyllin (5) at C-7 with different sugar units (a-g) led to synthesis of a series of diphyllin glycosides (26a-26g) , respectively (Figure 4) . The synthesis involved the production of glycosyl bromides through bromination reactions of the per-acetylated glycosides, followed by its phase transfer catalysis (PTC) glycosylation treatment with 0.1 mol/L aqueous sodium hydroxide (NaOH) in the presence of tetrabutylammonium bromide (TBAB) at 40 ℃. The resulted per-acetyl glycosides 25a-25g were subsequently deacetylated with K
2CO
3 in methanol (MeOH) to afford the deprotected glycosides 26a-26g, respectively.
To significantly increase the number of the ANL library compounds, further structural modification on the hydroxy groups in the sugar units of ANLs (Figure 5) were proposd. Firstly, 3”-O-acetyl diphyllin glycosides 27aa-27af and 27ba-27bf were prepared from the reactions of acetic anhydride (Ac
2O) and tetrabutylammonium acetate (TBOAc) with the corresponding 26a and 26b. Separation by silica gel column chromatography of the reaction mixture of 26a afforded the six single compounds 27aa-27af (27aa, 27ab, 27ac, 27ad, 27ae and 27af) . Separation by silica gel column chromatography of the reaction mixture of 26b afforded the six single compounds 27ba-27bf (27ba, 27bb, 27bc, 27bd, 27be and 27bf) . Compound 27ab or 27bb was treated with allyl chloroformate (AllocOCl) to give the bis-protected ANL glycosides the corresponding 28ab1-28ab3 and 28bb1-28bb3. Separation by silica gel column chromatography of the reaction mixture of 27ab afforded the three single compounds 28ab1-28ab3 (28ab1, 28ab2 and 28ab3) . Separation by silica gel column chromatography of the reaction mixture of 27bb afforded the three single compounds 28bb1-28bb3 (28bb1, 28bb2 and 28bb3) . The acetyl group in compound 28ab3 or 28bb3 was removed by further treatment with acetyl chloride (AcCl) to give the bis-choloroformate protected ANL glycosides 29a and 29b, respectively. Substitution of 29a or 29b with triethylamine (Et
3N) and DMAP, followed by different acyl chlorides yielded derivatives 30a-k, respectively. Addition of potassium hydroxide (KOH) , 18-crowm-6 and benzyl bromide to 29a in tetrahydrofuran (THF) under r.t. provided compound 30l. The two allyl groups of 30a-l were deprotected by treatment of tetrakis (triphenylphosphine) palladium (0) [Pd (PPh
3)
4] , triphenylphosphine (PPh
3) , Et
3N and HCOOH in THF to produce derivatives 31a-l, respectively.
The compounds described herein can exhibit broad antiviral properties. According to methods of the present disclosure, compounds of Formula (I) are administered to a patient to inhibit replication of or reduce cytopathic effects of viruses, such as HIV, coronaviruses, Ebola virus, Marburg virus or influenza viruses. Other viruses that may be inhibited by compounds of Formula (I) include, but are not limited to, cytomegalovirus (CMV) , HSV-1 (herpes simplex virus type 1) , HSV-2 (herpes simplex virus type 2) , HBV (hepatitis B virus) , HCV (hepatitis C virus) , HPV (human papilloma virus) , influenza A, influenza B, RSV (respiratory syncitial virus) , RV (rhinovirus) , AV (adenovirus) , PIV (human parainfluenza viruses) , Epstein-Barr virus (EBV) , varicella zoster virus (VZV) , dengue virus and Zika virus.
The compounds, pharmaceutical compositions, and therapeutic methods described herein are useful for preventing or treating or ameliorating HIV infections.
The compounds, pharmaceutical compositions, and therapeutic methods described herein are useful for preventing, treating, or ameliorating infections caused by influenza viruses, including but not limited to: any of the subtypes of influenza A, influenza B, or influenza C.
In certain embodiments, the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by influenza A viruses, including but not limited to, any of the strains of H1N1, H1N2, H1N3, H1N4, H1N5, HIN6, H1N7, HIN8, H1N9, H2N1, H2N2, H2N3, H2N4, H2N5, H2N6, H2N7, H2N8, H2N9, H3N1, H3N2, H3N3, H3N4, H3N5, H3N6, H3N7, H3N8, H3N9, H4N1, H5N2, H5N3, H5N4, H5N5, H5N6, H5N7, H5N8, H5N9, H6N1, H6N2, H6N3, H6N4, H6N5, H6N6, H6N7, H6N8, H6N9, H7N1, H7N2, H7N3, H7N4, H7N5, H7N6, H7N7, H7N8, H7N9, H8N1, H8N2, H8N3, H8N4, H8N5, H8N6, H8N7, H8N8, H8N9, H9N1, H9N2, H9N3, H9N4, H9N5, H9N6, H9N7, H9N8, H9N9, H10N1, H10N2, H10N3, H10N4, H10N5, H10N6, H10N7, H10N8, H10N9, H11N1, H11N2, H11N3, H11N4, H11N5, H11N6, H11N7, HI1N8, H11N9, H12N1, H12N2, H12N3, H12N4, H12N5, H12N6, H12N7, H12N8, H12N9, H13N1, H13N2, H13N3, H13N4, H13N5, H13N6, H13N7, H13N8, H13N9, H14N1, H14N2, H14N3, H14N4, H14N5, H14N6, H14N7, H14N8, H14N9, H15N1, H15N2, H15N3, H15N4, H15N5, H15N6, H1N7, H15N8, and H15N9.
In certain embodiments, the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by influenza A virus strains having a type 5 hemagglutinin protein. In certain embodiments, the influenza A virus strain has a type 5 hemagglutinin protein and neuraminidase protein selected from types 1 to 11. In certain embodiments, the influenza A virus is selected from the group consisting of H5N1 and H5N2.
In certain embodiments, the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by H5N1.
The term “HIV” , as used herein, refers to the human immunodeficiency virus and includes HIV-1, HIV-2 and SIV. In certain embodiments, HIV refers to HIV-1 and/or HIV-2. “HIV-1” means the human immunodeficiency virus type-1. HIV-1 can include but is not limited to extracellular virus particles and the forms of HIV-1 associated with HIV-1 infected cells. The HIV-1 virus can include any of the known major subtypes (classes A, B, C, D, E, F, G and H) or outlying subtype (group O) including laboratory strains and primary isolates. “HIV-2” means the human immunodeficiency virus type-2. HIV-2 can include but is not limited to extracellular virus particles and the forms of HIV-2 associated with HIV-2 infected cells. The term “SIV” refers to simian immunodeficiency virus, which is an HIV-like virus that infects monkeys, chimpanzees, and other nonhuman primates. SIV can include but is not limited to extracellular virus particles and the forms of SIV associated with SIV infected cells.
In certain embodiments, the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by HIV-1 and/or HIV-2. In certain embodiments, the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating or ameliorating infections caused by HIV-1 subtype B.
In certain embodiments, the compounds, pharmaceutical compositions, and therapeutic methods disclosed herein are useful for preventing, treating, or ameliorating infections caused by SIV.
The compounds, pharmaceutical compositions, and therapeutic methods described herein are useful for preventing, treating, or ameliorating infections caused by filoviruses, including but not limited to: Marburg virus, Zaire ebolavirus, Sudan ebolavirus, Cote d’Ivoire ebolavirus, Reston ebolavirus and Bundibugyo ebolavirus.
The compounds, pharmaceutical compositions, and therapeutic methods described herein are useful for preventing, treating, or ameliorating infections caused by coronaviruses including, but not limited to, SARS-CoV-2, SARS-CoV and MERS-CoV.
Antiviral Evaluation Using the “One-Stone-Two-Birds” Pseudo-type Assay.
Production of HIV Pseudovirions. This protocol is designed to identify potential inhibitors for HIV, coronavirus, Ebola, Marburg and influenza replication (post entry steps) . HIV/VSVG or HIV/SARSP or HIV/HA or HIV/EBOV or HIV/MARV virions were produced, respectively, by co-transfecting with either 0.5 μg VSVG (vesicular stomatitis virus glycoprotein) envelope expression plasmid 0.5 μg SARSP (SARS-Cov-2 spike protein) expression plasmid or 0.5 μg hemagglutinin (HA) envelope expression plasmid with 0.5 μg neuraminidase (NA) expression plasmid or 0.5 μg EBVG (Ebola virus glycoprotein) envelope expression plasmid or 0.5 μg MAVG (Marburg virus glycoprotein) envelope expression plasmid and 2 μg replication-defective HIV vector (pNL4-3. Luc. RE) into human embryonic kidney 293T cells (90%confluent) in six-well plates via PEI (polyethylenimine) (Invitrogen, Carlsbad, CA, USA) , as previously described with a modified procedure. The HIV vector pNL4-3. Luc. RE was obtained through the AIDS Research and Reference Reagent Program (Division of AIDS, NIAID, NIH) . Sixteen hours post-transfection, all media were replaced with fresh, complete DMEM. Eight hours post-transfection, all media were replaced with fresh complete DMEM. Forty-eight hours post-transfection, the supernatants were collected and filtered through a 0.45-μm-pore-size filter (Millipore, Billerica, MA, USA) and the pseudo virions were directly used for infection.
Anti-HIV and anti-H5N1 Influenza Virus Evaluation Assay. This protocol is to identify potential inhibitors for HIV and influenza virus replication (post-entry steps) . In this system, the HIV vector pNL4-3. Luc. RE was co-transfected with the VSVG to generate HIV/VSVG virions (HIV virion with VSV glycoprotein on the viral surface) , and the same HIV vector was co-transfected with the H5N1 HA and NA constructs to generate HIV virions with bird flu HA on the viral surface [HIV/HA (HIV virion with HA and NA glycoproteins on the viral surface) ] . This pNL4-3 was derived from an infectious molecular clone of a SI (syncytium inducing) , T-tropic virus, which is replication deficient since the HIV is Env
- and Vpr
-. In addition, the luciferase gene (luc) carried by this recombinant HIV vector served as the reporter for HIV replication (reverse transcription, integration and HIV gene expression) . The infection level was measured as relative light units (RLUs) in the infected cells. The luciferase activities of the 293T cells infected with the HIV vector pNL4-3. Luc. RE reached the range of 10
5-10
6 RLUs, approximately 100-fold higher than the background levels when measured using the HIV virions without VSVG. The evaluation principle is that the level of the luciferase activity in the cells should be proportional to the level of viral entry and replication. If a sample can interfere with HIV replication/or HA-mediated viral entry, the level of the luciferase activity in the infected cells will be reduced. Thus, using this protocol, a sample capable of inhibiting HIV or influenza virus replication was identified. The test fractions or compounds were evaluated as follows. Target A549 human lung cells were seeded at 0.5 × 10
5 cells per well (24-well plate) in complete DMEM. The lung cell line was used since it is susceptible to HA-mediated viral entry. The stock HIV/VSVG or HIV/HA virions (approximately 2 × 10
6 relative light units, or RLUs, on the target cells) were mixed with the individual sample first, and the mixture was incubated with the A549 target cells for 24 hours. Ten microliters of serial concentrations (for example, 20, 10, 5, 2.5, 1.25, 0.625 and 0.3125 μg/mL) and 190 μL of the pseudovirus were incubated with target cells. Twenty-four (24) hours post-infection, all media containing sample and virus was removed from target cells and replaced with fresh and complete DMEM. Forty-eight (48) hours post-infection, the target cells were lysed and the luciferase activity was determined. Two different outcomes may occur: 1) It is likely that some samples will “inhibit replication” of both HIV/VSVG and HIV/HA virions (lower Luc for HA and VSVG) , since some of these samples can block post-entry steps during viral entry, or some of them are just toxic to the target cells. These samples are classified as anti-HIV. 2) The samples which can specifically inhibit the HIV/HA viral entry (lower Luc for HIV/HA, but not for HIV/VSVG) will be classified as anti-HA inhibitors (influenza virus inhibitors) . The concentration of drug inhibiting 50%of virus infectivity (EC
50 value) was determined.
Anti-HIV, anti-Ebola and anti-Marburg Virus Evaluation Assay. This protocol was modified from the aforementioned anti-H5N1 influenza virus evaluation assay, which was designed to identify potential inhibitors for HIV, Ebola and Marburg viruses replication (post-entry steps) . In this system, the HIV vector pNL4-3. Luc. R.E. was co-transfected with the VSVG to generate HIV/VSVG virions, and the same HIV vector was co-transfected with the Ebola or Marburg glycoprotein (GP) constructs to generate HIV virions with Ebola or Marburg GP on the viral surface (HIV/EBVG or HIV/MAVG) . The infection level was measured as relative light units (RLUs) in the infected cells. The luciferase activities of the 293T cells infected with the HIV vector pNL4-3. Luc. R.E. reached the range of 10
5-10
6 RLUs, approximately 100-fold higher than the background levels when measured using the HIV virions without VSVG. The evaluation principle is that the level of the luciferase activity in the cells should be proportional to the level of viral entry and replication. If a compound can interfere with HIV replication/or EBVG or MAVG-mediated viral entry, the level of the luciferase activity in the infected cells will be reduced. Thus, using this protocol, compounds capable of inhibiting HIV, EBOV and MARV replication were identified. The test compounds were evaluated as follows. Target A549 human lung cells were seeded at 0.5 × 10
5 cells per well (24-well plate) in complete DMEM. The lung cell line was used since it is susceptible to EBVG or MAVG-mediated viral entry. The stock HIV/VSVG or HIV/EBVG or MAVG virions (approximately 2 × 10
6 relative light units, or RLUs, on the target cells) were mixed with the individual sample first, and the mixture was incubated with the A549 target cells for 24 hours. Ten microliter of each sample in varying concentrations and 190 μL of the pseudovirus were incubated with target cells. Twenty-four (24) hours post-infection, all media containing sample and virus was removed from target cells and replaced with fresh and complete DMEM. Forty-eight (48) hours post-infection, the target cells were lysed and the luciferase activity was determined.
Anti-SARS-CoV-2 Evaluation Assay. This protocol was modified from the aforementioned anti-H5N1 influenza virus evaluation assay, which was designed to identify potential inhibitors for SARS-CoV-2. In this assay, the HIV vector pNL4-3. Luc. R.E. was co-transfected with SARS-CoV-2 spike protein (SARSP) expression plasmid to generate SARS-CoV-2 pseudovirions (HIV/SARSP) . Target Hep G2 liver cancer cells were seeded at 4 × 10
3 cells per well (96-well plate) in complete EMEM. The liver cell line was used because it is susceptible to SARS-CoV-2 mediated viral entry. Ten microliter of each sample in varying concentrations and 190 μL of the HIV/SARSP were incubated with target cells. Forty-eight (48) hours post-infection, the target cells were lysed and the luciferase activity was determined. Arbidol was used as positive control in the experiments. The IC
50 value of arbidol against SARS-CoV-2 pseudovirion was measured as 5.23 μM, which was in agreement with the literature reported value (4.11 μM) .
Anti-HIV Evaluation Using HIV-1 Clinical Strains.
The HIV-1 clinical strains such as BAL and SF162 (macrophage-tropic: M-tropic) , BAL (T-cell line tropic: T-tropic) , and 89.6 (a dual tropic strain) , HIV-1
LAV (wild type) , NRTI (nucleoside reverse transcriptase inhibitor) -resistant isolate (HIV-1
1617-1) (AZT resistant strain from AIDS repository) and NNRTI (non-nucleoside reverse transcriptase inhibitor) -resistant isolate (HIV-1
N119) (nevaripine resistant strain from AIDS repository) were used in the study. A standardized human peripheral blood mononuclear cell culture (PBMC) assay was used to determine the compound susceptibility of these HIV-1 strains. AZT, an anti-HIV drug in clinical use, was used as a positive control. All data were generated from three independent experiments, each performed in triplicate. Prior to HIV-1 infection, fresh human PBMCs were used in each experiment. Briefly, donor PBMCs were suspended in R-3 medium [RPMI 1640 medium supplemented with 15-20%FBS (fetal bovine serum) , 5%IL-2 (human interleukin-2) , 250 U of penicillin per mL, 250 μg of streptomycin per mL and 2 mM L-glutamine] was stimulated with PHA (phytohaemagglutinin, 2-3 μg/mL) for seven days. The preparations (samples) were added to the cultured cells, and the different HIV-1 strains were used to challenge the cultured cells in 96-well plates [1 × 10
5 cells per well with 1000 TCID
50 (virus 50%tissue culture infectious doses) of HIV strain] . After seven days of incubation, the supernatants were collected and the HIV p24 levels of the infected cells were determined using a p24 antigen ELISA. To measure IC
50 values, each drug was tested using a serial of concentrations (for example, 5, 1, 0.2, 0.04, 0.008, 0.016 and 0 μg/mL) . The IC
50s were calculated by comparing p24 antigen values for the samples-containing wells with those for no drug control wells. For the p24 assay, the maximum cutoff should be around 120-150 pg/mL.
Antiviral Evaluation Using Infectious Influenza Viruses.
A panel of influenza viruses such as influenza H1N1 (A/HK/415742/09) , H3N2 (A/Hong Kong/1/1968) , H5N1 (A/Vietnam/1203/2004H) , H7N1 (A/Rhea/North Carolina/39482/93) , H7N7 (A/Netherlands/219/2003) , H7N9 (A/Anhui/1/2013) and H9N2 (A/Chicken/Y280/97) were used in the studies. Samples were evaluated for their antiviral activities against the influenza viruses in A549 cells. Briefly, the preparations (samples) were added to the cultured cells, and the different influenza strains were used to challenge the cultured cells in 24-well plates (1 × 10
5 cells per well) . After removal of the unbound viruses, the cells were incubated for 48 h. The viral supernatants were collected and viral titers were determined by standard plaque assay in MDCK (Madin-Darby canine kidney) cells.
Cytotoxicity Evaluation Using the SRB Assay.
The cytotoxicity of the sample for A549 cells was measured using the sulforhodamine B (SRB) assay (Vichai V, Kirtikara K. Nature protocols 2006; 1: 1112–1116) . Briefly, 190 μL of A549 cells (2 × 10
4 cells/mL) was seeded in each well of a 96-well cell culture plate. After 24 hours, 10 μL of DMSO alone, 10 μL of zidovudine (AZT) as positive controlin 10%DMSO, and 10 μL of each sample in 10% (v/v) DMSO were respectively added into wells of a 96-well tissueculture plate. 10 μL of 10% (v/v) DMSO was added into each blank well of a 96-well tissueculture plate as a background calculation plate. After incubation at 37 ℃ for 2 days, 50 μL cold 50% (w/v) trichloroacetic acid (TCA) were added into each well of the plates, and were further incubated at 4 ℃ for 1 h. The plates were then washed four times with low-running tap water, and they were allowed to dry at room temperature (r.t. ) . 50 μL of 0.4% (w/v) SRB solution was added to each well. The plate was left at r.t. for 5~10 mins and were quickly rinsed with 1% (v/v) acetic acid to remove unbound dye. The plates were allowed to dry at r.t. 100 mL of 10 mM Tris base solution (pH 10.5) was added to each well and the plates were shake on a gyratory shaker for at least 30 min to solubilize the protein-bound dye. The OD values were measured at 515 nm in a microplate reader. The CC
50 (the concentration of an agent causing 50%cytotoxicity) values were calculated using the GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA) .
Toxicity Evaluation in Mice. Repeated-dose toxicity study in mice was applied on the selected samples. The animal study was approved and performed according to Animal Care and Use Guidelines of the Animal Ethics Committee at Hong Kong Baptist University and performed following Animal Care and Use guidelines set by NIH (National Institute of Health, USA) . BALB/c nude mice, SPF class, male or female, 6-8 weeks old, were purchased from Charles River Laboratories. Before the experiment, the mice are kept for one week of acclimatization to SPF class laboratory conditions. The mice were then divided into three groups: two dose (25 and 50 mg/kg: 10 mice/each dose group) groups of an ANL compound and one dose of vehicle (negative control: 10 mice) . Daily injections at i. p. sites were scheduled for 28 days. Weights of mice were measured twice a week until the end of the experiment. Skin conditions, food intake, water consumption and posture of mice were also inspected. All mice were sacrificed as the end of the experiment to inspect the essential organs such as liver, heart, kidney, lung and spleen.
Table 1. Anti-HIV activity of ANLs.
a
a Results are expressed as CC
50 (the concentration caused inhibition of cell growth of host A549 cells by 50%) and EC
50 (effective concentration of compound to inhibit viral growth by 50%) values in nM, and data were obtained from triplicate experiments. SI = CC
50/EC
50.
b NE: No effect at the CC
50 tested in the host A549 cells.
c Positive control compound.
Table 2. Anti-H5N1 viral activity of ANLs.
a
a Results are from three triplicate experiments.
b Positive control compound.
Table 3. Inhibitory effects of selected ANLs against H5N1 virus, EBOV, VSV and A549 cells.
a
a Results are from three triplicate experiments.
b Positive control compounds.
Materials and methods
General experimental procedures
1D and 2D NMR spectra were recorded on a Bruker DRX-400 MHz spectrometer (Rheinstetten, Germany) . Chemical shifts (δ) were expressed in ppm and coupling constants (J) are reported in Hz. All NMR experiments were obtained by using standard pulse sequences supplied by the vendor. Chemical shifts (δ) were expressed in ppm with reference to the solvent signals (CD
3OD:
1H: 3.31 ppm,
13C: 49.00 ppm; CDCl
3:
1H: 7.27 ppm,
13C: 77.23 ppm; DMSO-d
6:
1H: 2.50 ppm,
13C: 39.51 ppm; acetone-d
6:
1H: 2.05 ppm,
13C: 29.92, 206.68 ppm. ) , and coupling constants (J) are reported in Hz. Column chromatography was carried out on silica gel (230-400 mesh, Natland International Corporation, Research Triangle Park, NC, USA) . Thin-layer chromatography (TLC) was performed on EMD glass-backed plates coated with 0.25 mm layers of silica gel 60 F254 (Kassel, Germany) . HRTOFMS spectra were recorded on a Micromass QTOF-2 (Milford, MA, USA) , an Agilent 6540 Q-TOF (Santa Clara, CA, USA) , an Agilent 6460 Triple Quadrupole, or a Bruker Q-TOF mass spectrometer (Bremen, Germany) . All reagents were purchased from commercial sources and used without further purification.
To a suspension of the crude 2-bromo-4, 5-dimethoxybenzaldehyde (30 g, 125 mmol) in toluene (1 L) was added ethylene glycol (14 mL, 250 mmol) and p-toluenesulfonic acid (TsOH) (5.2 g, 25 mmol) . A Dean-Stark apparatus filled with toluene (PhMe) was fitted to the round bottom flask, and the reaction was refluxed overnight. After cooling to room temperature (r.t. ) , toluene was removed under reduced pressure. The crude mixture was then dissolved in ethyl acetate (EtOAc) and washed with sodium bicarbonate (NaHCO
3) aqueous, water, then brine, dried with anhydrous sodium sulfate (Na
2SO
4) , and concentrated under reduced pressure. Separation of the mixture on silica gel flash chromatography (deactivated silica gel, 16%-25%EtOAc in n-hexane) afforded 2- (2-bromo-4, 5-dimethoxyphenyl) -1, 3-dioxolane (2) as an off-white solid (33.5 g, 95%) . To a stirring solution of the acetal (2) (30 g, 104 mmol) in 1 L of tetrahydrofuran (THF) , after cooled to -78 ℃, n-buyllithium (n-BuLi) (1.8 M, 69.3 mL, 124.8 mmol) was added drop-wise for an additional 30 min. Following the addition, the reaction mixture was stirred for 30 min at -50 ℃, and then piperonal (114.4 mmol) was added. The mixture was stirred at -78 ℃ for 0.5 h, and then the reaction was allowed to warm to r.t. for an additional 2 h. The reaction was then quenched with water, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with water, then brine, dried with Na
2SO
4, and concentrated under reduced pressure to afford a pale-yellow syrup (3) , which was immediately subjected to a Diels-Alder reaction. To a solution of the crude intermediate in dichloromethane (CH
2Cl
2) (100 mL) was added acetic acid (AcOH) (35 mL) and dimethyl acetylenedicarboxylate (DMADC) (16.7 mL, 104 mmol) . The reaction was stirred at 140 ℃ for 12 h. Upon cooling to r.t., the reaction was diluted with water, and the aqueous layer was extracted with CH
2Cl
2. The combined organic layers were washed, dried and filtered through a plug of silica gel to remove the majority of impurities. The resulted red viscous oil was purified by recrystallization in ethanol (EtOH) . The crude diester (4a, 5 mmol) was dissolved in THF (70 mL) with the drop-wise addition of sodium borohydride (NaBH
4) (0.945 g, 25 mmol) , and the reaction was stirred at 80 ℃for 12 h. The reaction was then cooled back to r.t. The resulting slurry was acidified to a pH value of approximately 2 with dilute HCl (2 M) . Following acidification, the aqueous layer was extracted with EtOAc, and the combined organic layer was washed with water, then brine, dried with Na
2SO
4 and concentrated. The resulted red viscous oil was purified by silica gel column chromatography to give the target compound 5. HR-EIMS: m/z [M+H]
+ 381.0974 (calcd. 381.0912) .
1H NMR (400 MHz, acetone-d
6) δ 7.69 (1H, s, H-2) , 7.09 (1H, s, H-5) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.85 (1H, d, J = 1.6 Hz, H-2’) , 6.91 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.09 (1H, br s, OCH
2O) , 6.07 (1H, br s, OCH
2O) , 5.37 (2H, s, H-9) , 3.99 (3H, s, 3-OCH
3) , 3.73 (3H, s, 4-OCH
3) .
Compound 12a
To a solution of diphyllin (5, 190 mg, 0.5 mmol) and t-BuOCOCH
2Br (193 mg, 1 mmol) in DMF (5 mL) was added Cs
2CO
3 (326 mg, 1 mmol) . The mixture was stirred at r.t. for 2 h. After quenched with water, the aqueous layer was then extracted with EtOAc and the combined organic layer were washed with water, then brine, dried with Na
2SO
4 and concentrated under reduced pressure. The mixture was purified by prep-TLC to afford a light-yellow solid (12a, 247 mg, 99%) . HR-EIMS: m/z [M+H]
+ 495.1638 (calcd. 495.1655) .
1H NMR (400 MHz, CDCl
3) δ 7.73 (1H, s, H-2) , 7.07 (1H, s, H-5) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.82 (1H, d, J = 1.3 Hz, H-2’) , 6.79 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.09 (1H, br s, -OCH
2O-) , 6.05 (1H, br s, -OCH
2O-) , 5.48 (2H, s, H-9) , 4.69 (2H, s, OCH
2C=O) , 4.09 (3H, s, 3-OCH
3) , 3.81 (3H, s, 4-OCH
3) , 1.51 (9H, s, t-Bu) .
13C NMR (100 MHz, CDCl
3) δ 169.5 (C-9’) , 167.8 (O-C=O) , 151.8 (C-3) , 150.4 (C-4) , 147.5 (C-4’, C-7) , 146.7 (C-3’) , 135.5 (C-7’) , 130.8 (C-6) , 128.3 (C-1’) , 126.4 (C-8’) , 126.2 (C-1) , 123.6 (C-6’) , 119.1 (C-8) , 110.7 (C-2’) , 108.2 (C-5’) , 106.2 (C-5) , 101.3 (C-2) , 100.9 (-OCH
2O-) , 82.9 (t-Bu) , 69.8 (OCH
2C=O) , 66.4 (C-9) , 56.2 (3-OCH
3) , 55.9 (4-OCH
3) , 28.1 (t-Bu) .
Compound 12b
To a solution of diphyllin (5, 38 mg, 0.1 mmol) and EtOCOCH
2Br (33 mg, 0.2 mmol) in 1 mL DMF was added Cs
2CO
3 (65 mg, 0.2 mmol) . The mixture was stirred at r.t. for 2 h. After quenched with water, the aqueous layer was then extracted with EtOAc and the combined organic layers were washed with water, then brine, dried with Na
2SO
4 and concentrated under reduced pressure. The mixture was purified by prep-TLC to afford 12b (46 mg, 99%) . HR-EIMS: m/z 467.1316 [M+H]
+ (calcd. 467.1342) .
1H NMR (400 MHz, DMSO-d
6) δ 7.73 (1H, s, H-2) , 7.03 (1H, d, J = 7.9 Hz, H-5’) , 6.96 (1H, s, H-5) , 6.87 (1H, d, J = 1.5 Hz, H-2’) , 6.75 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.12 (2H, br s, -OCH
2O-) , 5.59 (2H, s, H-9) , 5.02 (2H, s, OCH
2C=O) , 4.23 (2H, q, J = 7.1 Hz, Et) , 3.95 (3H, s, 3-OCH
3) , 3.66 (3H, s, 4-OCH
3) , 1.24 (3H, t, J = 7.1 Hz, Et) .
13C NMR (100 MHz, DMSO-d
6) δ 169.0 (C-9’) , 169.0 (O-C=O) , 151.4 (C-3) , 150.1 (C-4) , 147.0 (C-3’) , 146.9 (C-4’) , 146.0 (C-7) , 133.8 (C-7’) , 129.6 (C-6) , 128.2 (C-1’) , 126.0 (C-8’) , 125.6 (C-1) , 123.6 (C-6’) , 118.8 (C-8) , 110.8 (C-2’) , 108.0 (C-5’) , 105.5 (C-5) , 101.2 (C-2) , 100.9 (-OCH
2O-) , 68.7 (OCH
2C=O) , 66.4 (C-9) , 61.0 (Et) , 55.7 (3-OCH
3) , 55.3 (4-OCH
3) , 14.1 (Et) .
To a solution of 12a (247 mg, 0.5 mmol) in 10 mL CH
2Cl
2, 1 mL DMF and 2 mL TFA was added. The mixture was stirred for 12 h at r.t. TLC showed that the reaction had completed and a new spot with higher polarity appeared. After the reaction mixture was concentrated, EtOH was added to promote the precipitation. The solid was collected to afford 13 (210 mg, 95%) . HR-EIMS: m/z [M+H]
+ 439.100 (calcd. 439.1029) .
1H NMR (400 MHz, DMSO-d
6) δ 7.78 (1H, s, H-2) , 7.04 (1H, d, J = 8.0 Hz, H-5’) , 6.97 (1H, s, H-5) , 6.89 (1H, d, J = 1.5 Hz, H-2’) , 6.77 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.13 (2H, s, -OCH
2O-) , 5.76 (1H, s, OH) , 5.60 (2H, s, H-9) , 4.93 (2H, s, OCH
2C=O) , 3.96 (3H, s, 3-OCH
3) , 3.67 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 170.9 (C-9’) , 169.4 (O-C=O) , 151.7 (C-3) , 150.5 (C-4) , 147.4 (C-3’) , 147.3 (C-4’) , 146.7 (C-7) , 134.1 (C-7’) , 130.0 (C-6) , 128.7 (C-1’) , 126.3 (C-6’) , 126.1 (C-8’) , 124.0 (C-1) , 119.3 (C-8) , 111.3 (C-2’) , 108.4 (C-5’) , 105.9 (C-5) , 101.6 (C-2) , 101.5 (-OCH
2O-) , 69.1 (OCH
2C=O) , 66.8 (C-9) , 56.1 (3-OCH
3) , 55.7 (4-OCH
3) .
Compound 14a
To a solution of 13 (44 mg, 0.1 mmol) in CH
2Cl
2 (10.00 mL) were added Et
3N (30 mg, 0.3 mmol) NH
4Cl (16 mg, 0.3 mmol) and HATU (114 mg, 0.3 mmol) at 25 ℃, the reaction was stirred at 25 ℃ for 16 h. After quenched with water, the aqueous layer was then extracted with EtOAc and the combined organic layer were washed with water, then brine, dried with Na
2SO
4 and concentrated under reduced pressure. The mixture was purified by prep-TLC to afford 14a (40 mg, 92%) . HR-EIMS: m/z 438.1167 [M+H]
+ (calcd. 438.1189) .
1H NMR (400 MHz, DMSO-d
6) δ 7.80 (1H, s, NH
2) , 7.70 (1H, s, H-2) , 7.55 (1H, s, NH
2) , 7.04 (1H, d, J = 7.9 Hz, H-5’) , 6.97 (1H, s, H-5) , 6.89 (1H, d, J = 1.5 Hz, H-2’) , 6.77 (1H, dd, J = 7.9, 1.6 Hz, H-6’) , 6.12 (2H, s, -OCH
2O-) , 5.60 (2H, s, H-9) , 4.70 (2H, s, OCH
2C=O) , 3.97 (3H, s, 3-OCH
3) , 3.66 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 170.1 (C-9’) , 169.0 (O-C=O) , 151.3 (C-3) , 150.0 (C-4) , 147.0 (C-3’) , 146.9 (C-4’) , 146.1 (C-7) , 133.7 (C-7’) , 129.6 (C-6) , 128.3 (C-1’) , 126.1 (C-8’) , 125.7 (C-1) , 123.6 (C-6’) , 118.9 (C-8) , 110.9 (C-2’) , 108.0 (C-5’) , 105.5 (C-5) , 101.2 (C-2, -OCH
2O-) , 70.6 (OCH
2C=O) , 66.5 (C-9) , 55.8 (3-OCH
3) , 55.3 (4-OCH
3) .
Compound 14b
To a solution of 13 (44 mg, 0.1 mmol in CH
2Cl
2 (10.00 mL) and DMF (1 mL) were added Et
3N (30 mg, 0.3 mmol) and MeNH
2 (0.3 mL, 0.3 mmol) and HATU (114 mg, 0.3 mmol) at 25 ℃, the resulting mixture was stirred at 25 ℃ for 16 h. After quenched with water, the aqueous layer was then extracted with EtOAc and the combined organic layer were washed with water, then brine, dried with Na
2SO
4 and concentrated under reduced pressure. The mixture was purified by prep-TLC to afford 14b (30 mg, 66%) . HR-EIMS: m/z 452.1312 [M+H]
+ (calcd. 452.1345) .
1H NMR (400 MHz, DMSO-d
6) δ 7.61 (1H, s, H-2) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.90 (1H, s, H-5) , 6.81 (1H, d, J = 1.5 Hz, H-2’) , 6.69 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.04 (2H, s, -OCH
2O-) , 5.50 (2H, s, H-9) , 4.65 (2H, s, OCH
2C=O) , 3.90 (3H, s, 3-OCH
3) , 3.58 (3H, s, 4-OCH
3) , 2.60 (3H, s, NH-Me) .
13C NMR (100 MHz, DMSO-d
6) δ 169.0 (C-9’) , 168.2 (O-C=O) , 151.4 (C-3) , 150.1 (C-4) , 147.0 (C-3’) , 146.9 (C-4’) , 146.1 (C-7) , 133.9 (C-7’) , 129.6 (C-6) , 128.3 (C-1’) , 126.5 (C-8’) , 125.8 (C-1) , 123.6 (C-6’) , 118.9 (C-8) , 110.9 (C-2’) , 108.0 (C-5’) , 105.5 (C-5) , 101.2 (C-2) , 101.1 (-OCH
2O-) , 71.0 (OCH
2C=O) , 66.4 (C-9) , 55.8 (3-OCH
3) , 55.3 (4-OCH
3) , 25.6 (NH-Me) .
Compound 15a
A mixture of TBAB (16 mg, 0.05 mmol) , PdCl
2 (1.7 mg, 0.01 mmol) and K
2CO
3 (6.9 mg, 0.05 mmol) was dissolved in deionized H
2O (2.00 mL) and stirred at 60 ℃ for 15 mins. Then diphyllin (5, 38 mg, 0.1 mmol) and 0.3 mL ethylene oxide were added and stirred at 60 ℃ for 5 h. TLC showed the reaction completed and the one main spot with less polarity formed. The mixture was concentrated to give a yellow green solid which was washed by EtOH to give desired product 15a (40 mg, 95%) . HR-EIMS: 425.1207 m/z [M+H]
+ (calcd. 425.1236) .
1H NMR (400 MHz, DMSO-d
6) δ 7.76 (1H, s, H-2) , 7.03 (1H, d, J = 7.9 Hz, H-5’) , 6.97 (1H, s, H-5) , 6.89 (1H, d, J = 1.5 Hz, H-2’) , 6.77 (1H, dd, J = 7.9, 1.6 Hz, H-6’) , 6.12 (2H, s, -OCH
2O-) , 5.75 (1H, s, OH) , 5.58 (2H, s, H-9) , 4.28 -4.22 [2H, m, O (CH
2)
2OH] , 3.95 (3H, s, 3-OCH
3) , 3.81 [2H, m, O (CH
2)
2OH] , 3.66 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.2 (C-9’) , 151.2 (C-3) , 150.0 (C-4) , 146.9 (C-3’) , 146.8 (C-4’) , 146.6 (C-7) , 133.3 (C-7’) , 129.6 (C-6) , 128.4 (C-1’) , 126.6 (C-8’) , 126.1 (C-1) , 123.7 (C-6’) , 118.9 (C-8) , 110.9 (C-2’) , 108.0 (C-5’) , 105.5 (C-5) , 101.1 (C-2, -OCH
2O-) , 74.4 [O (CH
2)
2OH] , 66.6 (C-9) , 60.4 [O (CH
2)
2OH] , 55.7 (3-OCH
3) , 55.2 (4-OCH
3) .
Cs
2CO
3 (100 mg, 0.3 mmol) was added to a mixture of 5 (38 mg, 0.1 mmol) and isobutylene oxide (71 mg, 1 mmol) in 2 mL DMF and stirred at 120 ℃ for 12 h. TLC showed that the reaction had completed with one main spot with less polarity formed. The mixture was concentrated to give a yellow green solid, which was washed by EtOH to give desired product 15b (38 mg, 84%) . HR-EIMS: m/z [M+H]
+ 453.1524 (calcd. 453.1549) .
1H NMR (400 MHz, DMSO-d
6) δ 7.71 (1H, s, H-2) , 7.04 (1H, d, J = 7.9 Hz, H-5’) , 6.97 (1H, s, H-5) , 6.89 (1H, d, J = 1.6 Hz, H-2’) , 6.77 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.13 (2H, s, -OCH
2O-) , 5.63 (2H, s, H-9) , 4.03 (2H, s, CH
2) , 3.95 (3H, s, 3-OCH
3) , 3.67 (3H, s, 4-OCH
3) , 1.34 (6H, s, Me) .
13C NMR (100 MHz, DMSO-d
6) δ 169.1 (C-9’) , 151.1 (C-3) , 149.9 (C-4) , 146.9 (C-3’) , 146.8 (C-4’) , 146.7 (C-7) , 132.8 (C-7’) , 129.5 (C-6) , 128.4 (C-1’) , 125.5 (C-8’) , 125.5 (C-1) , 123.6 (C-6’) , 118.9 (C-8) , 110.8 (C-2’) , 107.9 (C-5’) , 105.5 (C-5) , 101.1 (C-2) , 101.0 (-OCH
2O-) , 79.9 (CH
2) , 69.1 (C) , 66.6 (C-9) , 55.5 (3-OCH
3) , 55.2 (4-OCH
3) , 26.4 (Me) .
A solution of 5 (19 mg, 0.05 mmol) in dry pyridine (1 mL) was added Ac
2O (7.1 μL, 0.075 mmol) . The resulting mixture was stirred under r.t. overnight. After the reaction was complete, it was diluted by CH
2Cl
2 and washed with 10%HCl solution. The combined organic phase was further extracted with a saturate aqueous solution of NaHCO
3 and dried over Na
2SO
4. After concentration, the crude product was purified prep-TLC (1: 1 n-hexane: ethyl acetate) to give 16 (20 mg, 94.6%) as a colorless solid. HR-EIMS: 423.1077 m/z [M+H]
+ (calcd. 423.1080) .
1H NMR (400 MHz, CDCl
3) δ 7.17 (1H, s, H-2) , 7.12 (1H, s, H-5) , 6.97 (1H, d, J = 7.8 Hz, H-5’) , 6.86 (1H, d, J =1.4 Hz, H-2’) , 6.83 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.10 (1H, d, J = 1.5 Hz, -OCH
2O-) , 6.05 (1H, d, J = 1.5 Hz, -OCH
2O-) , 5.26 (2H, s, H-9) , 4.06 (3H, s, 3-OCH
3) , 3.81 (3H, s, 4-OCH
3) , 2.53 (3H, s, OAc) .
To a solution of 5 (38 mg, 0.1 mmol) and bromoacetonitrile (24 mg, 0.2 mmol) in 1 mL acetone was added Cs
2CO
3 (65 mg, 0.2 mmol) . The mixture was stirred at r.t. for 2 hours. TLC show one spot with less polarity. The mixture was purified by prep-TLC to give desired product 17a (40 mg, 95%) . HR-EIMS: m/z [M+H]
+ 420.1053 (calcd. 420.1083) .
1H NMR (400 MHz, DMSO-d
6) δ 7.52 (1H, s, H-2) , 7.05 (1H, d, J = 7.9 Hz, H-5’) , 7.01 (1H, s, H-5) , 6.91 (1H, d, J = 1.6 Hz, H-2’) , 6.79 (1H, dd, J = 1.7, 7.9 Hz, H-6’) , 6.13 (2H, s, -OCH
2O-) , 5.60 (2H, s, CH
2) , 5.34 (2H, s, H-9) , 3.99 (3H, s, 3-OCH
3) , 3.68 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 168.8 (C-9’) , 151.8 (C-3) , 150.2 (C-4) , 147.1 (C-3’) , 147.0 (C-4’) , 144.7 (C-7) , 135.5 (C-7’) , 129.8 (C-6) , 128.4 (C-1’) , 127.9 (C-8’) , 126.0 (C-1) , 123.6 (C-6’) , 118.8 (C-8) , 117.1 (C≡N) , 110.8 (C-2’) , 108.1 (C-5’) , 105.8 (C-5) , 101.2 (C-2) , 100.3 (-OCH
2O-) , 66.1 (C-9) , 58.0 (CH
2) , 55.9 (3-OCH
3) , 55.3 (4-OCH
3) .
Compound 17b
To a solution of 5 (19 mg, 0.05 mmmol) in acetone (0.6 mL) was added Cs
2CO
3 (32.5 mg, 0.1mmol) and the solution was cooled to 0 ℃. Iodomethane (10.6 mg, 0.075 mmol) was added dropwise and the mixture was warmed to r.t. The reaction was complete after 12 h as shown by TLC. The mixture was quenched with saturated NH
4Cl solution, extracted with EtOAc, and washed with brine. After drying (Na
2SO
4) the solvent was removed under reduced pressure and the residue was purified by prep-TLC (n-hexane: ethyl acetate, 3: 1) to afford the product 17b as white solid (17.7mg, 90%) . HR-EIMS: m/z [M+H]
+ 395.1125 (calcd. 395.1131) .
1H NMR (400 MHz, CDCl
3) δ 7.54 (1H, s, H-2) , 7.05 (1H, s, H-5) , 6.95 (1H, d, J = 7.8 Hz, H-5’) , 6.78 (2H, m, H-2’, H-6’) , 6.09 (1H, d, J = 1.5 Hz, -OCH
2O-) , 6.04 (1H, d, J = 1.5 Hz, -OCH
2O-) , 5.54 (2H, s, H-9) , 4.13 (3H, s, OCH
3) , 4.07 (3H, s, 3-OCH
3) , 3.80 (3H, s, 4-OCH
3) .
Compound 17c
To a solution of 5 (38 mg, 0.1 mmol) and propynyl bromide (30 mg, 0.2 mmol) in acetone was added Cs
2CO
3 (65 mg, 0.2 mmol) . The mixture was stirred at r.t. for 2 h. TLC showed one spot with less polarity. The mixture was purified by a silica gel column to give desired product 17c (40 mg, 95%) . HR-EIMS: m/z [M+H]
+ 419.1112 (calcd. 419.1131) .
1H NMR (400 MHz, DMSO-d
6) δ 7.57 (1H, s, H-2) , 7.04 (1H, d, J = 7.9 Hz, H-5’) , 6.98 (1H, s, H-5) , 6.91 (1H, d, J = 1.5 Hz, H-2’) , 6.78 (1H, dd, J =7.9, 1.6 Hz, H-6’) , 6.12 (2H, s, -OCH
2O-) , 5.62 (2H, s, H-9) , 5.04 (2H, d, J = 2.4 Hz, CH
2) , 3.96 (3H, s, 3-OCH
3) , 3.71 (1H, t, J = 2.4 Hz, C≡CH) , 3.66 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.0 (C-9’) , 151.4 (C-3) , 150.1 (C-4) , 147.0 (C-3’) , 147.0 (C-4’) , 145.6 (C-7) , 134.2 (C-7’) , 129.7 (C-6) , 128.2 (C-1’) , 127.2 (C-1) , 126.3 (C-8’) , 123.7 (C-6’) , 118.8 (C-8) , 110.9 (C-2’) , 108.1 (C-5’) , 105.6 (C-5) , 101.2 (C-2) , 100.8 (-OCH
2O-) , 79.7 (CH
2) , 79.5 (C≡CH) , 66.6 (C-9) , 55.7 (3-OCH
3) , 55.3 (4-OCH
3) .
Compound 17d
To a solution of 5 (38 mg, 0.1 mmol) and 2-chloropyrimidine (23 mg, 0.2 mmol) in 1 mL DMF was added K
2CO
3 (40 mg, 0.3 mmol) . The mixture was stirred for 12 h at 100 ℃. TLC showed one spot with less polarity. The mixture was purified by prep-TLC to give desired product 17d (35 mg, 76%) . HR-EIMS: m/z [M+H]
+459.1161 (calcd. 459.1192) .
1H NMR (400 MHz, DMSO-d
6) δ 8.71 (2H, d, J = 4.8 Hz, pyrimidine) , 7.37 (1H, t, J = 4.8 Hz, pyrimidine) , 7.19 (1H, s, H-2) , 7.08 (1H, s, H-5) , 7.08 (1H, d, J = 7.9 Hz, H-5’) , 7.01 (1H, d, J = 1.5 Hz, H-2’) , 6.87 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.15 (2H, br s, -OCH
2O-) , 5.24 (2H, s, H-9) , 3.81 (3H, s, 3-OCH
3) , 3.69 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, CDCl
3) δ 169.8 (pyrimidine) , 169.1 (C-9’) , 160.1 (pyrimidine) , 160.0 (pyrimidine) , 151.6 (C-3) , 150.2 (C-4) , 147.1 (C-4’) , 147.1 (C-3’) , 146.8 (C-7) , 134.9 (C-7’) , 129.9 (C-6) , 128.8 (C-1’) , 127.7 (C-1) , 127.0 (C-8’) , 123.8 (pyrimidine) , 123.8 (C-6’) , 119.2 (C-8) , 110.9 (C-2’) , 108.4 (C-5’) , 106.2 (C-5) , 101.0 (C-2) , 100.8 (-OCH
2O-) , 66.7 (C-9) , 56.03 (3-OCH
3) , 55.4 (4-OCH
3) .
Compound 17e
5 (38 mg, 0.1 mmol) , Et
3N (30 mg, 0.3 mmol) and DMAP (catalyzed amount) were dissolved in 2 mL of dry CH
2Cl
2. Cyclopropanecarbonyl chloride (31 mg, 0.3 mmol) was added to the mixture at 0 ℃. The reaction mixture was allowed to warm up to 25 ℃ and kept stirred at 25 ℃ for 2 h. The mixture was purified by a silica gel column to give desired product 17e (43 mg, 98%) . HR-EIMS: m/z [M+H]
+ 449.1241 (calcd. 449.1236) .
1H NMR (400 MHz, CDCl
3) δ 7.20 (1H, s, H-2) , 7.10 (1H, s, H-5) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.85 (1H, d, J = 1.5 Hz, H-2’) , 6.82 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.09 (1H, br s, -OCH
2O-) , 6.04 (1H, br s, -OCH
2O-) , 5.24 (2H, s, H-9) , 4.05 (3H, s, 3-OCH
3) , 3.80 (3H, s, 4-OCH
3) , 2.12 -2.04 (1H, m, cyclopropanecarbonyl) , 1.34 -1.27 (2H, m, cyclopropanecarbonyl) , 1.20 (2H, dt, J = 3.3, 8.0 Hz, cyclopropanecarbonyl) .
13C NMR (100 MHz, CDCl
3) δ 172.2 (cyclopropanecarbonyl) , 169.4 (C-9’) , 152.3 (C-3) , 150.4 (C-4) , 147.7 (C-3’) , 147.6 (C-4’) , 138.2 (C-7) , 137.5 (C-7’) , 130.7 (C-6) , 130.3 (C-1) , 128.0 (C-1’) , 126.3 (C-8’) , 123.6 (C-6’) , 119.1 (C-8) , 110.7 (C-2’) , 108.3 (C-5’) , 106.4 (C-5) , 101.3 (C-2) , 99.2 (-OCH
2O-) , 66.3 (C-9) , 56.0 (3-OCH
3) , 55.9 (4-OCH
3) , 12.7 (cyclopropanecarbonyl) , 9.9 (cyclopropanecarbonyl) .
Compound 17f
5 (38 mg, 0.1 mmol) , Et
3N (30 mg, 0.3 mmol) and DMAP (catalyzed amount) were dissolved in 2 mL of dry CH
2Cl
2. Cyclopentanecarbonyl chloride (40 mg, 0.3 mmol) was added to the mixture at 0 ℃. The reaction mixture was allowed to warm up to 25 ℃ and kept stirred at 25 ℃ for 2 h. The mixture was purified by a silica gel column to give desired product 17f (45 mg, 97%) . HR-EIMS: m/z [M+H]
+ 477.1547 (calcd. 477.1549) .
1H NMR (400 MHz, CDCl
3) δ 7.12 (1H, s, H-2) , 7.04 (1H, s, H-5) , 6.90 (1H, d, J = 7.9 Hz, H-5’) , 6.79 (1H, d, J = 1.5 Hz, H-2’) , 6.76 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.09 (1H, br s, -OCH
2O-) , 6.04 (1H, br s, -OCH
2O-) , 5.16 (2H, s, H-9) , 3.96 (3H, s, 3-OCH
3) , 3.74 (3H, s, 4-OCH
3) , 3.16 (1H, p, J = 8.0 Hz, cyclopentanecarbonyl) , 2.19 -2.08 (2H, m, cyclopentanecarbonyl) , 2.07 -1.96 (2H, m, cyclopentanecarbonyl) , 1.80 (2H, dt, J = 6.1, 17.0 Hz, cyclopentanecarbonyl) , 1.70 (2H, tdd, J = 2.2, 4.0, 11.4Hz, cyclopentanecarbonyl) .
13C NMR (100 MHz, CDCl
3) δ 173.8 (cyclopentanecarbonyl) , 169.4 (C-9’) , 152.2 (C-3) , 150.4 (C-4) , 147.7 (C-3’) , 147.6 (C-4’) , 138.2 (C-7) , 137.5 (C-7’) , 130.7 (C-6) , 130.2 (C-1) , 128.0 (C-1’) , 126.3 (C-8’) , 123.7 (C-6’) , 119.1 (C-8) , 110.7 (C-2’) , 108.3 (C-5’) , 106.4 (C-5) , 101.3 (C-2) , 99.2 (-OCH
2O-) , 66.3 (C-9) , 56.0 (3-OCH
3) , 55.9 (4-OCH
3) , 43.8 (cyclopentanecarbonyl) , 30.5 (cyclopentanecarbonyl) , 25.9 (cyclopentanecarbonyl) .
5 (38 mg, 0.1 mmol) , Et
3N (30 mg, 0.3 mmol) and DMAP (catalyzed amount) were dissolved in 2 mL of dry CH
2Cl
2. 4-Fluorobenzoyl chloride (40 mg, 0.3 mmol) was added to the mixture at 0 ℃. The reaction mixture was allowed to warm up to 25 ℃ and kept stirred at 25 ℃ for 2 h. The mixture was purified by a silica gel column to give desired product 17g (45 mg, 90%) . HR-EIMS: m/z [M+H]
+ 503.1133 (calcd. 503.1142) .
1H NMR (400 MHz, CDCl
3) δ 8.37 (2H, dd, J = 8.9, 5.3 Hz, 4-fluorobenzoyl) , 7.29 (2H, t, J = 8.6 Hz, 4-fluorobenzoyl) , 7.21 (1H, s, H-2) , 7.15 (1H, s, H-5) , 6.98 (1H, d, J = 7.9 Hz, H-5’) , 6.88 (1H, d, J = 1.3 Hz, H-2’) , 6.85 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.09 (1H, br s, -OCH
2O-) , 6.04 (1H, br s, -OCH
2O-) , 5.29 (2H, s, H-9) , 3.95 (3H, s, 3-OCH
3) , 3.82 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, CDCl
3) δ 169.7 (C-9’) , 168.4 (4-fluorobenzoyl) , 165.8 (4-fluorobenzoyl) , 163.1 (4-fluorobenzoyl) , 152.8 (C-3) , 150.9 (C-4) , 148.1 (C-3’) , 148.0 (C-4’) , 138.5 (C-7) , 138.3 (C-7’) , 133.6 (4-fluorobenzoyl) , 133.5 (4-fluorobenzoyl) , 131.2 (C-1) , 130.8 (C-6) , 128.3 (C-1’) , 126.7 (C-8’) , 124.1 (C-6’) , 119.6 (C-8) , 116.9 (4-fluorobenzoyl) , 116.7 (4- fluorobenzoyl) , 111.1 (C-2’) , 108.7 (C-5’) , 106.9 (C-5) , 101.7 (C-2) , 99.5 (-OCH
2O-) , 66.8 (C-9) , 56.4 (3-OCH
3) , 56.3 (4-OCH
3) .
5 (38 mg, 0.1 mmol) , Et
3N (30 mg, 0.3 mmol) and DMAP (catalyzed amount) were dissolved in 2 mL of dry CH
2Cl
2. 4-Methoxybenzoyl chloride (51 mg, 0.3 mmol) was added to the mixture at 0 ℃. The reaction mixture was allowed to warm up to 25 ℃ and kept stirred at 25 ℃ for 2 h. The mixture was purified by a silica gel column to give desired product 17h (45 mg, 90%) . HR-EIMS: m/z [M+H]
+ 515.1338 (calcd. 515.1342) .
1H NMR (400 MHz, CDCl
3) δ 8.33 -8.25 (2H, m, 4-methoxybenzoyl) , 7.26 (1H, s, H-2) , 7.14 (1H, s, H-5) , 7.10 -7.03 (2H, m, 4-methoxybenzoyl) , 6.97 (1H, d, J = 7.9 Hz, H-5’) , 6.88 (1H, d, J = 1.4 Hz, H-2’) , 6.86 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.09 (1H, d, J = 1.4 Hz, -OCH
2O-) , 6.04 (1H, d, J = 1.4 Hz, -OCH
2O-) , 5.29 (2H, s, H-9) , 3.94 (3H, s, 3-OCH
3) , 3.93 (3H, s, 4-methoxybenzoyl) , 3.81 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, CDCl
3) δ 169.4 (C-9’) , 164.7 (4-methoxybenzoyl) , 163.4 (4-methoxybenzoyl) , 152.3 (C-3) , 150.4 (C-4) , 147.7 (C-3’) , 147.6 (C-4’) , 138.5 (C-7) , 137.5 (C-7’) , 132.7 (4-methoxybenzoyl) , 130.7 (C-6) , 130.6 (C-1) , 128.0 (C-1’) , 126.6 (C-8’) , 123.7 (C-6’) , 120.3 (4-methoxybenzoyl) , 119.2 (C-8) , 114.4 (4-methoxybenzoyl) , 110.7 (C-2’) , 108.3 (C-5’) , 106.4 (C-5) , 101.3 (C-2) , 99.4 (-OCH
2O-) , 66.6 (C-9) , 56.0 (3-OCH
3) , 55.9 (4-OCH
3) , 55.7 (4-methoxybenzoyl) .
Under nitrogen, diphyllin (5, 760 mg, 2 mmol) and DMAP (488 mg, 4 mmol) were dissolved in 10 mL dry CH
2Cl
2. The solution was cooled to 0 ℃. Then trifluoromethanesulfonic anhydride (Tf
2O) (0.5 mL, 2.4 mmol) was added slowly via syringe over 5 min. The reaction was allowed to warm up to r.t. and kept stirred at r.t. for 4 h. TLC showed that the reaction had completed, and a new spot formed. The mixture was concentrated in vacuo to give a yellow solid, which was washed with EtOH to give desired product 18 (0.97 g, 95%) . HR-EIMS: m/z [M+H]
+ 513.0455 (calcd. 513.0467) .
1H NMR (400 MHz, DMSO-d
6) δ 7.35 (1H, s, H-2) , 7.11 (1H, s, H-5) , 7.08 (1H, d, J = 7.9 Hz, H-5’) , 7.01 (1H, d, J = 1.6 Hz, H-2’) , 6.87 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.15 (2H, s, -OCH
2O-) , 5.56 (2H, s, H-9) , 3.99 (3H, s, 3-OCH
3) , 3.72 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 167.7 (C-9’) , 153.1 (C-3) , 150.6 (C-4) , 147.5 (C-3’) , 147.1 (C-4’) , 139.7 (C-7) , 135.2 (C-7’) , 131.6 (C-6) , 130.2 (C-1) , 126.8 (C-1’) , 125.2 (C-8’) , 123.6 (C-6’) , 119.7 (OTf) , 119.4 (C-8) , 110.7 (C-2’) , 108.1 (C-5’) , 106.2 (C-5) , 101.3 (C-2) , 98.7 (-OCH
2O-) , 65.4 (C-9) , 55.9 (3-OCH
3) , 55.5 (4-OCH
3) .
In an oven dried round bottom flask under an atmosphere of nitrogen was placed [Pd (dppf) Cl
2] CH
2Cl
2 complex (244 mg, 0.025 mmol) , B
2Pin
2 (191 mg, 0.75 mmol) , KOAc (147 mg, 1.5 mmol) and 18 (256 mg, 0.5 mmol) . To the flask was added freshly distilled 1, 4-dioxane (2 mL) . The mixture was degassed with N
2. The flask was equipped with a reflux condenser and heated at 100 ℃ for 3 h under a nitrogen atmosphere. The mixture was concentrated in vacuo to give a yellow solid, which was washed with EtOH to give desired product 19a (229.5 mg, 85%) . HR-EIMS: m/z [M+H]
+ 491.3626 (calcd. 491.1882) .
1H NMR (400 MHz, DMSO-d
6) δ 7.51 (1H, s, H-2) , 7.04 (1H, d, J = 7.9 Hz, H-5’) , 6.98 (1H, s, H-5) , 6.92 (1H, d, J = 1.6 Hz, H-2’) , 6.79 (1H, dd, J = 7.9, 1.7Hz, H-6’) , 6.13 (2H, br s, -OCH
2O-) , 5.43 (2H, s, H-9) , 3.94 (3H, s, 3-OCH
3) , 3.66 (3H, s, 4-OCH
3) , 1.06 (12H, s, Me) .
13C NMR (100 MHz, DMSO-d
6) δ 169.5 (C-9’) , 151.5 (C-3) , 149.8 (C-4) , 147.0 (C-3’, C-4’) , 139.9 (C-7) , 138.4 (C-7’) , 133.0 (C-6) , 128.4 (C-1’) , 127.8 (C-1) , 123.5 (C-6’) , 118.9 (C-8) , 117.9 (C-8’) , 110.7 (C-2’) , 108.0 (C-5’) , 106.7 (C-5) , 105.0 (C-2) , 101.2 (-OCH
2O-) , 79.1 (C-O) , 73.6 (C-O) , 68.1 (C-9) , 55.9 (3-OCH
3) , 55.2 (4-OCH
3) , 25.0 (CH
3) .
An oven-dried 10-mL flask was charged with Pd (dppf) Cl
2 (3.7 mg, 0.005 mmol) and 18 (51 mg, 0.1 mmol) . The flask was capped and then backfilled with N
2. Toluene (2.00 mL) was added via syringe, followed by the addition of AlMe
3 (0.15 mL, 0.3 mmol) . The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19b (25 mg, 66%) . HR-EIMS: m/z [M+H]
+ 379.1156 (calcd. 379.1182) .
1H NMR (400 MHz, DMSO-d
6) δ 7.40 (1H, s, H-2) , 7.04 (1H, d, J = 7.9 Hz, H-5’) , 7.01 (1H, s, H-5) , 6.88 (1H, d, J = 1.6 Hz, H-2’) , 6.77 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.12 (2H, s, -OCH
2O-) , 5.44 (s, 2H, H-9) , 3.99 (3H, s, 3-OCH
3) , 3.65 (3H, s, 4-OCH
3) , 2.57 (3H, s, Me) .
13C NMR (100 MHz, DMSO-d
6) δ 169.9 (C-9’) , 151.3 (C-3) , 149.3 (C-4) , 147.0 (C-3’, C-4’) , 138.2 (C-7) , 136.5 (C-7’) , 131.5 (C-6) , 128.6 (C-1’) , 128.1 (C-1) , 125.6 (C-8’) , 123.6 (C-6’) , 117.4 (C-8) , 110.8 (C-2’) , 108.0 (C-5’) , 105.9 (C-5) , 102.8 (C-2) , 101.2 (-OCH
2O-) , 67.9 (C-9) , 55.8 (3-OCH
3) , 55.2 (4-OCH
3) , 14.3 (CH
3) .
An oven-dried 10-mL flask was charged with Pd (dppf)
2Cl
2 (7.31 mg, 0.01 mmol) , Na
2CO
3 (65 mg, 0.6 mmol) , 18 (102 mg, 0.2 mmol) and pyridine-4-boronic acid (52 mg, 0.4 mmol) . The flask was capped and then backfilled with N
2. Dioxane and H
2O (2/0.4 mL) was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19c (22 mg, 50%) . HR-EIMS: m/z [M+H]
+ 442.1300 (calcd. 442.1291) .
1H NMR (400 MHz, DMSO-d
6) δ 8.79 (2H, d, J = 5.8 Hz, pyridine) , 7.62 (2H, s, H-2, pyridine) , 7.09 (1H, s, pyridine) , 7.08 (1H, d, J = 8.1 Hz, H-5’) , 7.01 (1H, s, H-5) , 6.97 (1H, d, J = 1.5 Hz, H-2’) , 6.85 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.14 (2H, s, -OCH
2O-) , 5.27 (2H, s, H-9) , 3.72 (3H, s, 3-OCH
3) , 3.68 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.2 (C-9’) , 151.8 (C-3) , 150.4 (pyridine) , 149.7 (C-4) , 147.1 (C-3’) , 147.0 (C-4’) , 143.8 (pyridine) , 138.9 (C-7) , 138.2 (C-7’) , 129.9 (C-6) , 128.5 (C-1) , 128.0 (C-1’) , 124.5 (pyridine, C-8’) , 123.5 (C-6’) , 117.9 (C-8) , 110.6 (C-2’) , 108.1 (C-5’) , 105.8 (C-5) , 103.3 (C-2) , 101.2 (-OCH
2O-) , 67.5 (C-9) , 55.4 (3-OCH
3) , 55.3 (4-OCH
3) .
An oven-dried 10-mL flask was charged with Pd (OAc)
2 (1.1 mg, 0.01 mmol) , PPh
3 (2.6 mg, 0.02 mmol) and 18 (0.1 mmol) . The flask was capped and then backfilled with argon (this was repeated two additional times) . DMF (1.00 mL) was added via syringe, followed by the addition of Et
3N (43 mL, 0.3 mmol) and HCO
2H (8 μL, 0.2 mmol) in a like manner. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19d (35 mg, 98%) . HR-EIMS: m/z [M+H]
+ 365.1010 (calcd. 365.1025) .
1H NMR (400 MHz, DMSO-d
6) δ 7.94 (1H, s, H-7) , 7.51 (1H, s, H-2) , 7.05 (1H, d, J = 7.9 Hz, H-5’) , 6.99 (1H, s, H-5) , 6.92 (1H, d, J = 1.6 Hz, H-2’) , 6.80 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.13 (2H, s, -OCH
2O-) , 5.43 (2H, s, H-9) , 3.94 (3H, s, 3-OCH
3) , 3.66 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.5 (C-9’) , 151.5 (C-3) , 149.8 (C-4) , 147.0 (C-3’, C-4’) , 139.9 (C-7) , 138.3 (C-7’) , 132.9 (C-6) , 128.4 (C-1’) , 127.8 (C-1) , 123.5 (C-6’) , 118.8 (C-8) , 117.9 (C-8’) , 110.7 (C-2’) , 108.0 (C-5’) , 106.7 (C-5) , 105.0 (C-2) , 101.2 (-OCH
2O-) , 68.1 (C-9) , 56.0 (3-OCH
3) , 55.8 (4-OCH
3) .
Compound 19e
An oven-dried 10-mL flask was charged with Pd (OAc)
2 (1.12 mg, 0.005 mmol) , BINAP (5 mg, 0.008 mmol) , Cs
2CO
3 (49 mg, 0.15 mmol) and 18 (51 mg, 0.1 mmol) . The flask was capped and then backfilled with N
2. A solution of 4-aminobenzotrifluoride (32 mg, 0.2 mmol) in PhMe was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19e (45 mg, 86%) . HR-EIMS: m/z [M+H]
+ (calcd. 524.1321) .
1H NMR (400 MHz, CDCl
3) δ 7.44 (2H, d, J = 8.5 Hz, benzotrifluoride) , 7.32 (1H, s, H-2) , 7.15 (1H, s, H-5) , 6.93 (1H, d, J = 7.9 Hz, H-5’) , 6.86 (1H, d, J = 1.5 Hz, H-2’) , 6.83 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.70 (2H, d, J = 8.4 Hz, benzotrifluoride) , 6.06 (1H, br s, -OCH
2O-) , 5.96 (1H, br s, -OCH
2O-) , 5.13 (2H, s, H-9) , 3.88 (3H, s, 3-OCH
3) , 3.81 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, CDCl
3) δ 170.6 (C-9’) , 152.6 (C-3) , 150.7 (C-4) , 148.2 (benzotrifluoride) , 148.1 (C-3’) , 148.0 (C-4’) , 138.3 (C-7) , 136.0 (C-7’) , 130.9 (benzotrifluoride) , 130.8 (C-6) , 128.6 (C-8’) , 128.5 (C-1) , 127.3 (C-1’) , 124.0 (C-6’) , 119.4 (C-8) , 114.3 (benzotrifluoride) , 111.0 (C-2’) , 108.6 (C-5’) , 107.1 (C-5) , 101.9 (C-2) , 101.8 (-OCH
2O-) , 67.8 (C-9) , 56.5 (3-OCH
3) , 56.3 (4-OCH
3) .
An oven-dried 10-mL flask was charged with Pd (OAc)
2 (1.12 mg, 0.005 mmol) , BINAP (5 mg, 0.008 mmol) , Cs
2CO
3 (49 mg, 0.15 mmol) and 18 (51 mg, 0.1 mmol) . The flask was capped and then backfilled with N
2. A solution of aminobenzene (19 mg, 0.2 mmol) in PhMe was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19g (38.7 mg, 85%) . HR-EIMS: m/z [M+H]
+ (calcd. 456.1447) .
1H NMR (400 MHz, CDCl
3) δ 7.40 (1H, s, H-2) , 7.22 (2H, dd, J = 8.5, 7.4 Hz, aminobenzene) , 7.14 (1H, s, H-5) , 6.93 (1H, d, J = 7.9 Hz, H-5’) , 6.89 -6.87 (1H, m, aminobenzene) , 6.86 (1H, d, J = 1.5 Hz, H-2’) , 6.83 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.72 (2H, dd, J = 1.0, 8.5 Hz, aminobenzene) , 6.06 (1H, br s, -OCH
2O-) , 5.98 (1H, br s, -OCH
2O-) , 5.07 (2H, s, H-9) , 3.89 (3H, s, 3-OCH
3) , 3.80 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, CDCl
3) δ 170.4 (C-9’) , 151.9 (C-3) , 150.1 (C-4) , 147.6 (C-3’) , 147.6 (C-4’) , 144.6 (C-7) , 136.4 (C-7’) , 133.9 (aminobenzene) , 130.4 (C-6) , 129.8 (C-1) , 129.7 (C-8’) , 129.5 (aminobenzene) , 128.6 (C-1’) , 123.7 (C-6’) , 120.2 (C-8) , 119.2 (aminobenzene) , 115.6 (aminobenzene) , 110.8 (C-2’) , 108.2 (C-5’) , 106.7 (C-5) , 101.7 (C-2) , 101.3 (-OCH
2O-) , 67.7 (C-9) , 56.1 (3-OCH
3) , 55.9 (4-OCH
3) .
An oven-dried 10-mL flask was charged with Pd (PPh
3)
4 (6.22 mg, 0.005 mmol) and 18 (51 mg, 0.1 mmol) . The flask was capped and then backfilled with N
2. THF (2.00 mL) was added via syringe, followed by the addition of Et
2Zn. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19g (25 mg, 64%) . HR-EIMS: m/z [M+H]
+ 393.1324 (calcd. 393.1338) .
1H NMR (400 MHz, DMSO-d
6) δ 7.43 (1H, s, H-2) , 7.04 (1H, d, J = 8.1 Hz, H-5’) , 7.02 (1H, s, H-5) , 6.90 (1H, d, J = 1.3 Hz, H-2’) , 6.77 (1H, dd, J = 7.7, 1.3 Hz, H-6’) , 6.12 (2H, s, -OCH
2O-) , 5.47 (2H, s, H-9) , 3.99 (3H, s, 3-OCH
3) , 3.65 (3H, s, 4-OCH
3) , 3.03 (2H, q, J = 7.3 Hz, Et) , 1.28 (3H, t, J = 7.5 Hz, Et) .
13C NMR (100 MHz, DMSO-d
6) δ 169.9 (C-9’) , 151.5 (C-3) , 149.3 (C-4) , 147.0 (C-3’) , 146.9 (C-4’) , 137.7 (C-7) , 136.7 (C-7’) , 131.7 (C-6) , 130.6 (C-1) , 128.7 (C-8’) , 128.5 (C-1’) , 123.6 (C-6’) , 117.6 (C-8) , 110.8 (C-2’) , 108.1 (C-5’) , 106.1 (C-5) , 102.5 (C-2) , 101.2 (-OCH
2O-) , 67.6 (C-9) , 55.8 (3-OCH
3) , 55.2 (4-OCH
3) , 21.5 (Et) , 13.9 (Et) .
An oven-dried 10-mL flask was charged with Pd (PPh
3)
4 (6.22 mg, 0.005 mmol) , K
2CO
3 (40 mg, 0.3 mmol) , 18 (51 mg, 0.1 mmol) and thiophene-2-boronic acid (26 mg, 0.2 mmol) . The flask was capped and then backfilled with N
2. DMF was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19h (38 mg, 92%) . HR-EIMS: m/z [M+H]
+ 447.0889 (calcd. 447.0902) .
1H NMR (400 MHz, DMSO-d
6) δ 7.87 (1H, dd, J = 5.1, 1.2 Hz, thiophene) , 7.42 (1H, dd, J = 3.5, 1.2 Hz, thiophene) , 7.41 (1H, s, H-2) , 7.33 (1H, dd, J = 5.1, 3.5 Hz, thiophene) , 7.07 (1H, d, J = 7.9 Hz, H-5’) , 7.06 (1H, s, H-5) , 6.95 (1H, d, J = 1.5 Hz, H-2’) , 6.83 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.13 (2H, br s, -OCH
2O-) , 5.32 (2H, s, H-9) , 3.77 (3H, s, 3-OCH
3) , 3.67 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.2 (C-9’) , 151.7 (C-3) , 149.6 (C-4) , 147.0 (C-3’, C-4’) , 139.6 (C-7) , 138.7 (thiophene) , 135.4 (C-7’) , 131.4 (C-6) , 129.0 (C-1) , 128.6 (C-1’) , 128.1 (thiophene) , 128.1 (thiophene) , 128.1 (thiophene) , 123.6 (C-6’) , 123.5 (C-8’) , 118.0 (C-8) , 110.6 (C-2’) , 108.1 (C-5’) , 105.7 (C-5) , 103.7 (C-2) , 101.2 (-OCH
2O-) , 67.9 (C-9) , 55.4 (3-OCH
3) , 55.3 (4-OCH
3) .
Compound 19i
An oven-dried 10-mL flask was charged with Pd (PPh
3)
4 (6.22 mg, 0.005 mmol) , K
2CO
3 (42 mg, 0.3 mmol) , 18 (51 mg, 0.1 mmol) and pyridine-3-boronic acid (25 mg, 0.2 mmol) . The flask was capped and then backfilled with N
2.2mL DMF was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19i (30 mg, 75%) . HR-EIMS: m/z [M+H]
+ 442.1293 (calcd. 442.1291) .
1H NMR (400 MHz, DMSO-d
6) δ 8.80 (2H, s, pyridine) , 8.09 (1H, s, pyridine) , 7.71 (1H, s, H-2) , 7.09 (1H, s, pyridine) , 7.08 (2H, d, J = 8.3 Hz, H-5’) , 6.97 (1H, d, J = 4.2 Hz, H-2’) , 6.95 (1H, s, H-5) , 6.85 (1H, dd, J = 8.6, 4.2 Hz, H-6’) , 6.14 (2H, br s, -OCH
2O-) , 5.36 -5.19 (2H, m, H-9) , 3.71 (3H, s, 3-OCH
3) , 3.68 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.3 (C-9’) , 151.7 (C-3) , 149.6 (C-4, pyridine) , 147.1 (C-3’, C-4’) , 139.0 (C-7, pyridine) , 138.7 (pyridine) , 138.0 (C-7’) , 130.8 (C-6, pyridine) , 128.5 (C-1’, C-1) , 128.1 (pyridine) , 127.1 (C-8’) , 123.5 (C-6’) , 117.8 (C-8) , 110.6 (C-2’) , 108.1 (C-5’) , 105.7 (C-5) , 103.4 (C-2) , 101.2 (-OCH
2O-) , 67.5 (C-9) , 55.4 (3-OCH
3) , 55.3 (4-OCH
3) .
An oven-dried 10-mL flask was charged with Pd (PPh
3)
4 (6.22 mg, 0.005 mmol) , K
2CO
3 (42 mg, 0.3 mmol) , 18 (51 mg, 0.1 mmol) and thiophene-3-boronic acid (26 mg, 0.2 mmol) . The flask was capped and then backfilled with N
2. DMF 2 mL was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19j (22 mg, 50%) . HR-EIMS: m/z [M+H]
+ 447.0867 (calcd. 447.0902) .
1H NMR (400 MHz, DMSO-d
6) δ 7.91 (1H, d, J = 1.4 Hz, thiophene) , 7.84 (1H, d, J = 4.7 Hz, thiophene) , 7.44 (1H, d, J = 4.9 Hz, thiophene) , 7.27 (1H, s, H-2) , 7.06 (1H, d, J = 7.9 Hz, H-5’) , 7.05 (1H, s, H-5) , 6.95 (1H, d, J = 1.0 Hz, H-2’) , 6.83 (1H, dd, J = 7.8, 1.3 Hz, H-6’) , 6.13 (2H, s, -OCH
2O-) , 5.32 (2H, s, H-9) , 3.76 (3H, s, 3-OCH
3) , 3.66 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO) δ 170.0 (C-9’) , 151.9 (C-3) , 150.0 (C-4) , 147.5 (C-3’, C-4’) , 139.0 (C-7) , 138.3 (C-7’) , 136.0 (thiophene) , 131.3 (C-6) , 129.2 (C-1) , 129.0 (thiophene) , 128.8 (C-1’) , 127.8 (C-8’) , 126.6 (thiophene) , 125.9 (thiophene) , 123.9 (C-6’) , 118.4 (C-8) , 111.1 (C-2’) , 108.5 (C-5’) , 106.1 (C-5) , 104.4 (C-2) , 101.7 (-OCH
2O-) , 68.4 (C-9) , 55.8 (3-OCH
3) , 55.7 (4-OCH
3) .
An oven-dried 10-mL flask was charged with Pd (PPh
3)
4 (6.22 mg, 0.005 mmol) , Na
2CO
3 (32 mg, 0.3 mmol) , 18 (51 mg, 0.1 mmol) and furan-2-boronic acid (26 mg, 0.2 mmol) . The flask was capped and then backfilled with N
2. Dioxane and H
2O (2/0.4 mL) was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19k (30 mg, 70%) . HR-EIMS: m/z [M+H]
+ 431.1098 (calcd. 431.1131) .
1H NMR (400 MHz, DMSO-d
6) δ 7.99 (1H, dd, J = 1.8, 0.7 Hz, furan) , 7.73 (1H, s, H-2) , 7.14 (1H, dd, J = 3.4, 0.6 Hz, furan) , 7.07 (1H, d, J = 7.9 Hz, H-5’) , 7.06 (1H, s, H-5) , 6.95 (d, 1H, J = 1.5 Hz, furan) , 6.82 (1H, dd, J = 7.9, 1.8 Hz, H-6’) , 6.82 (1H, d, J = 1.9 Hz, H-2’) , 6.14 (2H, s, -OCH
2O-) , 5.51 (2H, s, H-9) , 3.92 (3H, s, 3-OCH
3) , 3.68 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.2 (C-9’) , 152.0 (C-3) , 149.6 (C-4) , 148.9 (furan) , 147.1 (C-3’) , 147.0 (C-4’) , 143.9 (furan) , 138.5 (C-7) , 138.4 (C-7’) , 129.1 (C-6) , 128.9 (C-1) , 128.2 (C-1’) , 123.5 (C-6’) , 119.8 (C-8) , 118.3 (C-8’) , 112.1 (furan) , 111.8 (furan) , 110.7 (C-2’) , 108.1 (C-5’) , 105.9 (C-5) , 104.1 (C-2) , 101.3 (-OCH
2O-) , 68.6 (C-9) , 55.5 (3-OCH
3) , 55.2 (4-OCH
3) .
Compound 19l
An oven-dried 10-mL flask was charged with Pd (PPh
3)
4 (24 mg, 0.02 mmol) , Na
2CO
3 (120 mg, 1.2 mmol) , 18 (204 mg, 0.4 mmol) , 3, 6-dihydro-2H-pyridine-1-N-Boc-4-boronic acid, and pinacol ester (186 mg, 0.6 mmol) . The flask was capped and then backfilled with N
2. Dioxane and water (4/0.8 mL) were added via syringe. The reaction mixture was heated to 80 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The mixture was purified by a silica gel column to give desired product 19l (69 mg, 27%) . HR-EIMS: m/z [M+H]
+546.2109 (calcd. 546.2128) .
1H NMR (400 MHz, CDCl
3) δ 7.12 (1H, s, H-2) , 7.11 (1H, s, H-5) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.84 (1H, br s, H-2’) , 6.81 (1H, d, J = 8.1 Hz, H-6’) , 6.09 (1H, br s, -OCH
2O-) , 6.04 (1H, br s, -OCH
2O-) , 5.88 (1H, s, 3, 6-dihydro-2H-pyridine) , 5.29 (2H, s, H-9) , 4.42 -4.05 (2H, m, 3, 6-dihydro-2H-pyridine) 3.99 (3H, s, 3-OCH
3) , 3.80 (3H, s, 4-OCH
3) , 3.69 (2H, s, 3, 6-dihydro-2H-pyridine) , 2.59 -2.29 (2H, m, 3, 6-dihydro-2H-pyridine) , 1.53 (9H, s, Boc) .
13C NMR (100 MHz, CDCl
3) δ170.1 (C-9’) , 155.1 (Boc) , 151.7 (C-3) , 149.8 (C-4) , 147.6 (C-3’) , 147.6 (C-4’) , 138.9 (C-7) , 136.9 (C-7’) , 131.9 (3, 6-dihydro-2H-pyridine) , 130.7 (C-6) , 129.4 (C-1) , 128.4 (C-1’) , 124.5 (3, 6-dihydro-2H-pyridine) , 123.6 (C-6’) , 123.5 (C-8’) , 118.3 (C-8) , 108.3 (C-2’, C-5’) , 106.5 (C-5) , 103.3 (C-2) , 101.3 (-OCH
2O-) , 80.2 (Boc) , 67.7 (3, 6-dihydro-2H-pyridine) , 67.1 (C-9) , 55.9 (3-OCH
3) , 55.9 (4-OCH
3) , 53.5 (3, 6-dihydro-2H-pyridine) , 29.4 (3, 6-dihydro-2H-pyridine) , 28.5 (Boc) .
An oven-dried 10-mL flask was charged with Pd
2 (dba)
3 (4.58 mg, 0.005 mmol) , XantPhos (2.89 mg, 0.005 mmol) , Cs
2CO
3 (65 mg, 0.2 mmol) and 18 (51 mg, 0.1 mmol) . The flask was capped and then backfilled with N
2. A solution of morpholine (17 mg, 0.2 mmol) in toluene was added via syringe. The reaction mixture was heated to 100 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 19m (20 mg, 40%) . HR-EIMS: m/z [M+H]
+ (calcd. 450.1553) .
1H NMR (400 MHz, CDCl
3) δ 7.79 (1H, s, H-2) , 7.07 (1H, s, H-5) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.82 (1H, d, J = 1.4 Hz, H-2’) , 6.79 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.09 (1H, br s, -OCH
2O-) , 6.05 (1H, br s, -OCH
2O-) , 5.52 (2H, s, H-9) , 4.07 (3H, s, 3-OCH
3) , 4.05 -4.01 (2H, m, morpholine) , 3.93 (2H, td, J = 10.9, 2.2 Hz, morpholine) , 3.80 (3H, s, 4-OCH
3) , 3.28 (2H, td, J = 11.3, 2.9 Hz, morpholine) , 3.13 (2H, d, J = 11.8 Hz, morpholine) .
13C NMR (100 MHz, CDCl
3) δ 169.6 (C-9’) , 151.8 (C-3) , 150.1 (C-4) , 147.5 (C-3’, C-4’) , 142.2 (C-7) , 139.4 (C-7’) , 136.8 (C-6) , 132.1 (C-1) , 130.5 (C-8’) , 129.9 (C-1’) , 128.6 (C-8) , 123.5 (C-6’) , 110.6 (C-2’) , 108.2 (C-5’) , 106.5 (C-5) , 102.6 (C-2) , 101.2 (-OCH
2O-) , 67.8 (morpholine) , 67.3 (C-9) , 55.9 (3-OCH
3) , 55.9 (4-OCH
3) , 51.5 (morpholine) .
A solution of 18 (256 mg, 0.5 mmol) , tributyl (1-ethoxyvinyl) stannane (216 mg, 0.6 mmol) and 5 mL toluene was degassed for 30 min while stirring. PdCl
2 (PPh
3)
2 (34 mg, 0.05 mmol) was then added, the solution was heated to 100 ℃ overnight with stirring. 10 mL of 50%HCl (aq. ) was added to the reaction mixture and the solution was stirred for 6 h, followed by filtration through celite that effectively removed the palladium black. The mixture was purified by a silica gel column to give desired product 19n (180 mg, 88%) . HR-EIMS: m/z [M+H]
+ 393.1324 (calcd. 393.1338) .
1H NMR (400 MHz, DMSO-d
6) δ 7.64 (1H, s, H-2) , 7.07 (1H, d, J = 7.9 Hz, H-5’) , 7.06 (1H, s, H-5) , 6.96 (1H, d, J = 1.6 Hz, H-2’) , 6.82 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.14 (2H, s, -OCH
2O-) , 5.55 (2H, s, H-9) , 3.97 (3H, s, 3-OCH
3) , 3.68 (3H, s, 4-OCH
3) , 2.76 (3H, s, CH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 202.0 (Me-C=O) , 168.9 (C-9’) , 152.4 (C-3) , 149.7 (C-4) , 147.3 (C-3’) , 147.1 (C-4’) , 141.6 (C-7) , 139.6 (C-7’) , 129.4 (C-6) , 129.1 (C-1) , 129.0 (C-8’) , 127.9 (C-1’) , 123.5 (C-6’) , 118.0 (C-8) , 110.6 (C-2’) , 108.2 (C-5’) , 106.0 (C-5) , 104.4 (C-2) , 101.4 (-OCH
2O-) , 68.6 (C-9) , 55.9 (3-OCH
3) , 55.3 (4-OCH
3) , 31.8 (CH
3) .
Compound 19o
An oven-dried 25-mL flask was charged with Pd (PPh
3)
2Cl
2 (17.5 mg, 0.025 mmol) , CuI (14.3 mg, 0.075 mmol) and 18 (255 mg, 0.5 mmol) . The flask was capped and then backfilled with N
2. A solution of trimethylsilylacetylene (100 mg, 1 mmol) and Et
3N (150 mg, 1.5 mmol) in 5 mL DMF was added via syringe. The reaction mixture was heated to 80 ℃ for 10 h. After cooling to r.t., the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by a silica gel column to give desired product 19o (207 mg, 90%) . HR-EIMS: m/z [M+H]
+ 461.1404 (calcd. 461.1420) .
1H NMR (400 MHz, CDCl
3) δ 7.62 (1H, s, H-2) , 7.06 (1H, s, H-5) , 6.90 (1H, d, J = 7.9 Hz, H-5’) , 6.78 (1H, d, J = 1.5 Hz, H-2’) , 6.75 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.03 (1H, br s, -OCH
2O-) , 5.99 (1H, br s, -OCH
2O-) , 5.34 (2H, s, H-9) , 4.02 (3H, s, 3-OCH
3) , 3.75 (3H, s, 4-OCH
3) , 0.29 (9H, s, TMS) .
13C NMR (100 MHz, CDCl
3) δ 169.9 (C-9’) , 152.6 (C-3) , 150.3 (C-4) , 147.9 (C-3’) , 147.7 (C-4’) , 143.2 (C-7) , 140.1 (C-7’) , 133.3 (C-6) , 128.9 (C-1’) , 128.1 (C-1) , 123.7 (C-8’, C-6’) , 118.5 (C-8) , 110.7 (C-2’) , 108.4 (C-5’) , 106.5 (C-5) , 106.2 (C≡C) , 104.5 (C≡C) , 101.5 (C-2) , 98.8 (-OCH
2O-) , 68.3 (C-9) , 56.1 (3-OCH
3) , 56.0 (4-OCH
3) , 0.23 (TMS) .
A 25 mL round-bottomed flask (equipped with thermocouple, overhead stirring and a nitrogen inlet) was charged with cesium carbonate (74.1 mg, 0.228 mmol) , palladium (II) acetate (0.7 mg, 0.003 mmol) , and 4, 5-bis-diphenylphosphanyl-9, 9-dimethyl-9H-xanthene (Xantphos, 2.82 mg, 0.005 mmol) . The flask was evacuated and backfilled with nitrogen 3x. Dioxane (2 mL) was added followed by another set of three cycles of evacuation and backfilling with nitrogen. The canary yellow slurry was stirred at r.t. for 10 min, and triethylamine (0.68 μL, 0.005 mmol) was added. Continued stirring for 10 min at r.t. gradually changed the color from yellow to red. 18 (83 mg, 0.162 mmol) and benzophenone imine (32.7 μL, 0.195 mmol) were added in 1 mL of dioxane via syringe (1 mL wash) . The reaction mixture was warmed to an internal temperature of 100 ℃ for 12 h. Cooling the reaction mixture to ambient temperature was followed by pouring the slurry into 10 mL of ethyl acetate. The organics were washed with 2 x 50 mL of water, and the ethyl acetate solution was concentrated in vacuo. The mixture was purified by flash chromatography on silica gel, eluting with 1: 1 n-hexane: ethyl acetate, to give 19p (50 mg, 57%) as a yellow solid.
1H NMR (400 MHz, CDCl
3) δ 7.88 (2H, dt, J = 7.1, 1.4 Hz, phenyl) , 7.64 -7.55 (1H, m, H-2) , 7.50 (2H, ddd, J = 8.1, 6.5, 1.4 Hz, phenyl) , 7.37 -7.30 (2H, m, phenyl) , 7.25 -7.18 (2H, m, phenyl) , 7.16 -7.10 (2H, m, phenyl) , 7.10 (1H, s, H-5) , 6.94 (1H, dd, J = 7.9, 0.5 Hz, H-5’) , 6.82 (1H, dd, J = 1.7, 0.5 Hz, H-2’) , 6.79 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.08 (1H, d, J = 1.5 Hz, -OCH
2O-) , 6.03 (1H, d, J = 1.5 Hz, -OCH
2O-) , 5.29 (2H, s, H-9) , 3.98 (3H, s, 3-OCH
3) , 3.82 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, CDCl
3) δ 170.1 (C-9’) , 151.3 (C-3) , 149.8 (C-4) , 147.2 (C-3’) , 147.2 (C-4’) , 135.7 (C-7) , 134.6 (C-7’) , 131.5 (C-6) , 130.2 (C-1) , 129.9 (C-1’) , 129.8 (phenyl) , 129.3 (phenyl) , 128.4 (phenyl) , 128.3 (phenyl) , 128.2 (phenyl) , 128.1 (phenyl) , 126.0 (C-6’) , 123.6 (C-8’) , 118.3 (C-8) , 110.8 (C-2’) , 107.9 (C-5’) , 106.3 (C-5) , 101.7 (C-2) , 101.0 (-OCH
2O-) , 67.0 (C-9) , 56.0 (3-OCH
3) , 55.6 (4-OCH
3) .
To a solution of 19n (41 mg, 0.1 mmol) in 1 mL MeOH was added NaBH
4 (6 mg, 0.15 mmol) . The mixture was stirred at r.t. for 1 h. TLC showed that the reaction had finished with one spot and the mixture was purified by prep-TLC to give desired product 20 (40 mg, 99%) . HR-EIMS: m/z [M+H]
+ 409.1272 (calcd. 409.1287) .
1H NMR (400 MHz, DMSO-d
6) δ 7.48 (1H, d, J = 2.1 Hz, H-2) , 7.03 (1H, d, J = 7.9 Hz, H-5’) , 6.99 (1H, d, J = 4.0 Hz, H-5) , 6.89 (1H, dd, J = 5.8, 1.5 Hz, H-2’) , 6.76 (1H, ddd, J = 7.8, 6.0, 1.7 Hz, H-6’) , 6.12 (2H, s, -OCH
2O-) , 5.70 (1H, m, CH-OH) , 5.59 (2H, br s, H-9) , 3.97 (3H, s, 3-OCH
3) , 3.64 (3H, s, 4-OCH
3) , 1.51 (3H, dd, J = 6.3, 1.3 Hz, Me) .
13C NMR (100 MHz, DMSO-d
6) δ 169.5 (C-9’) , 151.2 (C-3) , 149.2 (C-4) , 147.0 (C-3’) , 146.9 (C-4’) , 137.2 (C-7) , 136.2 (C-7’) , 134.7 (C-6) , 128.8 (C-1) , 128.6 (C-1’) , 123.5 (C-8’) , 123.4 (C-6’) , 118.2 (C-8) , 110.9 (C-2’) , 108.0 (C-5’) , 105.8 (C-5) , 102.9 (C-2) , 101.2 (-OCH
2O-) , 68.9 (CH-OH) , 65.6 (C-9) , 55.8 (3-OCH
3) , 55.1 (4-OCH
3) , 23.3 (CH
3) .
Compound 21
To a solution of 19o (207 mg, 0.45 mmol) was added K
2CO
3. The mixture was stirred for 2 h. TLC showed one spot with less polarity. The mixture was purified by a silica gel column to give desired product 21 (122 mg, 70%) . HR-EIMS: m/z [M+H]
+ 389.1000 (calcd. 389.1025) .
1H NMR (400 MHz, CDCl
3) δ 7.68 (1H, s, H-2) , 7.14 (1H, s, H-5) , 6.97 (1H, d, J = 7.9 Hz, H-5’) , 6.85 (1H, d, J = 1.3 Hz, H-2’) , 6.82 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.03 (1H, br s, -OCH
2O-) , 5.99 (1H, br s, -OCH
2O-) , 5.43 (2H, s, H-9) , 4.10 (3H, s, 3-OCH
3) , 3.82 (3H, s, 4-OCH
3) , 3.78 (1H, s, C≡CH) .
13C NMR (100 MHz, CDCl
3) δ 169.6 (C-9’) , 152.7 (C-3) , 150.3 (C-4) , 147.8 (C-3’) , 147.6 (C-4’) , 143.8 (C-7) , 140.4 (C-7’) , 133.3 (C-6) , 128.8 (C-1’) , 127.9 (C-1) , 123.5 (C-6’) , 121.4 (C-8’) , 118.4 (C-8) , 110.5 (C-2’) , 108.3 (C-5’) , 106.4 (C-5) , 104.1 (C-2) , 101.4 (-OCH
2O-) , 87.7 (C≡CH) , 77.7 (C≡CH) , 68.2 (C-9) , 56.2 (3-OCH
3) , 55.9 (4-OCH
3) .
The crude ketimine 19p (115.8 mg, 0.21 mmol) was suspended in 1: 1 (v/v) ratio of 1N HCl: THF (4 mL) solution and stirred at r.t. for 3-5 h. Upon consumption of the ketimine as determined by TLC, THF was removed and the aqueous residue was basified using 1N KOH to a pH of 10-14. The aqueous layer was then extracted three times with ethyl acetate (30 mL) . The organic layer was dried with anhydrous NaSO
4, filtered and concentrated in vacuo to give the crude amine. Upon purification via column chromatography the pure product 22 (70 mg, 84%) was obtained after solvent removal. HR-EIMS: m/z [M+H]
+ 380.0849 (calcd. 380.1134) .
1H NMR (400 MHz, DMSO-d
6) δ 7.62 (1H, s, H-2) , 7.02 (1H d, J = 7.9 Hz, H-5’) , 6.95 (1H, s, H-5) , 6.86 (1H, d, J = 1.5 Hz, H-2’) , 6.75 (1H, dd, J = 7.9, 1.6 Hz, H-6’) , 6.11 (2H, s, -OCH
2O-) , 5.75 (1H, s, NH
2) , 5.36 (2H, s, H-9) , 3.94 (3H, s, 3-OCH
3) , 3.65 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ 169.9 (C-9’) , 150.6 (C-3) , 149.8 (C-4) , 147.0 (C-3’) , 146.7 (C-4’) , 145.1 (C-7) , 134.8 (C-7’) , 129.6 (C-6) , 129.0 (C-1) , 128.9 (C-1’) , 123.9 (C-6’) , 123.5 (C-8’) , 121.9 (C-8) , 111.2 (C-2’) , 108.0 (C-5’) , 105.5 (C-5) , 101.2 (C-2) , 101.0 (-OCH
2O-) , 67.0 (C-9) , 55.8 (3-OCH
3) , 55.3 (4-OCH
3) .
To solution of 22 (38 mg, 0.1 mmol) and propynyl bromide (30 mg, 0.2 mmol) in MeCN (2 mL) was added Cs
2CO
3. The mixture was stirred for 12 h at 60℃. After TLC show one spot with less polarity, the reaction solution was quenched with water and extracted with CH
2Cl
2. The obtained solution was concentrated and purified by prep-TLC to give desired product 23 (4.6 mg, 11%) . HR-EIMS: m/z [M+H]
+418.1279 (calcd. 418.1291) .
1H NMR (400 MHz, CDCl
3) δ 7.19 (1H, d, J = 4.2 Hz, H-2) , 7.14 (1H, s, H-5) , 6.97 (1H, d, J = 6.1 Hz, H-5’) , 6.83 (1H, d, J = 1.6 Hz, H-2’) , 6.80 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.10 (2H, m, -OCH
2O-) , 6.06 (2H, m, -OCH
2O-) , 5.75 (1H, s, NH) , 5.30 (2H, s, H-9) , 4.16 (2H, s, CH
2C≡CH) , 4.06 (3H, s, 3-OCH
3) , 3.83 (1H, s, CH
2C≡CH) , 3.81 (3H, s, 4-OCH
3) .
13C NMR (100 MHz, DMSO-d
6) δ169.7 (C-9’) , 150.5 (C-3) , 149.7 (C-4) , 146.8 (C-3’) , 146.6 (C-4’) , 144.9 (C-7) , 134.8 (C-7’) , 129.5 (C-1) , 129.5 (C-1’) , 128.7 (C-6) , 123.8 (C-6’) , 123.3 (C-8’) , 121.7 (C-8) , 111.0 (C-2’) , 107.9 (C-5’) , 105.4 (C-5) , 101.0 (C-2) , 100.7 (-OCH
2O-) , 79.7 (CH
2C≡CH) , 74.1 (CH
2C≡CH) , 66.6 (C-9) , 55.6 (3-OCH
3) , 55.1 (4-OCH
3) , 33.2 (CH
2C≡CH) .
A solution of 22 (38 mg, 0.1 mmol) in dry pyridine (2 mL) was added Ac
2O (14.2 μL, 0.15 mmol) . The resulting mixture was stirred under r.t. overnight. After the reaction was complete, it was diluted by CH
2Cl
2 and washed with 10%HCl solution. The combined organic phase was further extracted with a saturate aqueous solution of NaHCO
3 and dried over Na
2SO
4. After concentration, the crude product was purified prep-TLC (1: 1 n-hexane: ethyl acetate) , to give 24 (15 mg, 36%) as a white solid. HR-EIMS: m/z [M+H]
+ 433.1149 (calcd. 422.1240) .
1H NMR (400 MHz, CDCl
3) δ 7.18 (1H, s, H-2) , 7.01 (1H, s, H-5) , 6.82 (1H, d, J = 7.9 Hz, H-5’) , 6.77 (1H, d, J = 1.6 Hz, H-2’) , 6.72 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.01 (1H, d, J = 1.4 Hz, -OCH
2O-) , 5.93 (1H, d, J = 1.5 Hz, -OCH
2O-) , 5.17 (2H, s, H-9) , 3.90 (3H, s, 3-OCH
3) , 3.75 (3H, s, 4-OCH
3) , 2.30 (3H, d, J = 0.9 Hz, OAc) .
13C NMR (100 MHz, CDCl
3) δ 170.6 (OAc) , 169.7 (C-9’) , 152.2 (C-3) , 150.1 (C-4) , 147.6 (C-3’) , 147.6 (C-4’) , 138.5 (C-7) , 135.7 (C-7’) , 130.0 (C-1) , 128.9 (C-1’) , 128.2 (C-6) , 124.4 (C-8’) , 123.6 (C-6’) , 118.6 (C-8) , 110.7 (C-2’) , 108.2 (C-5’) , 106.5 (C-5) , 101.4 (C-2) , 100.9 (-OCH
2O-) , 68.3 (C-9) , 56.1 (3-OCH
3) , 55.9 (4-OCH
3) , 23.40 (OAc) .
General procedure A: glycosylated modification
A solution of sugar (0.61 mmol) in dry pyridine (2 mL) was added acetic anhydride (Ac
2O) (0.4 mL, 4.21 mmol) . The resulting mixture was stirred under r.t. overnight. After the reaction was complete, it was diluted by dichloromethane (CH
2Cl
2) and washed with 10%hydrogen chloride (HCl) solution. The combined organic phase was further extracted with a saturated aqueous solution of sodium bicarbonate (NaHCO
3) and dried over sodium sulfate (Na
2SO
4) . After concentration, the crude product was directly used for next step without further purification.
The crude per-acetylated glycoside was dissolved in CH
2Cl
2 (5 mL) and cooled to 0 ℃ before the drop-wise addition of hydrogen bromide (33%in acetic acid, 1.5 mL) . The reaction was warmed to r.t. and stirred for an additional 4 h. Following completion, the reaction was quenched with water, and the aqueous layer was extracted with CH
2Cl
2. The organic layers were combined and washed with water, sodium bicarbonate, and brine, dried with Na
2SO
4, and concentrated under reduced pressure to afford the glycosyl bromide. After concentration, the crude product was directly used for next step without further purification.
Diphyllin (5) (215 mg, 0.61 mmol) was dissolved in chloroform (CHCl
3) (15 mL) and aqueous sodium hydroxide (NaOH) (0.1 M, 20 mL) prior to adding tetra-n-butylammonium bromide (TBAB) (306 mg, 0.95 mmol) . The reaction was then heated to 40 ℃ for 10 min before adding the glycosyl bromide (0.61 mmol) , and the reaction was then stirred at 40 ℃ overnight. After cooling to r.t., the aqueous layer was extracted with CHCl
3 and the combined organic layers were washed with brine, dried with Na
2SO
4 and concentrated under reduced pressure. Flash chromatographic separation of the reaction mixture (silica gel, 45%-52%ethyl acetate in n-hexane) afford the target diphyllin per-acetylated glycoside (25a-25g) . The reaction mixtures of compounds 25c-25g were not purified, but they were directly treated with basic reagents to produce their corresponding hydrolyzed compounds 26c-26g.
Potassium carbonate (K
2CO
3) (168.4 mg, 1.2 mmol) was added to a solution of a diphyllin per-acetylated glycoside (25a-25g) in MeOH (10 mL) and stirred at r.t. for 30 min. When no starting material was observed by TLC, the reaction was quenched by the addition of dilute HCl (2 M) , filtered through filter paper, and concentrated under reduced pressure. Flash chromatographic separation of the reaction mixture (silica gel, 2%-10%MeOH in CHCl
3) afforded the target glycoside (26a-26g) .
Peracetylated 7β-D-xylosyloxydiphyllin (25a, total yield 80%)
HR-EIMS: m/z [M+H]
+ 639.5780 (calcd. 639.1714) .
1H NMR (400 MHz, CDCl
3) δ 7.51 (1H, d, J = 1.0 Hz, H-2) , 7.07 (1H, s, H-5) , 6.95 (1H, d, J = 7.8 Hz, H-5’) , 6.84 –6.80 (1H, m, H-2’) , 6.80 –6.76 (1H, m, H-6’) , 6.11 –6.03 (2H, m, -OCH
2O-) , 5.50 –5.44 (1H, m, H-1”) , 5.44 –5.40 (2H, m, H-9) , 5.31 (1H, br t, J = 8.9 Hz, H-3”) , 5.13 (1H, dd, J = 8.8, 5.2 Hz, H-2”) , 5.12 (1H, dd, J = 8.3, 6.2 Hz, H-4”) , 4.26 (1H, dd, J = 11.8, 5.2 Hz, H-5”a) , 4.16 –4.10 (1H, m, H-5”b) , 4.07 (3H, s, 3-OCH
3) , 3.80 (3H, s, 4-OCH
3) , 2.12 (3H, s, -OAc) , 2.10 (3H, s, -OAc) , 2.04 (3H, s, -OAc) .
Peracetylated Patentiflorin A (25b, total yield 71%) δ HR-EIMS: m/z [M+H]
+ 653.1744 (calcd. 653.1870) .
1H NMR (400 MHz, CDCl
3) δ7.53 (1H, d, J = 1.9 Hz, H-2) , 7.07 (1H, s, H-5) , 6.96 (1H, d, J = 7.8 Hz, H-5’) , 6.85 –6.81 (1H, m, H-2’) , 6.81 –6.77 (1H, m, H-6’) , 6.12 –6.04 (2H, m, -OCH
2O-) , 5.50 –5.43 (2H, m, H-9) , 5.39 (1H, dd, J = 14.7, 2.4 Hz, H-2”) , 5.27 (1H, t, J = 9.6 Hz, H-3”) , 5.12 (1H, d, J = 7.9 Hz, H-1”) , 5.00 (1H, t, J = 9.6 Hz, H-4”) , 4.07 (3H, s, 3-OCH
3) , 3.81 (3H, s, 4-OCH
3) , 3.61 (1H, ddd, J = 9.7, 6.1, 1.2 Hz, H-5”) , 2.12 (3H, s, -OAc) , 2.06 (3H, s, -OAc) , 2.06 (3H, s, -OAc) , 1.28 (3H, dd, J = 6.1, 1.4 Hz, H-6”) .
7β-D-xylosyloxydiphyllin (26a, total yield 66%)
HR-EIMS: m/z [M+H]
+ 513.1389 (calcd. 513.1397) .
1H NMR (400 MHz, methanol-d
6) δ 8.13 (1H, s, H-2) , 7.09 (1H, d, J = 1.8 Hz, H-5) , 6.97 (1H, d, J = 7.9 Hz, H-5’) , 6.82 (1H, dd, J = 3.1, 1.3 Hz, H-2’) , 6.79 (1H, dt, J = 7.9, 1.8 Hz, H-6’) , 6.08 -6.04 (2H, m, -OCH
2O-) , 5.58 (1H, dd, J = 15.2, 1.6 Hz, H-9) , 5.46 (1H, dd, J = 15.2, 2.0 Hz, H-9) , 4.03 (3H, s, 3-OCH
3) , 3.98 (1H, d, J = 6.5 Hz, H-1”) , 3.98 -3.92 (1H, m, H-5”) , 3.74 (3H, s, 4-OCH
3) , 3.64 (1H, m, H-2”) , 3.51 -3.44 (1H, m, H-4”) , 3.16 -3.11 (2H, m, H-3”, H-5”) .
Patentiflorin A (26b, total yield 68%)
HR-EIMS: m/z [M+H]
+ 527.1526 (calcd. 527.1553) .
1H NMR (400 MHz, CD
3OD) δ 7.99 -7.92 (1H, m, H-2) , 6.86 (1H, m, H-5) , 6.82 -6.77 (1H, m, H-5’) , 6.63 (1H, m, H-2’) , 6.59 (1H, m, H-6’) , 5.94 (1H, d, J = 1.2 Hz, -OCH
2O-) , 5.93 (1H, dd, J = 2.2, 1.3 Hz, -OCH
2O-) , 5.50 -5.27 (2H, m, H-9) , 4.67 (1H, d, J = 7.9 Hz, H-1”) , 3.88 (3H, s, 3-OCH
3) , 3.57 (3H, s, 4-OCH
3) , 3.54 (1H, m, H-2”) , 3.33 (1H, t, J = 9.1 Hz, H-3”) , 3.05 (1H, t, J = 9.2 Hz, H-4”) , 3.170 (1H, m, H-5”) , 1.21 (3H, m, H-6”) .
7-O-α-L-arabinosyldiphyllin (26c, total yield 45%)
HR-EIMS: m/z [M+H]
+ 513.1305 (calcd. 513.1397) .
1H NMR (400 MHz, acetone-d
6) δ 8.21 (1H, s, H-2) , 7.07 (1H, d, J = 2.2, H-5) , 6.95 (1H, d, J = 7.9 Hz, H-5’) , 6.85 (1H, dd, J = 5.8, 1.7 Hz, H-2’) , 6.79 (1H, dt, J = 7.9, 2.0 Hz, H-6’) , 6.10 -6.04 (2H, m, -OCH
2O-) , 5.62 -5.34 (3H, m, H-9, H-1”) , 4.98 (1H, dt, J = 4.2, 1.9 Hz, OH-3”) , 4.87 (1H, dd, J = 7.1, 2.0 Hz, H-1”) , 4.24 (1H, t, J = 5.9 Hz, OH-2”) , 4.03 (1H, ddd, J = 8.7, 7.0, 4.3 Hz, H-2”) , 3.96 (3H, s, 3-OCH
3) , 3.98 -3.94 (1H, m, H-5”) , 3.91 -3.84 (1H, m, H-4”) , 3.70 (3H, s, 4-OCH
3) , 3.68 -3.72 (1H, m, H-3”) , 3.57 (1H, d, J = 12.4 Hz, H-5”) .
7-O-β-L-fucopyranosyldiphyllin (26d, total yield 49%)
HR-EIMS: m/z [M+H]
+ 527.1433 (calcd. 527.1553) .
1H NMR (400 MHz, DMSO-d
6) δ 8.20 d (1.9 Hz, H-2) , 7.05 (1H, dd, J = 7.9, 1.4 Hz, H-5’) , 6.99 (1H, d, J = 2.1 Hz, H-5) , 6.94 (1H, dd, J = 11.1, 1.5 Hz, H-2’) , 6.81 (1H, ddd, J = 7.8, 6.0, 1.6 Hz, H-6’) , 6.13 (2H, s, -OCH
2O-) , 5.59 -5.44 (3H, m, H-9, OH-2”) , 4.89 (1H, dd, J = 14.7, 3.1 Hz, OH-3”) , 4.70 (1H, dd, J = 7.7, 4.9 Hz, H-1”) , 4.20 (1H, d, J = 7.3 Hz, OH-4”) , 3.95 (3H, s, 3-OCH
3) , 3.75 (dd, J = 9.4, 7.7 Hz, 1H) , 3.67 (3H, s, 4-OCH
3) , 3.62 (1H, d, J = 6.4 Hz, H-2”) , 3.50 -3.42 (3H, m, H-3”, H-4”, H-5”) , 1.19 (3H, d, J = 6.2 Hz, H-6”) .
7-O-β-D-fucopyranosyldiphyllin (26e, total yield 67%)
HR-EIMS: m/z [M+H]
+ 527.1550 (calcd. 527.1553) .
1H NMR (400 MHz, acetone-d
6) δ 8.29 -8.08 (1H, m, H-2) , 7.12 -7.01 (1H, m, H-5) , 6.96 (1H, q, J = 7.8 Hz, H-5’) , 6.81 (2H, m, H-2’, H-6’) , 6.08 (2H, t, J = 7.5 Hz, -OCH
2O-) , 5.62 -5.48 (1H, m, H-9) , 5.50 -5.35 (1H, m, H-9) , 5.30 -5.15 (1H, m, OH-2”) , 4.87 (1H, dt, J = 11.7, 6.2 Hz, H-1”) , 4.69 (1H, s, OH-4”) , 4.02-3.95 (2H, m, H-3”, H-4”) , 3.79 (3H, d, J = 7.4 Hz, 3-OCH
3) , 3.76-3.72 (1 H, m, H-2”) , 3.70 (4H, m, 4-OCH
3, H-5”) , 1.29 (q, J = 8.2, 7.7 Hz, 3H) .
7-O-β-D-glucopyranosyldiphyllin (26f, total yield 48%)
HR-EIMS: m/z [M+H]
+ 543.1500 (calcd. 543.1503) .
1H NMR (400 MHz, acetone-d
6) δ 8.22 (1H, dq, J = 9.0, 4.9 Hz, H-2) , 7.05 (1H, m, H-5) , 6.95 (1H, tq, J = 8.2, 4.0 Hz, H-5’) , 6.89 -6.74 (2H, m, H-2’, H-6’) , 6.07 (2H, m, -OCH
2O-) , 5.73 (1H, m, H-9) , 5.48 -5.36 (1H, m, H-9) , 5.22 (1H, q, J = 4.3 Hz, OH-3”) , 4.91 (1H, tt, J = 7.6, 3.9 Hz, OH-4”) , 4.65 (1H, d, J = 4.6 Hz, H-1”) , 4.43 (1H, d, J = 4.8 Hz, OH-6”) , 3.97 (4H, m, 3-OCH
3, H-6”) , 3.70 (5H, m, 4-OCH
3, H-6”, H-2”) , 3.61 -3.43 (2H, m, H-5”, H-3”) , 3.39 (1H, m, H-4”) .
7-O-β-D-galactopyranosyldiphyllin (26g, total yield 64%)
HR-EIMS: m/z [M+H]
+ 543.1370 (calcd. 543.1503) .
1H NMR (400 MHz, acetone-d
6) δ 8.22 (1H, d, J = 1.0 Hz, H-2) , 7.10 (1H, s, H-5) , 6.98 (1H, dt, J = 7.9, 0.6 Hz, H-5’) , 6.91 -6.85 (1H, m, H-2’) , 6.85 -6.79 (1H, m, H-6’) , 6.13 -6.06 (2H, m, -OCH
2O-) , 5.84 -5.35 (2H, m, H-9) , 4.96 -4.83 (1H, m, H-1”) , 4.34 -4.19 (1H, m, OH) , 4.08 -4.01 (2H, m, H-2”, H-4”) , 4.00 (3H, s, 3-OCH
3) , 3.97 -3.82 (3H, m, H-5”, H-6”) , 3.73 (3H, s, 4-OCH
3) , 3.54 -3.69 (1H, m, H-3”) .
General procedure B: Selective modification of 3”-hydroxy Group
The glycoside 26a or 26b (0.3 mmol) was allowed to react with acetic anhydride (32 μL, 0.32 mmol) in dry acetonitrile (MeCN) (1.5 mL) at 40 ℃ for 12 h in the presence of tetrabutylammonium acetate (TBOAc) (27 mg, 0.09 mmol) . The solution was concentrated in vacuo to yield a mixture containing 27aa-27af (the total mixture yield from 26a: 52%) or a mixture containing 27ba-27bf (the total mixture yield from 26b: 50%) as a pale-yellow solid. The compound mixture containing 27aa-27af was purified by flash column chromatography (petroleum ether/EtOAc = 1.5/1) to afford the six single compounds 27aa-27af (27aa, 27ab, 27ac, 27ad, 27ae and 27af) . The compound mixture containing 27ba-27bf was purified by flash column chromatography (petroleum ether/EtOAc = 1.5/1) to afford the six single compounds 27ba-27bf (27ba, 27bb, 27bc, 27bd, 27be and 27bf) .
To the suspension of the 27ab or 27bb (0.036 mmol) in CH
2Cl
2 (3 mL) was added triethylamine (Et
3N) (50μL, 0.36 mmol) and allyl chloroformate (AllocOCl) (10.7 μL, 0.1 mmol) at 0℃, and the reaction was slowly warmed to r.t.. After 12h, the reaction mixture was poured into H
2O and was extracted with CH
2Cl
2. The organic layer was washed with brine, dried over Na
2SO
4, and evaporated under reduced pressure to give a compound mixture containing 28ab1-28ab3 (the total mixture yield from 27ab: 45%) or a compound mixture containing 28bb1-28bb3 (the total mixture yield from 27bb: 52%) as white solids. The compound mixture containing 28ab1-28ab3 was purified by flash column chromatography (petroleum ether/EtOAc=1/1) to afford the three single compounds 28ab1-28ab3 (28ab1, 28ab2 and 28ab3) . The compound mixture containing 28bb1-28bb3 was purified by flash column chromatography (petroleum ether/EtOAc=1/1) to afford the three single compounds 28bb1-28bb3 (28bb1, 28bb2 and 28bb3) .
To a solution of 28ab3 or 28bb3 (0.004 mmol) in 6 mL of MeOH/CH
2Cl
2 (v/v = 1/2) was added acetyl chloride (AcCl) (15 μL) dropwise at 0℃. The reaction mixture was stirred for 72 h, and then quenched with Et
3N. The volatile was removed in vacuo. The resulting residue was purified by silica gel column chromatography (petroleum ether/EtOAc 1/1) to afford 29a or 29b (18.4 mg, 67%) as white solids.
29a or 29b (0.05 mmol) , Et
3N (20.8 μL, 0.15 mmol) and 4-dimethylaminopyridine (DMAP) (catalyzed amount) were dissolved in 2 mL of dry CH
2Cl
2. Selected acyl chloride (0.15 mmol) was added to the mixture at 0 ℃. The reaction mixture was allowed to warm up to 25 ℃ and kept stirred at 25 ℃ for 2 h. The mixture was purified by prep-TLC (petroleum ether/EtOAc =1/1) to give desired products 30a-30k.
To a solution of 29a (20 mg, 0.036 mmol) in dry THF (2 mL) were added successively, freshly powdered KOH (3.6 mg, 0.0648 mmol) , 18-crowm-6 (0.4 mg, 0.0014 mmol) and benzyl bromide (11 μL, 0.09 mmol) . The mixture was stirred at r.t. and the reaction is monitored by TLC; at the end of the reaction, the mixture was diluted with CH
2Cl
2 and washed several times with water. The combined organic phase dried over Na
2SO
4 and concentrated. The obtained residue was purified by s prep-TLC (petroleum ether/EtOAc =1/1) to give desired products 30l.
To a solution of 30a-30l (0.045 mmol) in dry THF (4 ml) were added triphenylphosphine (PPh
3) (5.9 mg, 0.023 mmol) , Et
3N (31.2 μL, 0.225) , HCOOH (17 μL, 0.45 mmol) and tetrakis (triphenylphosphine) palladium (0) [Pd (PPh
3)
4] (5 mg, 0.0025 mmol) in sequence. The solution was stirred for 4 h at 55 ℃ under nitrogen, and concentrated in vacuo to give a mixture, which was chromatographed on prep-TLC (petroleum ether/EtOAc =1/1) to give desired products 31a-31l.
4”-Acetyl-7-O-β-D-xylosyldiphyllin (27aa)
HR-EIMS: m/z [M+H]
+ 555.1406 (calcd. 555.1503) .
1H NMR (400 MHz, Acetone-d
6) δ 7.63 (1H, d, J = 1.0 Hz, H-2) , 7.07 (1H, d, J = 2.3 Hz, H-5) , 7.01 –6.94 (1H, m, H-5’) , 6.85 (1H, d, J = 1.6 Hz, H-2’) , 6.80 (1H, ddd, J = 7.9, 1.6, 0.4 Hz, H-6’) , 6.10 (2H, dt, J = 4.9, 1.0 Hz, -OCH2O-) , 5.60 –5.45 (2H, m, H-9) , 5.33 (1H, d, J =7.8 Hz, H-1”) , 5.22 (1H, dd, J = 9.1, 7.8 Hz, H-2”) , 4.08 (1H, dd, J = 11.4, 5.2 Hz, H-5”a) , 4.03 (3H, s, 3-OCH
3) , 3.70-3.80 (1H, m H-3”) , 3.70-3.80 (1H, m H-4”) , 3.73 (3H, s, 4-OCH
3) , 3.46 (1H, dd, J = 11.3, 10.1 Hz, H-5”b) , 2.09 (3H, s, OAc) .
3”-Acetyl-7-O-β-D-xylosyldiphyllin (27ab)
HR-EIMS: m/z [M+H]
+ 555.1439 (calcd. 555.1503) .
1H NMR (400 MHz, acetone-d
6) δ 8.08 (1H, d, J = 3.3 Hz, H-2) , 7.05 (1H, br s, H-5) , 6.99 -6.93 (1H, m, H-5’) , 6.89 (1H, m, H-2’) , 6.79 (1H dd, J = 1.8, 6.0 Hz, H-6’) , 6.13 -6.07 (2H, m, -OCH
2O-) , 5.53 (1H, d, J = 15.0 Hz, H-1”) , 5.41 (1H d, J = 15.1 Hz, H-3”) , 5.11 -5.01 (2H, m, br s, H-9) , 4.04 (1H, m, H-5”) , 3.94 (3H, s, 3-OCH
3) , 3.91 -3.82 (1H, m, H-2”) , 3.69 (3H, d, J = 6.5 Hz, 4-OCH
3) , 3.47 -3.35 (1H, m, H-5”) , 2.10 (3H, s, OAc) .
13C NMR (100 MHz, acetone-d
6) δ 171.0 (OAc) , 169.8 (C-9’) , 153.0 (C-3) , 151.5 (C-4) , 148.4 (C-3’) , 148.3 (C-4’) , 145.8 (C-7) , 136.7 (C-7’) , 131.4 (C-1) , 129.7 (C-6) , 128.1 (C-1’) , 124.6 (C-6’) , 120.0 (C-8) , 111.8 (C-8’) , 111.7 (C-2’) , 108.7 (C-5’) , 106.7 (C-5) , 106.6 (C-1”) , 102.4 (C-2) , 102.2 (-OCH
2O-) , 78.8 (C-3”) , 73.2 (C-2”) , 69.1 (C-4”) , 67.8 (C-9) , 66.8 (C-5”) , 56.4 (3-OCH
3) , 55.8 (4-OCH
3) , 21.2 (-OAc) .
3”, 4”-Diacetyl-7-O-β-D-xylosyldiphyllin (27ad)
HR-EIMS: m/z [M+H]
+ 597.1533 (calcd. 597.1608) .
1H NMR (400 MHz, Acetone-d
6) δ 7.53 (1H, d, J = 0.8 Hz, H-2) , 7.02 (1H, d, J = 2.1 Hz, H-5) , 6.91 (1H, d, J = 7.9 Hz, H-5’) , 6.79 (1H, dd, J = 3.3, 1.4 Hz, H-2’) , 6.74 (1H, ddd, J = 7.9, 2.7, 1.7 Hz, H-6’) , 6.03 (2H, dt, J = 4.8, 0.9 Hz, -OCH
2O-) , 5.59 –5.45 (2H, m, H-9) , 5.42 (1H, d, J = 7.6 Hz, H-1’') , 5.23 (1H, dd, J = 9.8, 7.6 Hz, H-2”) , 5.14 (1H, br t, J = 9.3 Hz, H-3”) , 4.06 (1H, dd, J = 11.5, 5.6 Hz, H-5”a) , 3.95 (3H, s, 3-O CH
3) , 3.94 (1H, br td, J = 10.3, 5.3 Hz, H-4”) , 3.66 (3H, s, 4-OCH
3) , 3.51 (1H, br t, J = 10.8 Hz, H-5”b) , 2.03 (3H, s, -OAc) , 1.98 (3H, s, -OAc) .
2”, 4”-Diacetyl-7-O-β-D-xylosyldiphyllin (27ae)
HR-EIMS: m/z [M+H]
+ 597.1509 (calcd. 597.1608) .
1H NMR (400 MHz, Acetone-d
6) δ 7.62 (1H, d, J = 1.8 Hz, H-2) , 7.03 (1H, d, J = 2.1 Hz, H-5) , 6.92 (1H, dd, J = 7.9, 1.1 Hz, H-5’) , 6.80 (1H, d, J = 1.6 Hz, H-2’) , 6.77 –6.71 (1H, m, H-6’) , 6.07 –6.00 (2H, m, -OCH
2O-) , 5.54 –5.40 (2H, m, H-9) , 5.43 (1H, d, J = 7.1, H-1”) , 5.27 (1H, dd, J = 8.8, 7.2 Hz, H-2”) , 4.90 (1H, br td, J = 9.0, 5.2 Hz, H-4”) , 4.15 (1H, dd, J = 11.6, 5.1 Hz, H-5”a) , 4.04 –3.99 (1H, br t, J = 8.7 Hz, H-3”) , 3.98 (3H, s, 3-OCH
3) , 3.67 (3H, s, 4-OCH
3) , 3.50 (1H, dd, J = 11.6, 9.5 Hz, H-5”b) , 2.10 (3H, s, -OAc) , 2.03 (3H, s, -OAc) .
2”, 3”-Diacetyl-7-O-β-D-xylosyldiphyllin (27af)
HR-EIMS: m/z [M+H]
+ 597.1505 (calcd. 597.1608) .
1H NMR (400 MHz, Acetone-d
6) δ 8.10 (1H, d, J = 1.5 Hz, H-2) , 7.10 (1H, d, J = 4.5 Hz, H-5) , 6.98 (1H, dd, J = 7.9, 1.2 Hz, H-5’) , 6.88 (1H, br d, J = 1.3 Hz, H-2’) , 6.81 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.10 (2H, ddd, J = 4.8, 1.6, 1.1 Hz, -OCH
2O-) , 5.58 –5.41 (2H, m, H-9) , 5.25 (1H, br t, J = 9.5 Hz, H-3”) , 5.13 (1H, d, J = 7.6 Hz, H-1”) , 5.00 (1H, br td, J = 9.6, 5.5 Hz, H-4”) , 4.16 (1H, dd, J = 11.5, 5.5Hz, H-5”a) , 4.02 (1H, d, J = 9.6, 7.7 Hz, H-2”) , 3.97 (3H, s, 3-OCH
3) , 3.72 (3H, s, 4-OCH
3) , 3.54 (1H, dd, J = 11.5, 9.9 Hz, H-5”b) , 2.06 (3H, s, -OAc) , 1.98 (3H, s, -OAc) .
4”-Acetyl-7-O-β-D-patentiflorin A (27ba)
HR-EIMS: m/z [M+H]
+ 569.1612 (calcd. 569.1659) .
1H NMR (400 MHz, CDCl
3) δ 7.58 (1H, d, J = 1.5 Hz, H-2) , 7.07 (1H, s, H-5) , 6.96 (1H, d, J = 7.8 Hz, H-5’) , 6.86 –6.81 (1H, m, H-2’) , 6.81 –6.77 (1H, m, H-6’) , 6.12 –6.01 (2H, m, -OCH
2O-) , 5.51 –5.37 (2H, m, H-9) , 5.272 (1H, dd, J = 9.8, 7.9 Hz, H-2”) , 5.06 (1H, d, J = 7.8 Hz, H-1”) , 4.07 (3H, s, 3-OCH
3) , 3.81 (3H, s, 4-OCH
3) , 3.67 (1H, t, J = 9.2 Hz, H-3”) , 3.44 (1H, m, H-4”) , 3.43 (1H, m, H-5”) , 2.20 (3H, s, OAc) , 1.39 (3H, d, J = 4.0 Hz, H-6”) .
3”-Acetyl-7-O-β-D-patentiflorin A (27bb)
HR-EIMS: m/z [M+H]
+ 569.1602 (calcd. 569.1659) .
1H NMR (400 MHz, CDCl
3) δ 7.93 (1H, s, H-2) , 7.02 (1H, d, J = 3.6 Hz, H-5) , 6.91 (1H, dd, J = 9.2, 8.0 Hz, H-5’) , 6.82 -6.67 (2H, m, H-2’, 6’) , 6.11 -5.99 (2H, m, -OCH
2O-) , 5.55 -5.34 (2H, m, H-9) , 4.86 (1H, t, J = 9.2 Hz, H-3”) , 4.82 (1H, d, J = 7.8 Hz, H-1”) , 3.99 (3H, s, 3-OCH
3) , 3.93 (1H, dd, J = 9.5, 7.8 Hz, H-2”) , 3.77 (3H, d, J = 2.3 Hz, 4-OCH
3) , 3.42 (1H, t, J = 9.2 Hz, H-4”) , 3.37 -3.28 (1H, m, H-5”) , 2.20 (3H, s, -OAc) , 1.34 (3H, dd, J = 6.0, 1.2 Hz, H-6”) .
13C NMR (100 MHz, CDCl
3) δ 173.5 (OAc) , 170.3 (C-9’) , 152.1 (C-3) , 150.3 (C-4) , 147.6 (C-3’) , 147.6 (C-4’) , 144.5 (C-7) , 136.8 (C-7’) , 131.2 (C-8) , 130.8 (C-6) , 128.3 (C-1’) , 127.4 (C-1) , 123.7 (C-6’) , 119.1 (C-8’) , 110.8 (C-2’) , 108.3 (C-5’) , 106.2 (C-1”) , 104.7 (C-5) , 101.4 (C-2) , 101.1 (-OCH
2O-) , 79.4 (C-3”) , 73.9 (C-4”) , 73.0 (C-2”) , 72.4 (C-5”) , 67.7 (C-9) , 56.4 (3-OCH
3) , 55.9 (4-OCH
3) , 21.20 (C-6”) , 17.7 (OAc) .
2”-Acetyl-7-O-β-D-patentiflorin A (27bc)
HR-EIMS: m/z [M+H]
+ 569.1596 (calcd. 569.1659) .
1H NMR (400 MHz, CDCl
3) δ 7.96 (1H, s, H-2) , 7.09 (1H, s, H-5) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.84 (1H, dd, J = 3.1, 1.4 Hz, H-2’) , 6.83 –6.78 (1H, m, H-6’) , 6.12 –6.03 (2H, m, -OCH
2O-) , 5.54-5.39 (2H, m, H-9) , 4.83 (1H, dt, J = 8.7, 1.4 Hz, H-4”) , 4.74 (1H, t, J = 9.5 Hz, H-1”) , 4.04 (3H, s, 3-OCH
3) , 3.92 (1H, dd, J = 9.3, 7.9 Hz, H-2”) , 3.81 (3H, s, 4-OCH
3) , 3.67 (1H, t, J = 9.3 Hz, H-3”) , 3.51 –3.44 (1H, m, H-5”) , 2.15 (3H, s, OAc) , 1.27 (3H, d, J = 1.5 Hz, H-6”) .
3”, 4”-Diacetyl-7-O-β-D-patentiflorin A (27bd)
HR-EIMS: m/z [M+H]
+ 611.1705 (calcd. 609.1972) .
1H NMR (400 MHz, CDCl
3) δ 7.53 (1H, d, J = 1.5 Hz, H-2) , 7.07 (1H, s, H-5) , 6.98 –6.94 (1H, m, H-5’) , 6.84 –6.80 (1H, m, H-2’) , 6.81 –6.76 (1H, m, H-6’) , 6.11 –6.02 (2H, m, -OCH
2O-) , 5.50 –5.43 (2H, m, H-9) , 5.42 –5.36 (1H, m, H-2”) , 5.12 (1H, d, J = 7.9 Hz, H-1”) , 5.06 (1H, t, J = 9.8 Hz, H-3”) , 4.06 (3H, s, 3-OCH
3) , 3.80 (3H, s, 4-OCH
3) , 3.54 (1H, t, J = 9.1 Hz, H-4”) , 3.48 (1H, ddd, J = 8.8, 5.6, 1.1 Hz, H-5”) , 2.14 (3H, s, -OAc) , 2.11 (3H, s, -OAc) , 1.40 (3H, dd, J = 5.8, 1.2 Hz, H-6”) .
2”, 4”-Diacetyl-7-O-β-D-patentiflorin A (27be)
HR-EIMS: m/z [M+H]
+ 611.1721 (calcd. 609.1972) .
1H NMR (400 MHz, CDCl
3) δ 7.58 (1H, d, J = 1.7 Hz, H-2) , 7.07 (1H, s, H-5) , 6.96 (1H, d, J = 7.9 Hz, H-5’) , 6.83 (1H, dd, J = 3.0, 1.5 Hz, H-2’) , 6.80 (1H, ddd, J = 7.9, 3.0, 1.7 Hz, H- 6’) , 6.12 –6.03 (2H, m, -OCH
2O-) , 5.50 –5.38 (2H, m, H-9) , 5.38 –5.29 (1H, m, H-2”) , 5.05 (1H, d, J = 7.9 Hz, H-1”) , 4.84 (1H, t, J = 9.5 Hz, H-4”) , 4.07 (3H, s, 3-OCH
3) , 3.81 (3H, s, 4-OCH
3) , 3.77 (1H, t, J = 9.6 Hz, H-3”) , 3.60 –3.50 (1H, m, H-5”) , 2.20 (3H, s, -OAc) , 2.15 (3H, s, -OAc) , 1.29 (3H, dd, J = 6.2, 1.4 Hz, H-6”) .
2”, 3”-Diacetyl-7-O-β-D-patentiflorin A (27bf)
HR-EIMS: m/z [M+H]
+ 611.1699 (calcd. 609.1972) .
1H NMR (400 MHz, Chloroform-d) δ 7.93 (1H, s, H-2) , 7.08 (1H, s, H-5) , 6.97 –6.93 (1H, m, H-5’) , 6.86 –6.81 (1H, m, H-2’) , 6.80 –6.76 (1H, m, H-6’) , 6.11 –6.02 (2H, m, -OCH
2O-) , 5.53 –5.37 (2H, m, H-9) , 5.08 (1H, t, J = 9.5 Hz, H-3’) , 4.92 (1H, t, J = 9.6 Hz, H-4”) , 4.88 (1H, d, J = 7.8 Hz, H-1”) , 4.04 (1H, dd, J = 9.3, 7.9 Hz, H-2”) , 4.02 (3H, s, 3-OCH
3) , 3.80 (3H, s, 4-OCH
3) , 3.55 –3.46 (1H, m, H-5”) , 2.15 (3H, s, -OAc) , 2.06 (3H, s, -OAc) , 1.24 (3H, d, J = 5.6 Hz, H-6”) .
4”-O-allyl oxycarbonyl-3”-acetyl-7-O-β-D-xylosyldiphyllin (28ab1)
HR-EIMS: m/z [M+H]
+ 639.1514 (calcd. 639.1714) .
1H NMR (400 MHz, Acetone-d
6) δ 7.66 (1H, s, H-2) , 7.10 (1H, d, J = 3.3 Hz, H-5) , 6.98 (1H, dd, J = 7.9, 1.8 Hz, H-5’) , 6.92 –6.77 (2H, m, H-2’, H-6’) , 6.10 (2H, dt, J = 4.8, 1.3 Hz, -OCH
2O-) , 5.96 (1H, ddt, J = 16.2, 10.9, 5.6 Hz, O-Alloc) , 5.63 –5.46 (2H, m, H-9) , 5.44 (1H, d, J = 7.6 Hz, H-1”) , 5.34 (1H, dq, J = 17.2, 1.6 Hz, O-Alloc) , 5.24 (1H, bt t, J = 9.4 Hz, H-3”) 5.29 –5.20 (1H, m, O-Alloc) , 5.08 (1H, dd, J = 9.8, 7.8 Hz, H-2”) , 4.85 (1H, dd, J = 5.1, 2.1 Hz, O-Alloc) , 4.71 (1H, m, O-Alloc) , 4.10 (1H, dd, J = 11.2, 5.5 Hz, H-5”a) , 4.02 (3H, s, 3-OCH
3) , 3.99 (1H, br td, J = 10.2, 5.5 Hz, H-4”) , 3.72 (3H, s, 4-OCH
3) , 3.51 (1H, br t, J = 10.9 Hz, H-5”b) , 2.08 (3H, s, OAc) .
2”-O-allyl oxycarbonyl-3”-acetyl-7-O-β-D-xylosyldiphyllin (28ab2)
HR-EIMS: m/z [M+H]
+ 639.1514 (calcd. 639.1714) .
1H NMR (400 MHz, Acetone-d
6) δ 8.09 (1H, s, H-2) , 7.10 (1H, dd, J = 4.1, 1.6 Hz, H-5) , 6.98 (1H, dd, J = 7.9, 1.6 Hz, H-5’) , 6.91 –6.85 (1H, m, H-2’) , 6.85 –6.78 (1H, m, H-6’) , 6.10 (2H, dt, J = 5.2, 1.3 Hz, -OCH
2O-) , 5.93 (1H, ddt, J = 16.2, 10.8, 5.6 Hz, O-Alloc) , 5.76 (1H, dt, J = 5.0, 2.4 Hz, O-Alloc) , 5.60 –5.41 (2H, m, H-9) , 5.29 (1H, bt t, J = 9.5 Hz, H-3”) , 5.25 –5.20 (1H, m, O-Alloc) , 5.14 (1H, d, J = 7.6 Hz, H-1”) , 4.88 (1H, br td, J = 9.5, 5.5 Hz, H-4”) , 4.68 –4.54 (2H, m, O-Alloc) , 4.26 (1H, dd, J = 11.6, 5.5 Hz, H-5”a) , 4.03 (1H, dd, J = 9.5, 7.6Hz, H-2”) , 3.96 (3H, s, 3-OCH
3) , 3.72 (3H, s, 4-OCH
3) , 3.61 (1H, br t, J = 11.2 Hz, H-5”b) , 2.06 (3H, s, OAc) .
2”, 4”-O-diallyl oxycarbonyl-3”-acetyl-7-O-β-D-xylosyldiphyllin (28ab3)
HR-EIMS: m/z [M+H]
+ 723.1703 (calcd. 723.1925) .
1H NMR (400 MHz, CDCl
3) δ 7.55 (1H, s, H-2) , 7.09 (1H, s, H-5) , 6.96 (1H, dd, J = 8.2, 1.0 Hz, H-2’) , 6.87 -6.77 (2H, m, H-5’, 6’) , 6.12 -6.04 (2H, m, -OCH
2O-) , 5.90 (2H, m, H-9) , 5.52 -5.20 (8H, m, O-alloc) , 5.05 (1H, d, J = 7.7 Hz, H-1”) , 5.04 -4.95 (1H, m, H-3”) , 4.75 -4.59 (4H, m, O-alloc) , 4.24 (1H, dd, J = 11.8, 5.5 Hz, H-5”) , 4.06 (3H, s, 3-OCH
3) , 3.81 (3H, s, 4-OCH
3) , 3.36 (1H, dd, J = 11.7, 10.1 Hz, H-5”) , 2.11 (3H, s, OAc) .
13C NMR (100 MHz, acetone-d
6) δ 170.2 (OAc) , 169.6 (C-9’) , 155.3 (O-alloc) , 155.1 (O-alloc) , 153.2 (C-3) , 151.5 (C-4) , 148.4 (C-3’) , 148.3 (C-4’) , 144.7 (C-7) , 132.9 (O-alloc) , 132.8 (O-alloc) , 136.7 (C-7’) , 131.4 (C-1) , 129.6 (C-6) , 127.2 (C-1’) , 124.6 (C-6’) , 120.1 (C-8) , 119.2 (O-alloc) , 118.9 (O-alloc) , 111.7 (C-2’) , 111.7 (C-8’) , 108.7 (C-1”, C-5’) , 106.9 (C-5) , 102.5 (C-2) , 102.2 (-OCH
2O-) , 79.1 (C-3”) , 75.7 (C-2”) , 72.1 (C-4”) , 69.6 (O-alloc) , 69.3 (Alloc) , 67.5 (C-9) , 63.4 (C-5”) , 56.5 (3-OCH
3) , 55.8 (4-OCH
3) , 21.2 (O-alloc) .
2”, 4”-O-diallyl oxycarbonyl-3”-acetyl-7-O-β-D-patentiflorin A (28bb3)
HR-EIMS: m/z [M+H]
+ 737.1950 (calcd. 737.2082) .
1H NMR (400 MHz, CDCl
3) δ 7.56 (1H, s, H-2) , 7.08 (1H, s, H-5) , 7.00 -6.91 (1H, m, H-5’) , 6.86 -6.73 (2H, m, H-2’, 6’) , 6.08 (1H, br s, OCH
2O) 6.04 (1H, br s, -OCH
2O-) , 5.90 (2H, m, H-9) , 5.53 -5.20 (9H, m, O-alloc, 2”, 4”) , 5.08 (1H, dd, J = 8.5, 4.4 Hz, H-1”) , 4.78 (1H, td, J = 9.4, 4.5 Hz, H-3”) , 4.65 (4H, dt, J = 22.0, 5.1 Hz, O-alloc) , 4.04 (3H, s, 3-OCH
3) , 3.79 (3H, s, 4-OCH
3) , 3.58 (1H, dq, J = 10.5, 5.0 Hz, H-5”) , 2.06 (3H, s, OAc) , 1.27 (3H, d, J = 25.1 Hz, H-6”) .
13C NMR (100 MHz, CDCl
3) δ 170.1 (OAc) , 169.6 (C-9’) , 154.1 (O-alloc) , 152.2 (C-3) , 150.3 (C-4) , 147.6 (C-3’) , 147.5 (C-4’) , 143.3 (C-7) , 137.0 (C-7’) , 131.5 (C-6) , 131.2 (C-8) , 131.0 (C-1) , 130.8 (O-alloc) , 128.1 (C-1’) , 123.6 (C-6’) , 119.9 (O-alloc) , 119.4 (O-alloc) , 118.9 (C-8’) , 110.6 (C-2’) , 108.2 (C-5’) , 106.3 (C-1”) , 101.5 (C-5) , 101.3 (C-2) , 100.0 (-OCH
2O-) , 75.9 (C-3”) , 72.3 (C-2”) , 70.4 (C-4”) , 69.4 (O-alloc) , 69.1 (O-alloc) , 68.5 (C-5”) , 67.2 (C-9) , 56.6 (3-OCH
3) , 55.9 (4-OCH
3) , 20.7 (C-6”) , 17.4 (OAc) .
2”, 4”-O-diallyl oxycarbonyl-7-O-β-D-xylosyldiphyllin (29a, yield 92%)
HR-EIMS: m/z [M+H]
+ 681.1696 (calcd. 681.1819) . H NMR (400 MHz, acetone-d
6) δ 7.58 (1H, s, H-2) , 6.99 (1H, s, H-5) , 6.86 (1H, m, H-5’) , 6.72 (2H, m, H-2’, 6’) , 5.98 (2H, m, H-9) , 5.85 (9H, m, O-alloc, -OCH
2O-, H-1”, H-2”, H-4”) , 4.73 (1H, d, J = 7.7 Hz, H-5”) , 4.56 (4H, m, O-alloc) , 4.12 (1H, m, H-3”) , 3.92 (3H, s, 3-OCH
3) , 3.61 (3H, s, 4-OCH
3) , 3.42 (1H, m, H-5”) .
13C NMR (100 MHz, acetone-d
6) δ169.6 (C-9’) , 155.4 (O-alloc) , 155.2 (O-alloc) , 153.2 (C-3) , 151.6 (C-4) , 148.4 (C-3’) , 148.3 (C-4’) , 144.7 (C-7) , 138.1 (C-7’) , 132.9 (O-alloc) , 132.8 (O-alloc) , 131.4 (C-1) , 129.1 (C-6) , 127.2 (C-1’) , 124.6 (C-8) , 124.5 (C-6’) , 120.1 (O-alloc) , 119.2 (O-alloc) , 118.9 (C-8’) , 111.7 (C-2’) , 108.7 (C-1”, C-5’) , 106.9 (C-5) , 102.6 (C-2) , 102.2 (-OCH
2O-) , 78.7 (C-3”) , 75.7 (C-2”) , 72.1 (C-4”) , 69.6 (O-alloc) , 69.3 (O-alloc) , 67.5 (C-9) , 63.4 (C-5”) , 56.5 (3-OCH
3) , 55.8 (4-OCH
3) .
2”, 4”-O-diallyl oxycarbonyl-7-O-β-D-patentiflorin A (29b, yield 83%)
HR-EIMS: m/z [M+H]
+ 695.1911 (calcd. 695.1976) .
1H NMR (400 MHz, CDCl
3) δ 7.62 (1H, s, H-2) , 7.09 (1H, s, H-5) , 6.95 (1H, dd, J = 8.2, 1.4 Hz, H-5’) , 6.84 -6.77 (2H, m, H-2’, 6’) , 6.12 -6.01 (2H, m, -OCH
2O-) , 5.93 (2H, m, O-alloc) , 5.50 -5.25 (6H, m, H-9, O-alloc) , 5.15 (1H, dd, J = 9.7, 8.1 Hz, H-1”) , 4.99 (1H, d, J = 8.1 Hz, H-2”) , 4.74 -4.63 (5H, m, H-4”, O-alloc) , 4.06 (3H, s, 3-OCH
3) , 3.88 (1H, t, J = 9.5 Hz, H-3”) , 3.80 (3H, s, 4-OCH
3) , 3.49 (1H, ddt, J = 12.7, 6.6, 4.9 Hz, H-5”) , 1.31 (3H, dd, J = 6.1, 1.7 Hz, H-6”) .
13C NMR (100 MHz, CDCl
3) δ 169.8 (C-9’) , 155.0 (O-alloc) , 154.9 (O-alloc) , 152.3 (C-3) , 150.4 (C-4) , 147.7 (C-3’) , 147.7 (C-4’) , 143.7 (C-7) , 137.0 (C-7’) , 131.1 (C-8) , 130.9 (C-1) , 128.3 (C-6) , 126.9 (C-1’) , 123.7 (C-6’) , 120.2 (O-alloc) , 119.7 (O-alloc) , 119.3 (C-8’) , 110.8 (C-2’) , 108.3 (C-5’) , 106.4 (C-1”) , 101.6 (C-5) , 101.4 (C-2) , 100.2 (-OCH
2O-) , 79.3 (C-3”) , 78.2 (C-1”) , 73.5 (C-4”) , 70.5 (C-5”) , 69.7 (O-alloc) , 69.4 (O-alloc) , 67.3 (C-9) , 56.7 (3-OCH
3) , 56.0 (4-OCH
3) , 17.5 (C-6”) .
2”, 4”-O-diallyl oxycarbonyl-3”-O-dimethylcarbamyl-7-O-β-D-xylosyldiphyllin (30a, yield 99%)
HR-EIMS: m/z [M+H]
+ 752.2133 (calcd. 752.2191) .
1H NMR (400 MHz, CDCl
3) δ 7.56 (1H, s, H-2) , 7.07 (1H, d, J = 1.8 Hz, H-5) , 6.93 (1H, dd, J = 8.1, 1.1 Hz, H-5’) , 6.83 –6.74 (2H, m, H-2’, H-6’) , 6.05 (2H, dt, J = 17.9, 1.5 Hz, -OCH
2O-) , 5.89 (2H, ddtd, J = 17.6, 10.4, 5.8, 1.5 Hz, O-Alloc) , 5.52 –5.39 (2H, m, H-9) , 5.35 (1H, m, H-1”) , 5.31 (1H, br t, J = 1.6 Hz, H-3”) , 5.27 –5.23 (4H, m, O-Alloc) , 5.10 –5.06 (1H, m, H-2”) , 5.02 (1H, tdd, J = 9.7, 4.8, 2.1 Hz, H-4”) , 4.73 –4.59 (4H, m, O-Alloc) , 4.20 (1H, ddd, J = 11.8, 5.4, 1.1 Hz, H-5”a) , 4.04 (3H, s, 3-OCH
3) , 3.78 (3H, s, 4-OCH
3) , 3.40 (1H, ddd, J = 11.9, 9.9, 0.9 Hz, H-5”b) , 2.91 [6H, s, OC (O) N (CH
3)
2] .
2”, 4”-O-diallyl oxycarbonyl-3”-O- (3, 5-dinitrobenzoyl) -7-O-β-D-xylosyldiphyllin (30b, yield 90%)
HR-EIMS: m/z [M+H]
+ 889.1763 (calcd. 889.1940) .
1H NMR (400 MHz, CDCl
3) δ 9.26 (1H, t, J = 2.1 Hz, 3, 5-dinitrobenzoyl) , 9.15 (2H, d, J = 2.1 Hz, 3, 5-dinitrobenzoyl) , 7.59 (1H, s, H-2) , 7.09 (1H, d, J = 1.2 Hz, H-5) , 6.94 (1H, dd, J = 7.9, 3.8 Hz, H-5’) , 6.81 (1H, dd, J = 9.7, 1.6 Hz, H-2’) , 6.78 –6.72 (1H, m, H-6’) , 6.10 –6.01 (2H, m, -OCH
2O-) , 5.76 (2H, ddt, J = 17.2, 16.1, 5.7 Hz, O-Alloc) , 5.61 (1H, t, J = 9.4 Hz, O-Alloc) , 5.54 –5.48 (1H, m, O-Alloc) , 5.48 –5.43 (2H, m, H-9) , 5.24 (1H, d, J = 8.2Hz, H-1”) , 5.20 (2H, ddd, J = 8.0, 2.8, 1.4 Hz, O-Alloc) , 5.14 (1H, dd, J = 6.4, 1.2 Hz, H-2”) , 5.11 (1H, dd, J = 6.5, 1.2 Hz, H-3”) , 5.02 (1H, t, J = 9.5 Hz, H-4”) , 4.55 (4H, ddt, J = 20.0, 5.7, 1.4 Hz, O-Alloc) , 4.06 (3H, s, 3-OCH
3) , 3.79 (3H, s, 4-OCH
3) , 3.73 –3.67 (1H, m, H-5”) , 1.37 (3H, dd, J = 6.1, 1.7 Hz, H-6”) .
3”-O-dimethylcarbamyl-7-O-β-D-xylosyldiphyllin (31a, yield 69%of two steps)
HR-EIMS: m/z [M+H]
+ 584.1723 (calcd. 584.1768) .
1H NMR (400 MHz, acetone-d
6) δ 8.15 (1H, d, J = 1.6 Hz, H-2) , 7.10 (1H, d, J = 4.4 Hz, H-5) , 6.98 (1H, dd, J = 7.9, 1.5 Hz, H-5’) , 6.88 (1H, dd, J = 15.7, 1.6 Hz, H-2’) , 6.83 (1H, td, J = 7.9, 1.7 Hz, H-6’) , 6.10 (2H, dt, J = 4.8, 1.3 Hz, -OCH
2O-) , 5.56 -5.38 (3H, m, H-9, H-1”) , 5.02 (1H, d, J = 7.6 Hz, H-3”) , 4.79 -4.67 (2H, m, OH-2”, OH-4”) , 4.05 (1H, ddd, J = 11.5, 5.5, 1.9 Hz, H-2”) , 3.97 (3H, s, 3-OCH
3) , 3.89 (2H, m, H-4”, H-5”) , 3.73 (3H, d, J = 1.4 Hz, 4-OCH
3) , 3.39 (1H, ddd, J = 11.4, 10.0, 1.1 Hz, H-5”) , 3.02 (3H, s, OCON (CH
3)
2) , 2.93 (3H, s, OCON (CH
3)
2) .
13C NMR (100 MHz, acetone-d
6) δ169.8 (C-9’) , 158.3 (OCON (CH
3)
2) , 153.0 (C-3) , 151.5 (C-4) , 148.4 (C-3’) , 148.3 (C-4’) , 145.9 (C-7) , 136.7 (C-7’) , 131.5 (C-1) , 131.4 (C-6) , 129.7 (C-1’) , 128.1 (C-8) , 124.6 (C-6’) , 120.0 (C-8’) , 111.8 (C-2’) , 111.7 (C-5’) , 108.7 (C-1”) , 106.8 (C-2) , 102.4 (C-5) , 102.2 (-OCH
2O-) , 81.5 (C-3”) , 73.5 (C-2”) , 69.3 (C-4”) , 67.8 (C-9) , 66.7 (C-5”) , 56.3 (3-OCH
3) , 55.8 (4-OCH
3) , 36.7 (OCON (CH
3)
2) , 36.2 (OCON (CH
3)
2) .
3”-O- (3, 5-dinitrobenzoyl) -7-O-β-D-patentiflorin A (31b, yield 77%of two steps)
HR-EIMS: m/z [M+H]
+ 721.1337 (calcd. 721.1517) .
1H NMR (400 MHz, acetone-d
6) δ 9.17 (3H, m, 3, 5-Dinitrobenzoyl) , 8.11 (1H, dt, J = 6.9, 3.1 Hz, H-2) , 7.13 -7.05 (1H, m, H-5) , 6.99 (1H, dd, J = 7.7, 1.7 Hz, H-5’) , 6.89 (1H, dd, J = 11.2, 1.5 Hz, H-2’) , 6.83 (1H, ddd, J = 9.4, 5.5, 1.6 Hz, H-6’) , 6.16 -6.08 (2H, m, -OCH
2O-) , 5.75 -5.41 (4H, m, H-9, OH-2”, OH-4”) , 5.18 (1H, d, J = 7.8 Hz, H-1”) , 4.95 (1H, d, J = 4.9 Hz, H-2”) , 4.21 (1H, ddd, J = 9.7, 7.8, 5.3 Hz, H-4”) , 3.95 (3H, s, 3-OCH
3) , 3.71 (5H, m, 4-OCH
3, H-3”, H-5”) , 1.41 (3H, d, J = 5.1 Hz, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.8 (C-9’) , 163.4 (3, 5-dinitrobenzoyl) , 152.9 (C-3) , 151.4 (3, 5-dinitrobenzoyl) , 151.3 (3, 5-dinitrobenzoyl) , 149.7 (C-4) , 148.3 (C-3’) , 148.3 (C-4’) , 145.8 (C-7) , 136.7 (C-7’) , 134.8 (3, 5-dinitrobenzoyl) , 131.4 (C-1) , 130.1 (3, 5-dinitrobenzoyl) , 129.6 (C-8) , 128.1 (C-6) , 124.6 (C-1’) , 123.3 (C-6’) , 120.0 (3, 5-dinitrobenzoyl) , 111.7 (C-8’) , 111.7 (C-2’) , 108.7 (C-5’) , 106.7 (C-2) , 105.5 (C-1”) , 102.3 (C-5) , 102.2 (-OCH
2O-) , 81.4 (C-3”) , 74.1 (C-2”) , 73.4 (C-4”) , 73.0 (C-5”) , 67.8 (C-9) , 56.3 (3-OCH
3) , 55.8 (4-OCH
3) , 18.1 (C-6”) .
3”-O-butyryl-7-O-β-D-patentiflorin A (31c, yield 77%of two steps)
HR-EIMS: m/z [M+H]
+ 597.1968 (calcd. 597.1972) .
1H NMR (400 MHz, acetone-d
6) δ 8.12 (1H, s, H-2) , 7.08 (1H, t, J = 4.7 Hz, H-5) , 6.98 (1H, ddd, J = 8.0, 3.6, 1.3 Hz, H-5’) , 6.93 -6.75 (2H, m, H-2’, H-6’) , 6.14 -6.05 (2H, m, H-9) , 5.64 -5.39 (2H, m, -OCH
2O-) , 5.31 (1H, ddt, J = 6.2, 4.6, 1.8 Hz, H-1”) , 5.13 -5.02 (2H, m, OH) , 4.52 (1H, d, J = 6.0 Hz, H-3”) , 3.96 (3H, d, J = 2.9 Hz, 3-OCH
3) , 3.91 -3.82 (1H, m, H-2”) , 3.71 (3H, dd, J = 5.5, 3.1 Hz, 4-OCH
3) , 3.55 (1H, dd, J = 9.7, 5.9 Hz, H-4”) , 3.37 (1H, ddd, J = 9.6, 5.6, 3.8 Hz, H-5”) , 2.38 (2H, td, J = 7.4, 1.6 Hz, O-butyryl) , 1.66 (2H, dd, J = 7.5, 1.6 Hz, O-butyryl) , 1.35 (3H, dd, J = 5.9, 1.8 Hz, O-butyryl) , 0.97 (3H, td, J = 7.4, 1.7 Hz, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 173.6 (O-butyryl) , 169.8 (C-9’) , 152.9 (C-3) , 151.4 (C-4) , 148.3 (C-3’) , 148.3 (C-4’) , 145.9 (C-7) , 136.6 (C-7’) , 131.4 (C-1) , 131.3 (C-6) , 129.7 (C-1’) , 128.2 (C-8) , 124.6 (C-6’) , 111.8 (C-8’) , 111.7 (C-2’) , 108.6 (C-5’) , 106.6 (C-2) , 105.8 (C-1”) , 102.4 (C-5) , 102.2 (-OCH
2O-) , 78.3 (C-3”) , 74.5 (C-2”) , 73.7 (C-4”) , 73.1 (C-5”) , 67.9 (C-9) , 56.3 (3-OCH
3) , 55.7 (4-OCH
3) , 36.7 (O-butyryl) , 19.0 (C-6”) , 18.1 (O-butyryl) , 13.9 (O-butyryl) .
3”-O-benzoyl-7-O-β-D-patentiflorin A (31d, yield 72%of two steps)
HR-EIMS: m/z [M+H]
+ 631.1810 (calcd. 631.1816) .
1H NMR (400 MHz, acetone-d
6) δ 8.13 (1H, dt, J = 6.2, 3.0 Hz, H-2) , 8.11 -8.04 (2H, m, O-Benzoyl) , 8.01 (1H, dd, J = 8.3, 2.7 Hz, O-Benzoyl) , 7.51 (2H, d, J = 6.1 Hz, O-Benzoyl) , 7.05 (1H, dq, J = 10.2, 3.4 Hz, H-5) , 6.95 (1H, dq, J = 6.9, 3.8 Hz, H-5’) , 6.90 -6.73 (2H, m, H-2’, H-6’) , 6.07 (2H, q, J = 2.9, 2.2 Hz, -OCH
2O-) , 5.62 -5.28 (4H, m, H-9, OH) , 5.12 (1H, dd, J = 7.8, 2.1 Hz, H-1”) , 4.07 (1H, q, J = 9.1, 6.1 Hz, H-3”) , 3.91 (3H, q, J = 2.9, 2.5 Hz, 3-OCH
3) , 3.67 (3H, dt, J = 7.1, 3.5 Hz, 4-OCH
3) , 3.64 -3.53 (3H, m, H-2”, 4” and 5”) , 1.42 -1.32 (3H, m, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.9 (C-9’) , 166.6 (O-benzoyl) , 152.9 (C-3) , 151.4 (C-4) , 148.3 (C-3’) , 148.3 (C-4’) , 146.0 (C-7) , 136.6 (C-7’) , 133.8 (O-benzoyl) , 133.7 (O-benzoyl) , 131.6 (C-1) , 131.5 (C-6) , 131.3 (C-8) , 130.5 (O-benzoyl) , 130.4 (O-benzoyl) , 129.3 (O-benzoyl) , 129.3 (O-benzoyl) , 128.2 (C-1’) , 124.6 (C-6’) , 111.8 (C-8’) , 111.7 (C-2’) , 108.7 (C-5’) , 106.6 (C-2) , 105.8 (C-1”) , 102.4 (C-5) , 102.2 (-OCH
2O-) , 79.5 (C-3”) , 74.5 (C-2”) , 73.8 (C-4”) , 73.1 (C-5”) , 67.9 (C-9) , 56.3 (3-OCH
3) , 55.7 (4-OCH
3) , 18.2 (C-6”) .
3”-O-p-dimethylaminobenzoyl-7-O-β-D-patentiflorin A (31e, yield 51%of two steps)
HR-EIMS: m/z [M+H]
+ 674.2099 (calcd. 674.2238) .
1H NMR (400 MHz, acetone-d
6) δ 8.21 (1H, d, J = 1.7 Hz, H-2) , 7.95 -7.90 (2H, m, O-p-dimethylaminobenzoyl) , 7.11 (1H, d, J = 2.9 Hz, H-5) , 7.01 -6.96 (1H, m, H-5’) , 6.93 -6.81 (2H, m, H-2’, 6’) , 6.79 -6.75 (m, 2H, O-p-dimethylaminobenzoyl) , 6.10 (2H, ddd, J = 4.4, 1.7, 1.1 Hz, -OCH
2O-) , 5.60 (1H, d, J = 15.0 Hz, H-1”) , 5.50 -5.42 (2H, m, H-9) , 5.24 (1H, t, J = 9.3 Hz, OH) , 5.11 (1H, d, J = 7.8 Hz, OH) , 4.67 (1H, dd, J = 5.7, 1.0 Hz, H-3”) , 4.07 -3.99 (1H, m, H-2”) , 3.96 (3H, s, 3-OCH
3) , 3.73 (3H, d, J = 1.2 Hz, 4-OCH
3) , 3.65 -3.57 (1H, m, H-5”) , 3.52 (1H, td, J = 9.2, 5.5 Hz, H-4”) , 3.07 (6H, s, O-p-dimethylaminobenzoyl) , 1.39 (3H, dd, J = 6.0, 1.5 Hz, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.9 (C-9’) , 167.4 (O-p-dimethylaminobenzoyl) , 154.6 (O-p-dimethylaminobenzoyl) , 153.0 (C-3) , 151.5 (C-4) , 148.4 (C-3’) , 148.3 (C-4’) , 146.1 (C-7) , 136.6 (C-7’) , 132.3 (O-p-dimethylaminobenzoyl) , 132.1 (O-p-dimethylaminobenzoyl) , 131.4 (C-1) , 131.4 (C-6) , 129.7 (C-8) , 128.2 (C-1’) , 124.6 (C-6’) , 120.0 (O-p-dimethylaminobenzoyl) , 117.8 (O-p-dimethylaminobenzoyl) , 111.8 (C-8’) , 111.5 (C-2’) , 108.7 (C-5’) , 106.7 (C-2) , 105.9 (C-1”) , 102.5 (C-5) , 102.2 (-OCH
2O-) , 78.9 (C-3”) , 74.7 (C-2”) , 74.0 (C-4”) , 73.2 (C-5”) , 67.9 (C-9) , 56.3 (3- OCH
3) , 55.8 (4-OCH
3) , 40.1 (O-p-dimethylaminobenzoyl) , 40.1 (O-p-dimethylaminobenzoyl) , 18.2 (C-6”) .
3”-O-dimethylcarbamyl-7-O-β-D-patentiflorin A (31f, yield 66%of two steps)
HR-EIMS: m/z [M+H]
+ 674.2099 (calcd. 598.1925) .
1H NMR (400 MHz, acetone-d
6) δ 8.16 (1H, d, J = 2.7 Hz, H-2) , 7.07 (1H, d, J = 4.9 Hz, H-5) , 6.97 (1H, dd, J = 7.9, 2.7 Hz, H-5’) , 6.92 -6.78 (2H, m, H-2’, 6’) , 6.13 -6.07 (2H, m, -OCH
2O-) , 5.59 -5.47 (2H, m, H-9) , 5.42 (1H, dd, J = 15.0, 0.8 Hz, H-1”) , 5.02 (1H, d, J = 7.8 Hz, H-3”) , 4.80 -4.72 (2H, m, OH) , 3.95 (3H, s, 3-OCH
3) , 3.90 (1H, ddd, J = 9.4, 7.8, 4.5 Hz, H-2”) , 3.70 (3H, d, J = 2.6 Hz, 4-OCH
3) , 3.56 -3.45 (1H, m, H-4”) , 3.39 (1H, td, J = 9.2, 4.4 Hz, H-5”) , 3.02 (3H, s, O-dimethylcarbamyl) , 2.92 (3H, s, O-dimethylcarbamyl) , 1.35 (3H, dd, J = 6.0, 1.5 Hz, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.9 (C-9’) , 158.4 (O-dimethylcarbamyl) , 152.9 (C-3) , 151.4 (C-4) , 148.3 (C-3’) , 148.2 (C-4’) , 146.0 (C-7) , 136.6 (C-7’) , 131.6 (C-1) , 131.5 (C-6) , 129.7 (C-8) , 128.2 (C-1’) , 124.6 (C-6’) , 111.8 (C-8’) , 111.7 (C-2’) , 108.6 (C-5’) , 106.6 (C-2) , 105.9 (C-1”) , 102.5 (C-5) , 102.2 (-OCH
2O-) , 81.4 (C-3”) , 74.7 (C-2”) , 74.0 (C-4”) , 73.0 (C-5”) , 67.9 (C-9) , 56.3 (3-OCH
3) , 55.7 (4-OCH
3) , 36.7 (O-dimethylcarbamyl) , 36.2 (O-dimethylcarbamyl) , 18.1 (C-6”) .
3”-O-cyclopropanecarbonyl-7-O-β-D-patentiflorin A (31g, yield 62%of two steps)
HR-EIMS: m/z [M+H]
+ 595.1808 (calcd. 595.1816) .
1H NMR (400 MHz, acetone-d
6) δ 8.15 (1H, d, J = 2.1 Hz, H-2) , 7.09 (1H, d, J = 4.2 Hz, H-5) , 6.98 (1H, dd, J = 7.9, 2.8 Hz, H-5’) , 6.91 -6.79 (2H, m, H-2’, 6’) , 6.12 -6.07 (2H, m, -OCH
2O-) , 5.61 -5.40 (3H, m, H-9, 1”) , 5.10 -5.01 (2H, m, OH) , 4.69 -4.61 (1H, m, H-3”) , 3.95 (3H, s, 3-OCH
3) , 3.89 (1H, ddd, J = 12.2, 8.3, 4.1 Hz, H-2”) , 3.71 (3H, d, J = 2.3 Hz, 4-OCH
3) , 3.59 -3.49 (1H, m, H-4”) , 3.38 (1H, dd, J = 10.7, 7.7 Hz, H-5”) , 1.69 (1H, tt, J = 7.9, 4.7 Hz, O-cyclopropanecarbonyl) , 1.35 (3H, dd, J = 6.1, 1.5 Hz, H-6”) , 0.90 -0.83 (4H, m, O-cyclopropanecarbonyl) .
13C NMR (100 MHz, acetone-d
6) δ 175.1 (O-cyclopropanecarbonyl) , 169.8 (C-9’) , 152.9 (C-3) , 151.4 (C-4) , 148.3 (C-3’) , 148.3 (C-4’) , 146.0 (C-7) , 136.6 (C-7’) , 131.4 (C-1) , 131.3 (C-6) , 129.7 (C-8) , 128.2 (C-1’) , 124.6 (C-6’) , 111.7 (C-8’) , 111.7 (C-2’) , 108.6 (C-5’) , 106.6 (C-2) , 105.8 (C-1”) , 102.5 (C-5) , 102.2 (-OCH
2O-) , 78.7 (C-3”) , 74.5 (C-2”) , 73.7 (C-4”) , 73.1 (C-5”) , 67.9 (C-9) , 56.3 (3-OCH
3) , 55.7 (4-OCH
3) , 18.1 (c-6”) , 13.6 (O-cyclopropanecarbonyl) , 8.7 (O-cyclopropanecarbonyl) , 8.2 (O-cyclopropanecarbonyl) .
3”-O-p-chlorobenzoyl-7-O-β-D-patentiflorin A (31h, yield 80%of two steps)
HR-EIMS: m/z [M+H]
+ 665.1413 (calcd. 665.1426) .
1H NMR (400 MHz, acetone-d
6) δ 8.15 (1H, d, J = 2.4 Hz, H-2) , 8.14 -8.08 (2H, m, O-p-chlorobenzoyl) , 7.61 -7.55 (2H, m, O-p-chlorobenzoyl) , 7.08 (1H, d, J = 6.3 Hz, H-5) , 7.00 -6.95 (1H, m, H-5’) , 6.93 -6.78 (2H, m, H-2’, 6’) , 6.13 -6.08 (2H, m, -OCH
2O-) , 5.61 -5.42 (3H, m, H-5, 1”) , 5.35 (1H, t, J = 9.2 Hz, OH) , 5.15 (1H, dd, J = 7.8, 1.2 Hz, OH) , 4.80 (1H, dd, J = 5.7, 1.1 Hz, H-3”) , 4.09 (1H, ddd, J = 9.5, 7.8, 5.4 Hz, H-2”) , 3.94 (3H, s, 3-OCH
3) , 3.70 (3H, d, J = 3.7 Hz, 4-OCH
3) , 3.68 -3.54 (2H, m, H-4”, 5”) , 1.40 (3H, dd, J = 5.9, 1.2 Hz, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.9 (C-9’) , 165.8 (O-p-chlorobenzoyl) , 152.9 (C-3) , 151.4 (C-4) , 148.3 (C-3’) , 148.3 (C-4’) , 145.9 (C-7) , 139.5 (O-p-chlorobenzoyl) , 136.7 (C-7’) , 132.2 (O-p-chlorobenzoyl) , 131.4 (C-1) , 131.3 (C-6) , 130.4 (C-8) , 129.5 (O-p-chlorobenzoyl) , 128.2 (C-1’) , 124.6 (C-6’) , 111.8 (C-8’) , 111.7 (C-2’) , 108.7 (C-5’) , 106.6 (C-2) , 105.7 (C-1”) , 102.4 (C-5) , 102.2 (-OCH
2O-) , 79.8 (C-3”) , 74.4 (C-2”) , 73.7 (C-4”) , 73.1 (C-5”) , 67.9 (C-9) , 56.3 (3-OCH
3) , 55.7 (4-OCH
3) , 18.2 (C-6”) .
3”-O-pyrazinecarbonyl-7-O-β-D-patentiflorin A (31i, yield 52%of two steps)
HR-EIMS: m/z [M+H]
+ 633.1709 (calcd. 633.1720) .
1H NMR (400 MHz, acetone-d
6) δ 8.89 (1H, d, J = 1.5 Hz, O-pyrazinecarbonyl) , 8.49 (1H, d, J = 2.4 Hz, O-pyrazinecarbonyl) , 8.43 (1H, dd, J = 2.5, 1.5 Hz, O-pyrazinecarbonyl) , 7.62 (1H, d, J = 2.1 Hz, H-2) , 6.60 (1H, dd, J = 7.9, 2.4 Hz, H-5’) , 6.55 (1H, d, J = 2.7 Hz, H-5) , 6.49 (1H, dd, J = 12.2, 1.7 Hz, H-6’) , 6.36 (1H, ddd, J = 8.6, 7.9, 1.7 Hz, H-2’) , 5.89 (1H, dd, J = 5.6, 3.3 Hz, H-3”) , 5.68 (2H, q, J = 1.2 Hz, -OCH
2O-) , 5.16 -5.01 (3H, m, H-9, 1”) , 4.76 (1H, t, J = 9.3 Hz, OH) , 4.60 (1H, dd, J = 7.8, 4.9 Hz, OH) , 3.47 (3H, s, 3-OCH
3) , 3.45 -3.39 (1H, m, H-2”) , 3.22 (3H, s, 4-OCH
3) , 3.16 -3.07 (2H, m, H-4”, 5”) , 0.86 -0.80 (3H, m, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.9 (C-9’) , 168.6 (O-pyrazinecarbonyl) , 153.0 (C-3) , 151.5 (C-4) , 149.7 (C-3’) , 148.3 (C-4’) , 146.2 (O-pyrazinecarbonyl) , 145.9 (O-pyrazinecarbonyl) , 145.5 (C-7) , 144.8 (O-pyrazinecarbonyl) , 144.2 (O-pyrazinecarbonyl) , 136.8 (C-7’) , 131.5 (C-1) , 131.4 (C- 6) , 130.1 (C-8) , 128.2 (C-1’) , 124.6 (C-6’) , 111.8 (C-8’) , 111.7 (C-2’) , 108.7 (C-5’) , 105.6 (C-1”) , 102.4 (C-5) , 102.2, (-OCH
2O-) , 81.5 (C-3”) , 74.2 (C-2”) , 73.5 (C-4”) , 73.0 (C-5”) , 67.9 (C-9) , 56.3 (3-OCH
3) , 55.8 (4-OCH
3) , 18.2 (C-6”) .
3”-O-cyanoacetyl-7-O-β-D-patentiflorin A (31j, yield 49%of two steps)
HR-EIMS: m/z [M+H]
+ 594.1609 (calcd. 594.1612) .
1H NMR (400 MHz, acetone-d
6) δ 7.85 (1H, s, H-2) , 7.09 (1H, m, H-5) , 6.98 (1H, dd, J = 7.9, 2.5 Hz, H-5’) , 6.89 (1H, dd, J = 12.2, 1.6 Hz, H-2’) , 6.85 -6.79 (1H, m, H-6’) , 6.15 -6.02 (2H, m, -OCH
2O-) , 5.70 -5.37 (2H, m, H-9) , 5.12 -4.98 (2H, m, H-1”, H-3”) , 3.96 (3H, d, J = 1.6 Hz, 3-OCH
3) , 3.91 (1H, dd, J = 9.5, 7.8 Hz, H-2”) , 3.78 -3.66 (3H, m, 4-OCH
3) , 3.55 (1H, ddd, J = 9.5, 6.1, 1.2 Hz, H-4”) , 3.35 (3H, m, O-cyanoacetyl, H-5”) , 1.36 (3H, dd, J = 6.0, 1.3 Hz, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.9 (C-9’) , 167.8 (O-cyanoacetyl) , 153.0 (C-3) , 151.5 (C-4) , 148.4 (C-3’) , 148.3 (C-4’) , 146.0 (C-7) , 136.6 (C-7’) , 131.4 (C-1) , 131.3 (C-6) 129.7 (C-8) , 128.2 (C-1’) , 124.6 (C-6’) , 113.8 (O-cyanoacetyl) , 111.8 (C-2’) , 111.8 (C-8’) , 108.7 (C-5’) , 106.7 (C-2) , 105.8 (C-1”) , 102.5 (C-5) , 102.2 (-OCH
2O-) , 79.2 (C-3”) , 74.6 (C-2”) , 73.9 (C-4”) , 73.1 (C-5”) , 67.9 (C-9) , 56.4 (3-OCH
3) , 55.8 (4-OCH
3) , 25.1 (O-cyanoacetyl) , 18.2 (C-6”) .
3”-O-trichloroacetyl-7-O-β-D-patentiflorin A (31k, yield 53%of two steps)
HR-EIMS: m/z [M+H]
+ 671.0325 (calcd. 671.0490) .
1H NMR (400 MHz, acetone-d
6) δ 8.15 (1H, d, J = 1.5 Hz, H-2) , 7.11 (1H, t, J = 2.4 Hz, H-5) , 6.98 (1H, dd, J = 7.9, 2.5 Hz, H-5’) , 6.90 (1H, d, J = 1.6 Hz, H-2’) , 6.88 -6.80 (1H, m, H-6’) , 6.10 (2H, dt, J = 4.7, 1.2 Hz, -OCH
2O-) , 5.74 -5.66 (1H, m, 4”-OH) , 5.61 -5.41 (2H, m, H-9) , 5.12 -5.02 (1H, m, 2”-OH) , 4.92 (1H, t, J = 9.3 Hz, H-1”) , 4.84 (1H, d, J = 8.7 Hz, H-3”) , 3.97 (3H, d, J = 1.3 Hz, 3-OCH
3) , 3.91 (1H, ddd, J = 9.5, 7.8, 5.4 Hz, H-2”) , 3.73 (3H, d, J = 1.6 Hz, 4-OCH
3) , 3.56 (1H, dq, J = 12.2, 6.2 Hz, H-4”) , 3.42 (1H, td, J = 9.3, 5.9 Hz, H-5”) , 1.36 (3H, dd, J = 6.1, 1.5 Hz, H-6”) .
13C NMR (100 MHz, acetone-d
6) δ 169.8 (C-9’) , 162.5 (O-trichloroacetyl) , 153.0 (C-3) , 151.5 (C-4) , 148.4 (C-3’) , 148.3 (C-4’) , 145.9 (C-7) , 136.7 (C-7’) , 131.5 (C-1) , 131.4 (C-6) , 129.7 (C-8) , 128.2 (C-1’) , 124.6 (C-6’) , 111.8 (C-8’) , 111.7 (C-2’) , 108.7 (C-5’) , 106.7 (C-2) , 105.7 (C-1”) , 102.5 (C-5) , 102.2 (-OCH
2O-) , 91.4 (O-trichloroacetyl) , 79.6 (C- 3”) , 74.1 (C-2”) , 73.3 (C-4”) , 73.1 (C-5”) , 67.9 (C-9) , 56.4 (3-OCH
3) , 55.8 (4-OCH
3) , 18.1 (C-6”) .
3”-O-benzyl-7-O-β-D-xylosyldiphyllin (31l, yield 59%of two steps)
HR-EIMS: m/z [M+H]
+ 603.1676 (calcd. 603.1866) .
1H NMR (400 MHz, CDCl
3) δ 7.85 (1H, s, H-2) , 7.30 (5H, m, O-Bn) , 7.01 (1H, m, H-5) , 6.89 (1H, m, H-5’) , 6.74 (1H, m, H-2’) , 6.74 (1H, m, H-6’) , 5.99 (2H, m, -OCH
2O-) , 5.38 (2H, m, H-9) , 4.96 (1H, m, H-1”) , 4.69 (2H, m, O-Bn) , 3.96 (3H, s, 3-OCH
3) , 3.81 (1H, dd J = 8.6, 7.2 Hz, H-3”) , 3.73 (3H, s, 4-OCH
3) , 3.60 (3H, m, H-2”, 4”, 5”) , 3.12 (1H, m, H-5”) .
13C NMR (100 MHz, CDCl
3) δ 169.9 (C-9’) , 152.0 (C-3) , 150.2 (C-4) , 147.6 (C-3’) , 147.5 (C-4’) , 144.3 (C-7) , 137.6 (C-7’) , 136.6 (O-Bn) , 130.8 (C-1) , 130.7 (C-6) , 128.8 (C-8) , 128.8 (O-Bn) , 128.5 (O-Bn) , 128.3 (O-Bn) , 128.3 (C-1’) , 127.9 (O-Bn) , 127.0 (O-Bn) , 123.6 (C-6’) , 119.2 (C-8’) , 110.7 (C-2’) , 108.2 (C-5’) , 106.4 (C-2) , 104.8 (C-1”) , 101.3 (C-5) , 100.9 (-OCH
2O-) , 81.1 (C-3”) , 75.6 (C-2”) , 75.3 (C-4”) , 73.4 (C-5”) , 73.04 (O-Bn) , 67.4 (C-9) , 56.3 (3-OCH
3) , 55.9 (4-OCH
3) .
3”, 4”-Acetonide-4-O-β-D-glucopyranosyldiphyllin (32a)
To the solution of compound 26f (54.2 mg, 0.1 mmol) in 3 mL of 2, 2-dimethoxypropane (DMP) was added catalytic amount of TsOH (0.19 mg, 0.001 mmol) (As illustrated in Figure 6) . After the reaction was stirred for 12 h at r.t., the excess DMP was removed under evaporation in reduced pressure. The residue was purified by a silica gel column separation (n-hexane: ethyl acetate = 1: 1) to afford 32a as a white solid (11.4 mg, 20%) : HR-EIMS: m/z [M+H]
+ 583.1656 (calcd. 583.1816) .
1H NMR (400 MHz, Acetone-d
6) δ 8.22 (1H, s, H-2) , 7.09 (1H, s, H-5) , 6.97 (1H, dd, J = 7.8, 2.2 Hz, H-5’) , 6.87 (1H, dd, J = 6.8, 2.2 Hz, H-2’) , 6.81 (1H, q, J = 7.4 Hz, H-6’) , 6.10 (2H, d, J = 3.6 Hz, -OCH
2O-) , 5.52 –5.34 (2H, m, H-9) , 5.32 (1H, s, -OH) , 5.03 (1H, dd, J = 7.7, 2.8 Hz, H-1”) , 4.66 (1H, s, -OH) , 3.98 (3H, s, 3-OCH
3) , 3.96-3.82 (2H, m, H-2”, H-3”) , 3.79 (1H, td, J = 7.9, 3.3 Hz, H-6”) , 3.72 (3H, s, 4-OCH
3) , 3.68-3.64 (2H, m, H-5”, H-6”) , 3.34 (1H, q, J = 7.9, 6.8 Hz, H-4”) , 1.52 (3H, s, O-isopropylidene) , 1.32 (3H, s, O-isopropylidene) .
To the solution of compound 26g (50 mg, 0.09 mmol) in 3 mL of DMP was added catalytic amount of TsOH (0.19 mg, 0.001 mmol) (As illustrated in Figure 6) . After the reaction was stirred for 12 h at r.t., the excess DMP was removed under evaporation in reduced pressure. The residue was purified by a silica gel column separation (45-52 %ethyl acetate in n-hexane) to afford 32b (18 mg, 34 %) , 32c (20 mg, 38 %) and 32d (2 mg, 4 %) with each as a white solid, respectively.
3”, 4”-Acetonide-4-O-β-D-galactopyranosyldiphyllin (32b)
HR-EIMS: m/z [M+H]
+ 583.1666 (calcd. 583.1816) .
1H NMR (400 MHz, Acetone-d
6) δ 8.21 (1H, s, H-2) , 7.09 (1H, s, H-5) , 6.97 (1H, d, J = 7.4 Hz, H-5’) , 6.90 –6.75 (2H, m, H-2’, H-6’) , 6.10 (2H, d, J = 4.5 Hz, -OCH
2O-) , 5.78 (1H, d, J = 15.6 Hz, -OH) , 5.48 –5.39 (2H, m, H-9) , 4.88 (1H, d, J = 9.5 Hz, H-1”) , 4.28 (1H, d, J = 5.9 Hz, H-3”) , 4.23 (1H, t, J = 6.0 Hz, H-4”) , 4.07 (1H, q, J = 5.7, 5.2 Hz, H-2”) , 4.00 (3H, s, 3-OCH
3) , 3.96-3.83 (3H, m, H-5”, H-6”) , 3.73 (3H, s, 4-OCH
3) , 1.53 (3H, s, O-isopropylidene) , 1.33 (3H, s, O-isopropylidene) .
4”, 6”-Acetonide-4-O-β-D-galactopyranosyldiphyllin (32c)
HR-EIMS: m/z [M+H]
+ 583.1688 (calcd. 583.1816) .
1H NMR (400 MHz, Acetone-d
6) δ 8.28 –8.19 (1H, m, H-2) , 7.09 (1H, s, H-5) , 6.98 (1H, dt, J = 8.0, 1.1 Hz, H-5’) , 6.90 –6.78 (2H, m, H-2’, H-6’) , 6.10 (2H, dt, J = 5.0, 1.1 Hz, -OCH
2O-) , 5.84 –5.32 (2H, m, H-9) , 4.94 –4.83 (1H, m, H-1”) , 4.32 –4.20 (1H, m, H-6”) , 4.04 (1H, dt, J = 9.6, 7.6 Hz, H-2”) , 4.00 (3H, s, 3-OCH
3) , 3.97 –3.81 (3H, m, H-3”, H-4”, H-6”) , 3.73 (3H, s, 4-OCH
3) , 3.66 (1H, tt, J = 6.7, 4.3 Hz, H-5”) , 1.53 (3H, s, O-isopropylidene) , 1.33 (3H, s, O-isopropylidene) .
2”, 3”-Acetonide-4-O-β-D-galactopyranosyldiphyllin (32d)
HR-EIMS: m/z [M+H]
+ 583.1648 (calcd. 583.1816) .
1H NMR (400 MHz, Acetone-d
6) δ 8.25 (1H, s, H-5) , 7.11 (1H, s, H-5) , 6.98 (1H, dd, J = 7.8, 1.0 Hz, H-5’) , 6.90 –6.86 (1H, m, H-2’) , 6.83 (1H, dd, J = 7.9, 1.7 Hz, H-6’) , 6.10 (2H, dd, J = 4.3, 1.0 Hz, -OCH
2O-) , 5.65 –5.45 (2H, m, H-9) , 4.96 –4.90 (1H, m, H-1”) , 4.26 (1H, d, J = 3.5 Hz, H-3”) , 4.15 (1H, dt, J = 12.8, 2.1 Hz, H-2”) , 4.01 (3H, s, 3-OCH
3) , 3.93 –3.83 (2H, m, H-6”) , 3.73 (3H, s, 4-OCH
3) , 3.68 (1H, ddd, J = 9.5, 7.9, 3.6 Hz, H-4”) , 3.57-3.50 (1H, m, H-5”) , 1.47 (3H, s, O-isopropylidene) , 1.41 (3H, s, O-isopropylidene) .
Having now fully described the present invention in some detail by way of illustration and examples for purposes of clarity of understanding, it will be obvious to one of ordinary skill in the art that the same can be performed by modifying or changing the invention within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any specific embodiment thereof, and that such modifications or changes are intended to be encompassed within the scope of the appended claims. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.
As used herein, “comprising” is synonymous with “including. ” “containing, ” or “characterized by, ” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim element. As used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. In each instance herein any of the terms “comprising” , “consisting essentially of” and “consisting of” may be replaced with either of the other two terms.
When a group of materials, compositions, components or compounds are disclosed herein, it is understood that all individual members of those groups and all subgroups thereof are disclosed separately. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure. Every formulation or combination of components described or exemplified herein can be used to practice the invention, unless otherwise stated. Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition range, all intermediate ranges and subranges, as well as all individual values included in the ranges given are intended to be included in the disclosure. In the disclosure and the claims, “and/or” means additionally or alternatively. Moreover, any use of a term in the singular also encompasses plural forms.
All references cited herein are hereby incorporated by reference in their entirety to the extent that there is no inconsistency with the disclosure of this specification. Some references provided herein are incorporated by reference to provide details concerning sources of starting materials, additional starting materials, additional reagents, additional methods of synthesis, additional methods of analysis, additional biological materials, additional cells, and additional uses of the invention. All headings used herein are for convenience only. All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains, and are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference. References cited herein are incorporated by reference herein in their entirety to indicate the state of the art as of their publication or filing date and it is intended that this information can be employed herein, if needed, to exclude specific embodiments that are in the prior art. For example, when composition of matter is claimed, it should be understood that compounds known and available in the art prior to applicants’ invention, including compounds for which an enabling disclosure is provided in the references cited herein, are not intended to be included in the composition of matter claims herein.
Claims (23)
- Use of a compound in the manufacture of a medicament for treating a viral infection, wherein the compound has the Formula (I) :or a pharmaceutically acceptable salt or pro-drug thereof wherein,X is oxygen or sulphur;R 1 is R 15, -OR 15, -C (O) R 15, or -C (O) OR 15;R 2, R 5, R 6, R 10, R 13, and R 14 are each hydrogen;R 3 and R 4 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15; or R 3 and R 4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16;R 7, R 8, and R 9 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15; or R 7 and R 8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16; or R 8 and R 9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16;R 11 and R 12 taken together form oxo; or while one of R 11 and R 12 is hydrogen or halogen, the other one of R 11 and R 12 is selected from the group consisting of R 15, -OR 15, -C (O) R 15 and -C (O) OR 15;R 15 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, heteroaryl, -OR 17, -C (O) R 18, -C (O) N (R 17) R 18, -C (O) OR 17, -OC (O) R 17, -S (O) 2R 17, -S (O) 2N (R 17) R 18, - N=C (R 17) R 18, -N (R 17) R 18, -N (R 17) N (R 17) R 18, -N (R 17) C (O) R 18, -N (R 17) S (O) 2R 18, 1, 3, 2-dioxaborolane optionally substituted with 1, 2, 3, or 4 group (s) independently selected from alkyl, a glycosidic group, alkynyl optionally substituted with a trialkylsilane, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16, and - (CH 2) k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16, wherein k is an integer between 1-6;R 16 for each occurrence is independently selected from the group consisting of alkynyl, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR 17, -OR 17, -C (O) R 18, -C (O) N (R 17) R 18, -C (O) OR 17, -OC (O) R 17, -S (O) 2R 17, -S (O) 2N (R 17) R 18, -N (R 17) R 18, -N (R 17) N (R 17) R 18, -N (R 17) C (O) R 18 and -N (R 17) S (O) 2R 18; andR 17 and R 18 for each occurrence are independently hydrogen, alkyl, alkynyl, cycloalkyl, aryl, or heteroaryl, or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy;with the proviso that the compound of Formula (I) is not a compound selected from the group consisting of 5, 15a, 15b, 16, 17b, 19d, 25a-25g, and 26a-26g:
- The use of claim 1, wherein each of R 3 and R 4 is -O-alkyl; R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring;R 1 is heteroaryl, -OR 15, -C (O) R 15, -N (R 17) R 18, -N (R 17) C (O) R 18, -N=C (R 17) R 18, pinacolboryl, -OS (O) 2CF 3, a glycosidic group, heterocyclcyl optionally substituted with 1 or 2 group (s) independently selected from R 16, or alkynyl optionally substituted with a trialkylsilane; orR 1 is -O (CH 2) m-cyano, -O (CH 2) m-alkynyl, -O (CH 2) m-C (O) N (R 17) R 18, or -O (CH 2) m-C (O) OR 17, wherein m is a whole number elected from 1-4; and R 11 and R 12 taken together form oxo.
- The use of any one of claims 1-3, wherein the viral infection is selected from the group consisting of HIV, coronaviruses, influenza viruses, Ebola virus, and Marburg virus.
- The use of claim 1, wherein R 1 is alkynyl, pinacolboryl, -OCH 2-cyano, -OCH 2-C (O) N (R 17) R 18, or -OCH 2-C (O) OR 17;each of R 3 and R 4 is -OCH 3;R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring;R 11 and R 12 taken together form oxo; andthe viral infection is HIV.
- The use of claim 1 or 2, wherein R 1 is a glycosidic group represented by the Formula (V):wherein, R 19 and R 20 taken together to form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, and -OC (O) OR 27;R 21 and R 22 taken together to form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 21 and R 22 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, and -OC (O) OR 27; or R 20 and R 22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16;R 23 and R 24 taken together to form oxo; or while one of R 23 and R 24 is hydrogen or halogen, the other one of R 23 and R 24 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, and -OC (O) OR 27; or R 22 and R 24 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16;R 25 and R 26 taken together form oxo; or while one of R 25 and R 26 is hydrogen or halogen, the other one of R 25 and R 26 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, -OC (O) OR 27, -CH 2R 27, and -C (O) R 27; or R 24 and R 26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16;R 27 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29, -C (O) R 30, - C (O) N (R 29) R 30, -C (O) OR 29, -OC (O) R 29, -S (O) 2R 29, -S (O) 2N (R 29) R 30, -N (R 29) R 30, -N (R 29) N (R 29) R 30, -N (R 29) C (O) R 30, -N (R 29) S (O) 2R 30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28, and - (CH 2) k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28, wherein k is an integer between 1-6;R 28 for each occurrence is independently selected from halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR 29, -OR 29, -C (O) R 30, -C (O) N (R 29) R 30, -C (O) OR 29, -OC (O) R 29, -S (O) 2R 29, -S (O) 2N (R 29) R 30, -N (R 29) R 30, -N (R 29) N (R 29) R 30, -N (R 29) C (O) R 30 and -N (R 29) S (O) 2R 30; andR 29 and R 30 for each occurrence areeach independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- The use of claim 6, wherein R 19, R 21, R 23, and R 25 are each hydrogen; R 20, R 22 and R 24 are each independently selected from the group consisting of -OR 27, -OC (O) N (R 27) R 27, -OC (O) R 27 and -OC (O) OR 27; and R 26 is hydrogen, methyl, -OR 27, -OC (O) R 27 or -CH 2-OC (O) R 27; or R 20 and R 22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; or R 22 and R 24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; or R 24 and R 26 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; and the glycloside is a monosaccaride.
- The use of claim 6 or 7, wherein the glycloside is a monosacchairde selected from the group consisting of an α-L isomer and an β-L isomer.
- The use of claim 1, wherein the compound is selected from the group consisting of 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
- The use of any one of claims 6-9, wherein the viral infection is selected from the group consisting of HIV, coronaviruses, influenza viruses, Ebola virus, and Marburg virus.
- The use of claim 6, wherein each of R 3 and R 4 is -OCH 3;R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring;R 11 and R 12 taken together form oxo;R 19, R 21, R 23, and R 25 are each hydrogen;R 20, R 22, and R 24 are each independently selected from the group consisting of -OR 27, -OC (O) N (R 27) R 27, -OC (O) R 27 and -OC (O) OR 27;R 26 is hydrogen, methyl, -OR 27, -OC (O) R 27 or -CH 2-OC (O) R 27; or R 20 and R 22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1 or 2 group (s) independently selected from C 1-6 alkyl; or R 22 and R 24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1 or 2 group (s) independently selected from C 1-6 alkyl; or R 24 and R 26 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1 or 2 group (s) independently selected from C 1-6 alkyl; and the glycloside is a monosaccaride; andthe viral infection is HIV, coronaviruses, influenza viruses, Ebola virus, or Marburg virus.
- A compound of Formula (I) :or a pharmaceutically acceptable salt or pro-drug thereof wherein,X is oxygen or sulphur;R 1 is R 15, -OR 15, -C (O) R 15, or -C (O) OR 15;R 2, R 5, R 6, R 10, R 13, and R 14 are each hydrogen;R 3 and R 4 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15; or R 3 and R 4 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;R 7, R 8, and R 9 are each independently selected from the group consisting of -OR 15 and -OC (O) R 15; or R 7 and R 8 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; or R 8 and R 9 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;R 11 and R 12 taken together form oxo; or while one of R 11 and R 12 is hydrogen or halogen, the other one of R 11 and R 12 is selected from the group consisting of R 15, -OR 15, -C (O) R 15 and -C (O) OR 15;R 15 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, heteroaryl, -OR 17, -C (O) R 18, -C (O) N (R 17) R 18, -C (O) OR 17, -OC (O) R 17, -S (O) 2R 17, -S (O) 2N (R 17) R 18, -N=C (R 17) R 18, -N (R 17) R 18, -N (R 17) N (R 17) R 18, -N (R 17) C (O) R 18, -N (R 17) S (O) 2R 18, 1, 3, 2-dioxaborolane optionally substituted with 1, 2, 3, or 4 group (s) independently selected from alkyl, a glycosidic group, alkynyl optionally substituted with a trialkylsilane, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16, and - (CH 2) k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 16, wherein k is an integer between 1-6;R 16 for each occurrence is independently selected from the group consisting of alkynyl, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR 17, -OR 17, -C (O) R 18, -C (O) N (R 17) R 18, -C (O) OR 17, -OC (O) R 17, -S (O) 2R 17, -S (O) 2N (R 17) R 18, -N (R 17) R 18, -N (R 17) N (R 17) R 18, -N (R 17) C (O) R 18 and -N (R 17) S (O) 2R 18; andR 17 and R 18 for each occurrence are independently hydrogen, alkyl, alkynyl, cycloalkyl, aryl, or heteroaryl, or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from the group consisting of halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy,with the proviso that the compound of Formula (I) is not a compound selected from the group consisting of 5, 15a, 15b, 16, 17b, 19d, 25a-25g, and 26a-26g:
- The compound of claim 12, wherein each of R 3 and R 4 is -O-alkyl; R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; and R 11 and R 12 taken together form oxo.
- The compound of claim 12 or 13, wherein R 1 is heteroaryl, -OR 15, -C (O) R 15, -N (R 17) R 18, -N (R 17) C (O) R 18, -N=C (R 17) R 18, pinacolboryl, -OS (O) 2CF 3, alkynyl optionally substituted with a trialkylsilane, or heterocyclcyl optionally substituted with 1 or 2 group (s) independently selected from R 16; orR 1 is -O (CH 2) m-cyano, -O (CH 2) m-alkynyl, -O (CH 2) m-C (O) N (R 17) R 18, or -O (CH 2) m-C (O) OR 17, wherein m is a whole number selected from 1-4.
- The compound of claim 12, wherein R 1 is heteroaryl, -OR 15, -C (O) R 15, -N (R 17) R 18, -N (R 17) C (O) R 18, -N=C (R 17) R 18, pinacolboryl, -OS (O) 2CF 3, heterocyclcyl optionally substituted with 1 or 2 group (s) independently selected from R 16, or alkynyl optionally substituted with a trialkylsilane; orR 1 is -O (CH 2) m-cyano, -O (CH 2) m-alkynyl, -O (CH 2) m-C (O) N (R 17) R 18, or -O (CH 2) m-C (O) OR 17, wherein m is a whole number selected from 1-4;each of R 3 and R 4 is -OMe;R 8 and R 9 taken together with the carbon atoms to which they are attached form a methylenedioxy ring; andR 11 and R 12 taken together form oxo.
- The compound of any one of claims 12-15, wherein R 1 is alkynyl, pinacolboryl; -N (R 17) R 18, -OCH 2-cyano, -OCH 2-alkynyl, -OCH 2-C (O) N (R 17) R 18, or -OCH 2-C (O) OR 17.
- The compound of claim 12 or 13, wherein R 1 is a glycosidic group selected from the group consisting of a monosaccharide, disaccharide, trisaccharide, tetrasaccharide and polysaccharide group containing less than 30 monosaccharides, wherein the glycosidic group comprises one or more monosacchairdes isomers selected from the group consisting of α-D, α-L, β-D, and β-L.
- The compound of claim 12, 13, or 18, wherein R 1 is a glycosidic group represented by the Formula (V) :wherein, R 19 and R 20 taken together to form oxo; or while one of R 19 and R 20 is hydrogen or halogen, the other one of R 19 and R 20 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, and -OC (O) OR 27;R 21 and R 22 taken together to form oxo; or while one of R 21 and R 22 is hydrogen or halogen, the other one of R 21 and R 22 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, and -OC (O) OR 27; or R 20 and R 22 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;R 23 and R 24 taken together to form oxo; or while one of R 23 and R 24 is hydrogen or halogen, the other one of R 23 and R 24 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, and -OC (O) OR 27; or R 22 and R 24 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;R 25 and R 26 taken together to form oxo; or while one of R 24 and R 25 is hydrogen or halogen, the other one of R 25 and R 26 is selected from the group consisting of R 27, -OR 27, -OC (O) R 27, -OC (O) N (R 27) R 27, -OC (O) OR 27, -CH 2R 27, and -C (O) R 27; or R 24 andR 26 taken together with the carbon atoms to which they are attached to form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy;R 27 for each occurrence is independently selected from the group consisting of hydrogen, halogen, trichloromethyl, trifluoromethyl, cyano, nitro, -OR 29, -C (O) R 30, -C (O) N (R 29) R 30, -C (O) OR 29, -OC (O) R 29, -S (O) 2R 29, -S (O) 2N (R 29) R 30, -N (R 29) R 30, -N (R 29) N (R 29) R 30, -N (R 29) C (O) R 30, -N (R 29) S (O) 2R 30, hydrocarbyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28, heterocyclcyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28, and - (CH 2) k-heterocyclyl optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from R 28, wherein k is an integer between 1-6;R 28 for each occurrence is independently selected from halogen, trichloromethyl, trifluoromethyl, cyano, nitro, oxo, =NR 29, -OR 29, -C (O) R 30, -C (O) N (R 29) R 30, - C (O) OR 29, -OC (O) R 29, -S (O) 2R 29, -S (O) 2N (R 29) R 30, -N (R 29) R 30, -N (R 29) N (R 29) R 30, -N (R 29) C (O) R 30 and -N (R 29) S (O) 2R 30; andR 29 and R 30 for each occurrence areeach independently hydrogen or selected from hydrocarbyl and heterocyclyl, either of which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from halogen, cyano, amino, hydroxy, C 1-6 alkyl and C 1-6 alkoxy.
- The compound of claim 19, wherein R 19, R 21, R 23, and R 25 are each hydrogen; R 20, R 2, and R 24 are each independently selected from the group consisting of -OR 27, -OC (O) N (R 27) R 27, -OC (O) R 27 and -OC (O) OR 27; and R 26 is hydrogen, methyl, -OR 27, -OC (O) R 27, or -CH 2-OC (O) R 27; or R 20 and R 22 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; or R 22 and R 24 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; or R 24 and R 26 taken together with the carbon atoms to which they are attached form a 5-6 membered heterocyclyl, which is optionally substituted with 1, 2, 3, 4 or 5 group (s) independently selected from C 1-6 alkyl and C 1-6 alkoxy; and the glycloside is a monosaccaride.
- The compound of claim 19 or 20, wherein the glycloside is a monosacchairde selected from the group consisting of an α-L isomer and an β-L isomer.
- The compound of claim 12, wherein the compound is selected from the group consisting of 27aa, 27ab, 27ac, 27ad, 27ae, 27af, 27ba, 27bb, 27bc, 27bd, 27be, 27bf, 28ab1, 28ab2, 28ab3, 28bb1, 28bb2, 28bb3, 29a, 29b, 30a, 30b, 30c, 30d, 30e, 30f, 30g, 30h, 30i, 30j, 30k, 30l, 31a, 31b, 31c, 31d, 31e, 31f, 31g, 31h, 31i, 31j, 31k, 31l, 32a, 32b, 32c and 32d:
- A pharmaceutical composition comprising a compound of claim 12 and at least one pharmaceutically acceptable excipient.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080060363.8A CN114555077A (en) | 2019-08-26 | 2020-08-26 | Patentiflorin A analogs as antiviral agents |
EP20858852.5A EP4021438A4 (en) | 2019-08-26 | 2020-08-26 | Patentiflorin a analogs as antiviral agents |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962891441P | 2019-08-26 | 2019-08-26 | |
US62/891,441 | 2019-08-26 | ||
US16/947,935 US11638713B2 (en) | 2019-08-26 | 2020-08-25 | Patentiflorin A analogs as antiviral agents |
US16/947,935 | 2020-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021037077A1 true WO2021037077A1 (en) | 2021-03-04 |
Family
ID=74682082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/111463 WO2021037077A1 (en) | 2019-08-26 | 2020-08-26 | Patentiflorin a analogs as antiviral agents |
Country Status (4)
Country | Link |
---|---|
US (2) | US11638713B2 (en) |
EP (1) | EP4021438A4 (en) |
CN (1) | CN114555077A (en) |
WO (1) | WO2021037077A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022135136A1 (en) * | 2020-12-21 | 2022-06-30 | Hong Kong Baptist University | Tuberculatin analogs as antiviral agents |
WO2022208382A1 (en) * | 2021-03-31 | 2022-10-06 | 동화약품주식회사 | Novel dialkoxynaphtho[2,3-c]furan-1(3h)-one derivatives and pharmaceutical composition for preventing or treating respiratory disease or sars-cov-2 infection disease, comprising same |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11884653B2 (en) * | 2018-03-19 | 2024-01-30 | Purdue Research Foundation | Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof |
CN115160301A (en) * | 2021-04-06 | 2022-10-11 | 上海交通大学 | Diphyllin derivative, preparation method and application thereof |
CN113304165B (en) * | 2021-07-15 | 2022-07-22 | 重庆医科大学 | Application of monomeric compound Ciliaoside A in preparation of hepatitis B treatment drug |
CN116987719B (en) * | 2023-06-21 | 2024-03-15 | 华南农业大学 | H9N2AIV multi-epitope recombinant baculovirus, preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4486445A (en) * | 1983-01-12 | 1984-12-04 | E. I. Du Pont De Nemours And Company | Justicidin insecticidal and antiviral compounds |
US20140357584A1 (en) * | 2011-07-29 | 2014-12-04 | The Board Of Trustees Of The University Of Illinois | Aryl naphthalide lignans as anti-hiv agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103127159A (en) * | 2013-02-05 | 2013-06-05 | 广西壮族自治区药用植物园 | Application of aryl naphthalene type lignan in hepatitis C virus (HCV) therapy |
US11884653B2 (en) * | 2018-03-19 | 2024-01-30 | Purdue Research Foundation | Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof |
US11542257B2 (en) * | 2018-03-19 | 2023-01-03 | Purdue Research Foundation | Arylnaphthalene compounds as vacuolar-ATPase inhibitors and the use thereof |
-
2020
- 2020-08-25 US US16/947,935 patent/US11638713B2/en active Active
- 2020-08-26 EP EP20858852.5A patent/EP4021438A4/en active Pending
- 2020-08-26 CN CN202080060363.8A patent/CN114555077A/en active Pending
- 2020-08-26 WO PCT/CN2020/111463 patent/WO2021037077A1/en unknown
-
2023
- 2023-02-24 US US18/173,865 patent/US20230248754A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4486445A (en) * | 1983-01-12 | 1984-12-04 | E. I. Du Pont De Nemours And Company | Justicidin insecticidal and antiviral compounds |
US20140357584A1 (en) * | 2011-07-29 | 2014-12-04 | The Board Of Trustees Of The University Of Illinois | Aryl naphthalide lignans as anti-hiv agents |
Non-Patent Citations (4)
Title |
---|
See also references of EP4021438A4 |
VICHAI VKIRTIKARA K, NATURE PROTOCOLS, vol. 1, 2006, pages 1112 - 1116 |
ZHANG HONG-JIE, RUMSCHLAG-BOOMS EMILY, GUAN YI-FU, WANG DONG-YING, LIU KANG-LUN, LI WAN-FEI, NGUYEN VAN H., CUONG NGUYEN M., SOEJA: "Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 80, no. 6, 23 June 2017 (2017-06-23), US, pages 1798 - 1807, XP055785691, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.7b00004 * |
ZHANG HONG-JIE; RUMSCHLAG-BOOMS EMILY; GUAN YI-FU; LIU KANG-LUN; WANG DONG-YING; LI WAN-FEI; NGUYEN VAN HUNG; CUONG NGUYEN MANH; S: "Anti-HIV diphyllin glycosides fromJusticia gendarussa", PHYTOCHEMISTRY, ELSEVIER, AMSTERDAM , NL, vol. 136, 1 January 1900 (1900-01-01), Amsterdam , NL, pages 94 - 100, XP029934524, ISSN: 0031-9422, DOI: 10.1016/j.phytochem.2017.01.005 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022135136A1 (en) * | 2020-12-21 | 2022-06-30 | Hong Kong Baptist University | Tuberculatin analogs as antiviral agents |
WO2022208382A1 (en) * | 2021-03-31 | 2022-10-06 | 동화약품주식회사 | Novel dialkoxynaphtho[2,3-c]furan-1(3h)-one derivatives and pharmaceutical composition for preventing or treating respiratory disease or sars-cov-2 infection disease, comprising same |
Also Published As
Publication number | Publication date |
---|---|
EP4021438A4 (en) | 2023-09-13 |
EP4021438A1 (en) | 2022-07-06 |
US20230248754A1 (en) | 2023-08-10 |
CN114555077A (en) | 2022-05-27 |
US20210060042A1 (en) | 2021-03-04 |
US11638713B2 (en) | 2023-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021037077A1 (en) | Patentiflorin a analogs as antiviral agents | |
AU2014348752B2 (en) | Methods of preparing inhibitors of influenza viruses replication | |
CA3093222A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
AU2006262059B2 (en) | Antiviral compounds | |
CN108473477A (en) | The pyrimidine of aryl substitution for being used in influenza infection | |
EP2910563A1 (en) | Triterpene derivative and its anti-influenza use | |
WO2010083732A1 (en) | N-acetylneuraminic acid compounds, pharmaceutical composition, preparation method and uses thereof | |
CN103145617A (en) | Phenanthridine derivative as well as medicinal composition, preparation method and application thereof | |
WO2017155923A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
WO2017189978A1 (en) | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
US20140357584A1 (en) | Aryl naphthalide lignans as anti-hiv agents | |
EP2504326B1 (en) | Sialochimeric compounds | |
WO2022174179A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
AU2004269930B2 (en) | Entry inhibitors of the HIV virus | |
WO2022135136A1 (en) | Tuberculatin analogs as antiviral agents | |
CN105367558A (en) | Andrographolide derivative and preparation method and application thereof | |
CN115160301A (en) | Diphyllin derivative, preparation method and application thereof | |
CN112079785A (en) | Novel anti-influenza virus oseltamivir derivative, preparation method and application thereof | |
CN109745309B (en) | Mitsuma as antiviral agent | |
US10323012B2 (en) | Miliusanes as antiviral agents | |
KR102049140B1 (en) | Isoquinolinone derivatives, preparation method thereof and pharmaceutical composition for treating influenza virus containing the same | |
CN112300147B (en) | Pyridine compound, preparation method and application thereof, and pharmaceutical composition | |
JP2003246792A (en) | Anti-influenza-viral compound | |
JP2011032180A (en) | Compound having high affinity to cd22 molecule and enhancing proliferation of b cell | |
WO2024086592A2 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20858852 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020858852 Country of ref document: EP Effective date: 20220328 |